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General Introduction

General Introduction
General Introduction
This thesis focuses on a number of aspects that are all linked to the 
neurodegenerative disorder Alzheimer’s disease. An overview of the various 
topics will be given in this introductory section.
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder first described by Alois 
Alzheimer (1907). The prevalence of AD increases from 0.5 % at age 65, and 10­
20 % at age 85 to 40 % or more at higher ages (Evans et al., 1989; Breteler et al., 
1992). Patients with AD can be characterized only post-mortem, by the presence 
of neurofibrillary tangles, neuropil threads and neuritic plaques in the brain. The 
neurofibrillary tangles are intraneuronal lesions consisting of paired helical 
filaments. The major component of these filaments is the hyperphosphorylated 
form of the microtubule-associated protein tau (Goedert et al., 1989; Grundke- 
Iqbal et al., 1986a-b; Kosik et al., 1986; Lee et al., 1991). Multiple tau isoforms 
are derived from a single gene through alternative mRNA splicing (Goedert et al., 
1989). Tau is a phosphoprotein and phosphorylation appears to be develop­
mentally regulated in that tau from immature brain is phosphorylated at more sites 
than tau from adult brain (Butler and Shelanski, 1986). Normally tau is an 
abundant protein in both central and peripheral nervous systems, and 
predominantly found in nerve cells where it is concentrated in axons (Binder et 
al., 1985). This contrasts with the neurofibrillary lesions in AD, which are found 
in nerve cell bodies, axons and dendrites. Another characteristic of AD are the 
senile neuritic plaques, that are surrounded and invaded by variable number of 
microglia and reactive astrocytes, indicating an inflammatory component in the 
neurodegenerative process (Eikelenboom and Stam, 1982; Eikelenboom et 
al.,1994; Kalaria et al., 1993; Haga et al., 1989; Itagaki et al., 1989; Rozemuller et 
al., 1992). An important constituent of these plaques is ß-amyloid (Aß), a peptide 
of 40-42 amino acids that is proteolytically derived from the amyloid precursor 
protein APP (Glenner and Wong, 1984a). The APP gene is a housekeeping gene, 
localized on chromosome 21, comprising 18 exons and encoding an N- and O- 
glycosylated type I transmembrane protein of 770 amino acids with a large 
lumenal domain and a short cytoplasmic tail (Figure 1-1) (Goldgaber et al., 1987; 
Kang et al., 1987; Tanzi et al., 1987,1988; Robakis et al., 1987; Ponte et al., 1988; 
Konig et al., 1992; Sandbrink et al., 1994).
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Figure 1-1
The ß-amyloid precursor protein APP
The signal-peptide (SP), the various domains (cysteine rich domain, acidic domain, and ß-amyloid (Aß) domain) 
and the position of the transmembrane region (TM) in the APP protein are indicated in the 695-amino acid 
variant of APP. The alternatively spliced variant of 751 amino acids results from the presence of the Kunitz 
protease inhibitor (KPI), and in the 770-amino acid form KPI and the OX-2 domain are present. Below, the 
amino acid sequence o f Aß is boxed and shown in the one-letter amino acid code; amino acid substitutions 
occurring in familial AD are indicated with arrows. The open arrow indicated the a-secretase cleavage site. Swe 
= Swedish mutation, Dutch = Dutch mutation.
Genetic risk factors
AD occurs mostly in the elderly population, but in 10-20 % of the cases the first 
symptoms become apparent before the age of 60-65 years. This has led to the 
discrimination of AD in two different types: the early-onset (familial; below the 
age of 60-65) and the late-onset (sporadic) forms. The familial types of AD have 
been investigated thoroughly and three genes, namely the APP, presenilin 1 (PS1) 
and presenilin 2 (PS2) gene, account for almost all known cases of early-onset 
AD. Surprisingly, the first mutation in the APP gene was not found in AD 
patients, but in patients suffering from recurrent cerebral hemorrhages and 
progressive dementia of the multi-infarct type i.e. hereditary cerebral 
hemorrhages with amyloidosis of the Dutch type (HCHWA-D) (Haan et al., 
1991). This type of disease has been referred to as the vascular form of AD since 
the vascular deposits contain the same Aß peptide as has been found in senile 
plaques. However, no or only a few dystrophic neurites or neurofibrillary tangles 
have been observed in these patients (Van Duinen et al., 1987). The patients carry 
a missense mutation resulting in an E to Q amino acid substitution at codon 693
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(numbering refers to the APP770 isoform) within the Aß sequence (Levy et al., 
1990; Figure 1-1). Subsequently, 6 different APP mutations were identified in less 
than 20 families worldwide: a double mutation K670N/M671L was detected in a 
Swedish family (Mullan et al., 1992), 3 different mutations have been observed at 
codon 717 (V717I, Goate et al., 1991; V717G, Chartier-Harlin et al., 1991; 
V717F, Murrell et al., 1991) and recently an I716V mutation (Eckman et al.,
1997) and a L723P mutation (Kwok et al., 1998) have been discovered in the APP 
gene (Figure 1-1). Another mutation within the APP gene (A692G) was identified 
in patients with cerebral hemorrhages due to congophilic amyloid angiopathy and 
also in early onset AD of patients belonging to the above-mentioned Dutch family 
(Cras et al., 1998; Hendriks et al., 1992; Figure 1-1). Mutations in the APP gene 
itself are estimated to account for about 5 % of early-onset AD and they are 
therefore a rare cause of AD (Van Broeckhoven, 1995b). The majority of the 
early-onset form of AD (50-70 %; Van Broeckhoven, 1995b; Cruts et al., 1998) is 
caused by mutations in the genes encoding PS1 and PS2, located on chromosome 
14q24.3 (Schellenberg et al., 1992; Van Broeckhoven et al., 1992) and 1q31-42 
(Levy-Lahad et al., 1995b), respectively. Over 40 different mutations have been 
detected in the PS1 gene in a large number of families of different ethnic origin 
(Cruts and Van Broeckhoven, 1998). All PS1 mutations published, with two 
exceptions, are missense mutations. A splice site mutation results in the deletion 
of exon 9 (A9) and an amino acid substitution (S290L) at the splice junction of 
exons 8 and 10 (Perez-Tur et al., 1995). Moreover, a PS1 truncation mutation, 
resulting from a single-basepair deletion in the splice donor site of intron 4 (A4), 
causes a frameshift and conse2quently a premature termination codon (Tysoe et 
al., 1998). In PS2 only four different mutations have been detected (Levy-Lahad 
et al., 1995a; Cruts et al., 1998; Lao et al., 1998), suggesting that PS2 mutations 
are a rare cause of AD. All AD causing mutations are located in regions that are 
conserved between PS1 and PS2. The occurrence of a mutation in any of the three 
genes (APP, PS1, PS2) might cause an acceleration of the formation and 
accumulation of Aß, which is generally accepted to be involved in AD. 
Transgenic mice expressing mutant APP, PS1 or PS2 have been created to study 
the formation of plaques and tangles (review Hardy, 1997). Thus far, these mouse 
models for AD only show the neuritic plaques, and never the neurofibrillary 
tangles, suggesting that mutations in one of the three genes can not fully explain 
the characteristics of AD in human. Moreover, at least 60 % of AD patients does 
not have a familial history of the disease.
A genetic linkage of familial late-onset AD revealed a locus on chromosome 19 
(Pericak-Vance et al., 1991). The gene encoding apolipoprotein E (ApoE) was
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one of the genes located in the chromosomal region that co-segregated with the 
disease and became immediately a candidate gene since ApoE immunoreactivity 
was found in senile plaques, neurofibrillary tangles and congophilic amyloid 
angiopathy. ApoE is a protein that has been extensively studied because of its role 
in cholesterol metabolism (Mahley, 1988). Three common alleles of the ApoE 
gene have been identified (e2, e3, e4) and encode three isoforms that differ from 
each other in one or two amino acids at positions 112 (C in e2 and e3, R in e4) 
and 158 (C in e2, R in e3 and e4). ApoE has been assigned as a risk factor in that 
individuals carrying allele ApoE4 have a higher risk to develop AD and the onset 
can be advanced (Corder et al., 1993; Poirier et al., 1993; Saunders et al., 1993; 
Strittmatter et al., 1993). A protective effect has been suggested for the ApoE e2 
allele (Corder et al., 1994), but other studies are in contradiction with these results 
(Van Duijn et al., 1995). The mechanisms explaining aging and 
neurodegeneration may, however, be more general than suggested by models 
based on the genetic and risk factors.
The ß-amyloid precursor protein APP
APP and its derivatives
The APP gene comprises 18 exons, of which exons 7 and 8 can be alternatively 
spliced, resulting in three major APP proteins of 695, 751 and 770 amino acids 
(Kang et al., 1987; Tanzi et al., 1988; Kitaguchi et al., 1988). Another splice 
variant of APP, lacking exon 15, has also been identified (designated L-APP; 
König et al., 1992). Orthologues of human APP have been identified in rat 
(Shivers et al., 1988), mouse (Yamada et al., 1987) and Xenopus (Okado and 
Okamoto, 1992,1995). In addition, several members have been identified within 
the APP superfamily, including human APP-like protein-1 APLP1, APLP2 
(Wasco et al., 1993; Sprecher et al., 1993), mouse APLP1, APLP2 (Vidal et al., 
1992; Hanes et al., 1993; Wasco et al., 1992), Drosophila APPL (Rosen et al.,
1989) and C. elegans APL-1 (Daigle and Li, 1993). Three main regions of 
identity have been identified within these members, of which two regions are 
located in the extracellular domain (designated E1 and E2), and one region in the 
cytoplasmic domain. E1 contains the twelve conserved cysteines, E2 contains a 
large number of negatively charged residues and N-linked glycosylation sites, 
whereas the cytoplasmic domain contains the NPXY-sequence implicated in 
clathrin-coated vesicle targeting (Chen et al., 1990). Analysis of the members of 
the APP supergene family supports an adhesion function for all members, with
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specificity determined by the sequences that are not conserved between the 
various APP family members (Coulson et al., 2000). The strong structural 
conservation within the superfamily indicates an important function for APP and 
APP-like proteins.
APP is processed during its transport through the secretory pathway. Normal 
cleavage of APP by a-secretase effectively prevents formation of Aß and results 
in the production of a form of APP that can be secreted (APPas) and a membrane- 
associated 83 amino acids carboxy-terminal fragment (Figure 1-2) (Palmert et al., 
1989; Weidemann et al., 1989; Esch et al., 1990; Kametani et al., 1990; Wang et 
al., 1991). ß-secretase cleavage of APP leads to the release of secreted forms of 
APP (APPßs) and leaves intact Aß behind in a membrane-associated 99 amino 
acids carboxy-terminal fragment of APP (C99; A4CT). This fragment can be 
further processed by g-secretase to release the toxic Aß (Estus et al., 1992; 
Selkoe, 1993; Higaki et al., 1995; Knops et al., 1995). The same protease, g-
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Figure 1-2
The normal and pathological processing o f  APP
Normal processing of APP involves cleavage by a-secretase (resulting in APPsa and C83) and followed by g- 
secretase cleavage (resulting in p3 and a C-terminal fragment CT). Pathological processing of APP involves 
cleavage by the ß-secretase (resulting in APPsß and C99/A5CT) and followed by g-secretase cleavage, leading to 
the neurotoxic peptide ß-amyloid (Aß) and CT. The Aß domain is in grey and the transmembrane (TM) domain 
is dashed.
sa
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secretase, is assumed to be able to generate Aß with heterogeneous C-termini 
resulting in peptides of 39-43 amino acids. The 40-amino acid form of Aß (Aß40) 
accounts for approximately 90 % of all Aß normally released from cells, whereas 
the longer 42-residue form (Aß42) accounts for less than 10 % of the total Aß 
(Dovey et al., 1993; Asami-Odaka et al., 1995). Although accounting for only a 
minor portion of total secreted Aß, Aß42 plays a key role in plaque formation 
(Roher et al., 1993; Iwatsubo et al., 1994; Gravina et al., 1995) and is increased in 
all forms of early-onset AD that have been analyzed (Suzuki et al., 1994; 
Scheuner et al., 1996). Prevention of the production of Aß (especially Aß42) by 
inhibiting g-secretase might lead to the development of a therapeutic treatment. 
Calpain inhibitor MDL 28170 inhibits g-secretase leading to a decrease of total 
Aß and p3, and an accumulation of C83 and C99 (Higaki et al., 1995). Citron et 
al. (1996) have shown that MDL 28170 primarily decreases Aß40 and p340, 
whereas Aß42 and p342 remain largely unaffected, indicating that 
pharmacologically dissociable pathways and potentially different g-secretases are 
responsible for the cleavages at residue 40 and 42 of Aß.
Expression o f APP
The APP protein is ubiquitously expressed and its overall distribution in neuronal 
and non-neuronal tissues is comparable between all investigated mammals 
(Bahmanyar et al., 1987; Fisher et al., 1991; Goedert, 1987; Sandbrink et al., 
1994; Shivers et al., 1988; Tanzi et al., 1987; Zimmermann et al., 1988). The 
expression levels of the splicing variants, resulting in APP proteins of 695, 751 
and 770 amino acids differ between tissues. Neuronal cells predominantly express 
APP695 (Bendotti et al., 1988; Goedert, 1987; Shivers et al., 1988), whereas the 
APP75i/770 is mainly expressed by nonneuronal such as heart, lung, liver, kidney, 
muscle and spleen (Forloni et al., 1992; Mattson, 1997; Sandbrink et al, 1994; 
Tanzi et al., 1987; Zimmermann et al., 1988). Many investigators have shown that 
the pattern of APP695 mRNA expression in neuronal tissues shows regional 
differences (Bahmanyar et al., 1987; Bendotti et al., 1988; Goedert 1987; 
Sandbrink et al., 1994; Shivers et al., 1988; Tanzi et al., 1987; Zimmermann et al., 
1988). An other APP alternatively spliced variant, lacking exon 15 (named L­
APP), was first discovered to be present in peripheral leukocytes and microglial 
cells (Banati et al., 1993; König et al., 1992), and this form, again in all three 
spliced variants described before, was shown to be ubiquitously expressed in rat, 
including brain, but not in neurons (Sandbrink et al., 1994). There are some
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discrepancies between RNA and protein data concerning APP-expression, since 
immunoreactivity can not be detected in all tissues, probably reflecting an 
inefficient translation of APP mRNA or a rapid turnover of the protein, or a 
combination of both in some tissues (Arai et al., 1991).
Mouse APLP2 (initially described under the name Cdebp, a DNA-binding 
protein; Vidal et al., 1992; Hanes et al., 1993) has been shown to be required for 
correct genomic segregation in dividing mouse cells (Rassoulzadegan et al., 1998) 
and a possible role in pre-implantation development has been suggested (Blangy 
et al., 1991/1995). Neuronal overexpression of Drosophila APPL leads to a 
disruption of axonal transport (Torroja et al., 1999). APP might also be of 
developmental importance. In mouse hypothalamus, APP-expression has been 
shown to increase during the development of the hypothalamus (Apert et al.,
1998). Differences between fetal and adult APP mRNA-expression have been 
detected, for example the absence of APP mRNA-expression in human fetal liver 
(Tanzi et al., 1987), whereas the RNA is clearly present in adult liver. In mouse 
oocytes and embryos, the different splice forms of APP were all expressed, but 
the ratio varied at the different stages. Further investigation is necessary to obtain 
more insight into the actual involvement of APP in developmental processes.
APP and its post-translational modifications
During trafficking of APP through the secretory pathway, several post- 
translational modifications of the protein have been shown to occur in mammalian 
APP, such as O-linked glycosylation at sites S124 and L172 (Tomita et al., 1998) 
and N-linked glycosylation at sites Asn467 and Asn496 (Kang et al., 1987; 
Pchlsson et al., 1992; Pchlsson and Spitalnik 1996; Yazaki et al., 1996;). Another 
potential O-linked glycosylation site has been proposed for cytoplasmic serine or 
threonine residues in human APP (Griffith et al., 1995). Several potential 
phosphorylation sites (S198, S206, S655 and T668) have been identified in 
human APP, that were shown to be phosphorylated in cell lines by protein kinase 
C and calcium/calmodulin dependent (cdc) protein kinase II (S655; Gandy et al., 
1993; Suzuki et al., 1992; T668; Suzuki et al., 1994), cyclin-dependent kinase 5 
(T668; Iijima et al., 2000) and casein kinase (CK)-1 and CK-2 (S198 and S206; 
Walter et al., 1997). These post-translational modifications have been proposed to 
influence trafficking, targeting and processing of APP, and as such they may 
contribute to the physiological role of this protein (Buxbaum et al., 1993; 
Caporaso et al., 1992; Gabuzda et al., 1993; Gandy and Greengard, 1994; 
Graebert et al., 1995; Hung and Selkoe, 1994; Tomita et al., 1998a-b).
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Function o f APP
Initially, a function for APP as a cell surface receptor was suggested, based on the 
topology of the protein (Kang et al., 1987), but also functions as heparan sulfate 
proteoglycan core protein (Schubert et al., 1988), modulator of cell-cell adhesion 
(Shivers et al., 1988), and cargo membrane receptor during axonal transport 
(Kamal et al., 2000) have been proposed. Furthermore, APP has been shown to 
have neuroprotective functions (Mattson et al.,, 1993; Smith-Swintosky et al., 
1994), adhesive properties (Beyreuther et al., 1996; Shivers et al.,1988; Storey et 
al., 1996) and synaptic functions (Scott et al., 1991). Several researchers have 
shown that neuronal APP is up-regulated after various traumatic (Bramlett et al., 
1997; Kawarabayashi et al., 1991; Otsuka et al., 1991; Pierce et al., 1996; Scott et 
al., 1991) and ischaemic insults (Siman et al., 1989; Wallace et al., 1997a-b), 
indicating that the protein might play an important role in the response of the 
brain to injury (Van den Heuvel et al., 1999). In addition, an increase in APP 
might enhance the production of Aß, leading to deposition of diffuse Aß plaques 
resulting in AD (Gentleman et al., 1993; Graham et al., 1995; Roberts et al., 
1991/1994). Finally, several regulatory functions for the fragments that are 
proteolytically derived from APP have been suggested (for review see Mattson, 
1997). However, we have to conclude that the function of APP remains elusive.
Secretases
During many years, the enzymes responsible for the processing of APP have been 
able to conceal their secrets. Through recent research the mystery surrounding the 
so-called a-, ß- and g-secretases is starting to be unraveled (reviewed by Sinha 
and Lieberburg, 1999). The major proteolytic pathway of APP is the constitutive 
secretory pathway that involves cleavage by the putative a-secretase within the ß- 
amyloid sequence between amino acids K16 and L17 (Figure 1-1) (Esch et al.,
1990). This cleavage occurs either at the cell surface (Haass et al, 1992; Ikezu et 
al., 1998; Sisodia 1992) or in the trans-Golgi network (De Strooper et al., 1993; 
Kuentzel et al., 1993; Sambamurti et al., 1992; Tornita et al., 1998). Tumor 
necrosis factor a  converting enzyme (TACE), a member of the ADAM family (a 
disintegrin and metalloprotease-family), plays a role in the regulatory component 
of the a-secretase processing of APP. This was concluded from the observed 
reduced level of secretion of APPsa by fibroblasts derived from TACE-knockout 
mice (Buxbaum et al., 1998). Recently, two other metalloproteases, ADAM10 
(Lammich et al., 1999) and MDC9 (also known as meltrin g; Koike et al., 1999), 
belonging to the same family, have also been shown to be involved in a-cleavage
16
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of APP in cultured cells. Both enzymes possess a-secretase activity and show 
many properties expected for the proteolytic processing of APP, but whether 
these enzymes are in vivo responsible for the cleavage of APP remains unclear.
To generate Aß, APP has to be cleaved by ß-secretase instead of a-secretase. The 
ß-cleavage-site has been suggested to be a substrate for aspartyl proteases, and 
indeed, cathepsin D is able to cleave synthetic ß-secretase substrates (Ladror et 
al., 1994). However, in cultured hippocampal neurons derived from cathepsin D 
null mice, APP is still processed to Aß (Saftig et al., 1996). Recently, four 
research groups identified the same convincing candidate for the ß-site APP- 
cleavaging enzyme (BACE), also known as Asp2 (Hussain et al., 1999; Sinha et 
al., 1999; Vassar et al., 1999; Yan et al., 1999). These groups used different 
strategies: Vassar et al., (1999) inserted unknown cDNAs into HEK293 and 
screened the clones for changes in Aß levels; Hussain et al., (1999) searched for 
membrane-bound aspartyl protease sequences in a proprietary EST database; 
Sinha et al., (1999) purified a ß-secretase activity from human brain and Yan et al. 
(1999) have searched for candidate aspartyl proteases in C.elegans and then 
identified the vertebrate homologues. Asp2 (BACE) was identified as a type I 
transmembrane protein with a pH-optimum of activity at 5.5 (Sinha et al., 1999), 
and in transfection studies colocalizes with APP (Hussain et al., 1999; Vassar et 
al., 1999). The ubiquitous tissue distribution of Asp2 resembles the distribution of 
APP (Vassar et al., 1999). Experiments with antisense Asp2 RNA, which indeed 
decreased ß-secretase activity, have revealed that Asp2 is capable of cleaving 
APP at the ß-site (Yan et al., 1999). Furthermore, the mutation of the active site of 
Asp2 led to a decrease in ß-secretase activity (Hussain et al., 1999). Recently, a 
second BACE (BACE2) has already been identified (Acquati et al., 2000; Bennett 
et al., 2000; Solans et al., 2000) and shown to display ß-secretase activity (Farzan 
et al., 2000).
The enzyme responsible for the carboxy-terminal cleavage of Aß has gained most 
attention from the pharmacological point of view, since this is the final cleavage 
event that releases Aß. But the cleavage activity of this secretase (g-secretase) is 
more complex than that of the other secretases in that it generates Aß with 
heterogeneous C-termini and because it has to recognize and cleave the APP 
within its transmembrane region (Glenner and Wong, 1984a; Haass et al., 1992; 
Kang et al., 1987; Shoji et al., 1992). By peptidomimetic probes and molecular 
modeling, it has been suggested that g-secretase is an intramembrane-cleaving 
aspartyl protease (Wolfe et al., 1999b). Phenylalanine-scanning mutagenesis of 
the transmembrane domain of APP provided a model for the active site for the g- 
secretase, suggesting that g-secretase interacts with A4CT by binding to one side
17
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of the a-helical transmembrane domain of A4CT. Mutations in the 
transmembrane region of A4CT (for instance the Dutch mutation) interfere with 
the interaction between g-secretase and A4CT, in that way altering the specificity 
of g-secretase (Lichtenthaler et al., 1999). This intramembranous processing event 
has now also been observed in the sterol regulatory element binding protein 
(SREBP) (Brown and Goldstein, 1997) and in the Notch-1 protein (Schroeter et 
al., 1998). Although the discussion concerning the identity of the g-secretase is 
still ongoing, it appears that presenilin is in some way part of the cleavage 
process. Presenilins are involved in the cleavage of APP and Notch-1 (Annaert et 
al., 1999; De Strooper et al., 1999; Octave et al., 2000; Struhl and Greenwald, 
1999; Ye et al.,, 1999) by either only modulating the activity of g-secretase or 
being the g-secretases themselves (De Strooper et al., 1999; Kimberly et al., 2000; 
Li et al., 2000; Russo et al., 2000; Wolfe et al., 1999a-1999c). PS1 knockout mice 
result in a technical knockout for Aß with an accumulation of C83 and C99, the 
substrates for g-secretase, indicating that presenilin influences g-secretase activity 
(De Strooper et al., 1998). PS1 knockout cells have also increased levels of APP 
cleavage products, secretion of APP, and APP C-terminal fragments, but reduced 
secretion of Aß. Furthermore, the loss of PS1 prevents protein kinase C or 
extracellular regulated kinase from increasing the production of the APP cleavage 
products, a response that can be restored via transfection of PS1 (Palacino et al., 
2000). In presenilin, two transmembrane aspartates (in TM6 and TM7) have been 
identified to be required for presenilin endoproteolysis, g-secretase activity and 
Aß generation (Kimberly et al., 2000; Wolfe et al., 1999a-1999c) and PS1 
mutations affect the activity of both ß- and g-secretase (Russo et al., 2000). 
However, direct proof that presenilins possess proteolytic activity is still not 
available, although a study using photoactivated g-secretase inhibitors suggests 
that PS1 may contain the active site of g-secretase (Li et al., 2000). In conclusion, 
presenilins are somehow linked to g-secretase activity, but the discussion 
concerning the exact role of presenilins in the generation of g-secretase activity 
remains.
Presenilins
The PS1 gene comprises 10 coding exons and encodes a 467 amino acid protein 
(Cruts et al., 1996; Sherrington et al., 1995). The exons have been numbered 4-13, 
because three additional exons have later been identified in the 5’ untranslated 
region (UTR), of which the first two can be transcribed alternatively (Sherrington
18
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et al., 1995). The transcription of the PS1 gene is driven by two alternative 
promoters producing transcripts with different 5’UTRs (Rogaev et al., 1997). Two 
polyadenylation signals can be used resulting in transcripts of 2.7 and 7.5 kb 
(Rogaev et al., 1997) and several alternatively spliced variants have been reported 
for PS1. Transcripts lacking exon 8 have been observed only in leukocytes 
(Sherrington et al., 1995)., Like PS1, PS2 contains 10 coding exons, but only 2 
exons were identified in the 5’UTR (Levy-Lahad et al., 1996). Two PS2 gene 
transcripts of 2.4 and 2.8 kb can be generated, and alternative splicing occurs in 
the same way as described for PS1. But in addition to a gene transcript lacking 
exon 8, a PS2 mRNA lacking exons 3 and 4 has been identified (Prihar et al., 
1996). Since exon 3 contains the start codon, the latter transcript is predicted to be 
translated from an alternative translation initiation codon.
PS1 encodes a multispanning integral membrane protein with six to nine 
predicted transmembrane (TM) domains (Sherrington et al., 1995). At the amino 
acid level, PS1 is 67 % identical to PS2, and the two proteins share the predicted 
overall serpentine structure (Levy-Lahad et al., 1995a-b; Rogaev et al., 1995). 
The presenilins do not contain a signal peptide, and the hydrophilic amino- 
terminal protrudes into the cytoplasm. A second hydrophilic domain, between TM 
6 and 7, and the relatively hydrophobic carboxyl-terminal tail also protrude into 
the cytoplasm (De Strooper et al., 1997; Doan et al., 1996; Li and Greenwald
1996). Although the proposed structure implies eight transmembrane domains 
(Doan et al., 1996; Li and Greenwald 1996-1998), alternative models for the 
insertion of presenilins into biological membranes are possible (Lehmann et al.,
1997). Presenilin proteins have been localized to the endoplasmic reticulum (ER) 
and the Golgi (De Strooper et al., 1997; Kovacs et al., 1996; Walter et al., 1996). 
The finding of overexpressed presenilin proteins in the Golgi must be interpreted 
with caution, since recent research indicates that proteins with many 
transmembrane domains can accumulate in structures called aggresomes. These 
cytoplasmic structures merely reflect cell stress and overloading of the 
proteasome compartment (Johnston et al., 1998).
Caspases
A prominent feature of AD is the loss of hippocampal neurons caused by 
apoptotic cell death (Smale et al., 1995; Cotman and Su, 1996; Li et al., 1997; Su 
et al., 1997). When the death switch is triggered, the suicide program will be 
activated. Among the most prominent death-specific enzymes is a family of 
cysteine-dependent aspartate-specific proteases, the so-called caspases (Wolf and
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Green, 1999). These enzymes can be divided into two groups: the initiator 
caspases (like caspase-8 and caspase-9) whose main function is to activate 
downstream caspases, and executor caspases (such as caspase-3, -6 and -7), that 
are responsible for dismantling cellular proteins.
Caspases recognize four amino acid residues as their target and cleave C-terminal 
of an obligatory aspartic acid (XXXD). Based on their specific substrates, 
caspases have been subdivided in three classes: group I (caspase-1, -4, and -5; 
target: WEHD or YVAD), group II (caspase-2, -3, -7, and -10; DEXD) and group 
III (caspase-6, -8, and -9; (I,V,L)EXD) (Thornberry et al., 1997). The activation 
of the proenzyme form of a caspase is a key determinant of apoptotic function 
(Alnemri, 1997). The role of caspases in neuronal cell death is evident in 
developmental and injury-mediated neuronal apoptosis of the peripheral and 
central nervous systems. Caspase-3 and possibly caspase-2 play a role in 
developmental neuronal cell death (Kuida et al., 1996; Kumar et al., 1994; 
Srinivasan et al., 1998).
APP itself has been shown to be a substrate for the caspases: it can be cleaved at 
the endogenous caspase consensus sites DNVD197(P1)/S, DYAD219(P1)/G and, 
predominantly, VEVD664(Pi)/A (Gervais et al., 1999; LeBlanc et al., 1999; 
Pellegrini et al., 1999; Weidemann et al., 1999). These cleavages probably 
prevent the normal intracellular processing of APP that would otherwise preclude 
it from Aß peptide formation or accumulation (Gervais et al., 1999). It is unclear 
whether caspase-3, -6, or -8  is the main mediator of these cleavages. Aß has been 
shown to be capable to induce apoptosis and activate caspases (Loo et al., 1993). 
The caspases can on their turn cleave APP, releasing Aß, which activates 
downstream caspases, including caspase-3 (Gervais et al., 1999) and possibly 
caspase-12 to enhance the effects, since caspase-12 deficient cortical neurons are 
defective in apoptosis induced by Aß (Nakagawa et al., 2000). Caspase-12 is a 
recently identified caspases hiding in the ER and responsible for mediating ER- 
specific apoptosis (Nakagawa et al., 2000). Caspases may thus play an important 
role in the production of the neurotoxic Aß peptide and in AD in the ultimate 
death of neurons by apoptosis. Which caspases are exactly involved remains to be 
established.
Age-related frameshift mutations
An exciting new view on the cause of the development of age-related diseases has 
recently been proposed. This view was based on an earlier observation by 
Richards et al. (1985) in adult di/di Brattleboro rats, suffering from diabetes
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insipidus due to a single-base deletion in the vasopressin gene. Surprisingly, in 
these rats solitary neurons immunoreactive for wild-type vasopressin and an age- 
related reversion to a hemizygous wild-type vasopressin peptide phenotype were 
found (Richards et al., 1985; Van Leeuwen et al., 1989). Analysis of polymerase 
chain reaction (PCR) products generated from hypothalamic cDNA led to an 
explanation of the revertant peptide phenotypes, namely an age-related 
dinucleotide deletion in the vasopressin transcript (Evans et al., 1994; 1995). This 
mutation restored the normal reading frame, resulting in the production of wild 
type vasopressin in solitary neurons. The deletion (DGA) occurred at the mRNA 
level at two specific hotspots within GAGAG motifs that were downstream of the 
initial one-base deletion in the gene. The mutation was also found in a small 
percentage of the wild type vasopressin transcripts, generating a truncated protein 
with an altered carboxy-terminal region. On the basis of these findings the 
hypothesis was put forward that this kind of mutation might also occur in other 
transcripts, and in other species e.g. in transcripts involved in human aging and 
age-related diseases.
Internal initiation of translation
As mentioned above, Aß is generally accepted as a key-peptide in AD. To obtain 
Aß, APP has to be processed by ß-and g-secretases. The fact that Aß is 
continuously produced and secreted at low levels has led to the suggestion that it 
can arise by internal initiation of translation at the Met596 codon, explaining a 
continuous low level production of Aß (Breimer and Denny, 1987). The 
nucleotide sequence surrounding the Met596 codon (GAAAGATGG) is a good 
initiation region by Kozak’s hypothesis (CAg/a AGATGG; Kozak 1989). To test 
the hypothesis of internal initiation of translation, Citron et al. (1993) have used 
an in vitro model of Aß production and secretion (Haass et al., 1992). Frameshift 
mutations were engineered in APP6 9 5  cDNA by inserting or deleting a single 
nucleotide, 10 or 5 nucleotides in front of the codon for Met596, such that only 
internal initiation of translation would generate Aß. However, no Aß was detected 
and thus no evidence for internal translational initiation was found.
The carboxy-terminal product resulting from processing of APP by ß-secretase is 
the same as the one that would be produced by internal initiation at Met596. This 
product (A4CT), rather than APP itself, has been extensively used for the 
enzymatic characterization of g-secretase, since it does not involve the need of an 
additional cleavage by ß-secretase. Studies on A4CT have shown that this protein 
is produced, processed to Aß and transported through axons but, when inserted
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into the membrane, no amyloidogenic properties were found (Dyrks et al., 
1988/1992a-b/1993a-b; Lichtenthaler et al., 1999a-b; Shoji et al., 1992; Tienari et 
al., 1996). Transgenic mice expressing A4CT show impaired learning, deficits in 
maintenance of long-term potentiation and extracellular Aß immunoreactivity in 
brain cells (Nalbantoglu et al., 1997). These results indicate that formation of 
A4CT, either via processing or via internal initiation, can contribute to Aß­
generation.
Xenopus laevis as a model system
The clawed toad Xenopus laevis is the only non-mammalian species in which 
APP has been cloned. This animal provides us with a model system with 
potentials to gain more insight into the physiological function of APP. Xenopus is 
namely capable of adapting the color of its skin to the background. When adapted 
to a black background, the melanotrope cells in the intermediate pituitary are 
highly active in producing and secreting peptide hormones, while the cells are in 
an inactive state during adaptation to a white background (Jenks et al., 1993). The 
prohormone synthesized by the melanotrope cells is proopiomelanocortin 
(POMC). POMC is the prohormone for a-melanophore-stimulating hormone (a- 
MSH), a hormone that stimulates the dispersion of the black pigment melanin in 
the skin melanophores causing a darkening of the animal. In the melanotrope 
cells, an elevated level of a-MSH is accompanied by a higher rate of POMC gene 
transcription (Martens et al., 1987; Ayoubi et al., 1991). Differential screening of 
an intermediate pituitary cDNA library of black-background adapted Xenopus 
allowed the identification of genes whose transcripts parallel that of POMC 
during background adaptation, one of which was identified as APP (Holthuis et 
al., 1995). We reasoned that it could be of great interest to investigate the 
expression levels of APP in the active and inactive Xenopus melanotrope cells. 
An increase in the levels of APP has been proposed to underly AD, e.g. patients 
suffering from Down’s syndrome (DS), who are carrying an extra copy of the 
APP gene (Delabar et al., 1987), show the same neurodegenerating characteristics 
as patients suffering from AD.
Aim and outline of this thesis
The purpose of the research described in this thesis was to provide more insight 
into the molecular events underlying the neurodegenerative disorder AD. Several 
molecular and cell biological aspects of this disorder have been investigated from
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different points of view. Chapters 2, 3 and 4 focus on the occurrence of frameshift 
mutations in transcripts derived from patients that had suffered from AD or DS, a 
process referred to as molecular misreading. Chapter 2 reveals the presence of 
dinucleotide deletions at GAGAG-motifs in AD and DS transcripts encoding APP 
and the cytoplasmic garbage-protein ubiquitin-B (Ubi-B), resulting in the 
production of so-called +1-proteins (A PP 1 and Ubi-B+1, respectively). In chapter
3, human neuroblastoma cells are stably transfected with Ubi-B+1 to investigate 
the effects of overexpression of this aberrant protein. We could show in vitro that 
Ubi-B+1 was unable to ubiquitinilate proteins, but under the transfection 
conditions used no effect on cell proliferation and morphology was observed and 
only a minor effect on protein degradation was detected. Chapter 4 presents a 
sensitive bacterial expression system that has been developed to illuminate 
frameshift mutations in AD-related transcripts at locations other than the 
GAGAG-motif, showing that molecular misreading is a widespread phenomenon 
occurring in close proximity of short simple repeats.
In chapter 5, the process of internal translational initiation in APP transcripts has 
been investigated. This chapter describes the use of enhanced green fluorescent 
protein as a marker-protein for the determination of internal initiation. We found 
that in exon 9 of the APP gene a methionine can be used as initiation site. An 
alternative way to generate Aß can be via internal initiation at Met695, which 
results in the production of A4CT. Furthermore, we performed transfection 
studies to investigate the biosynthesis of A4CT. We were able to show that A4CT 
is recognized by g-secretase and can be processed to A ß.
The last three chapters (6, 7, 8) focus on the expression, tissue-distribution and 
biosynthesis of APP in the clawed toad Xenopus laevis. In chapter 6, the 
developmental expression of the isoforms of APP is studied. APP is present 
throughout all developmental stages, showing expression of APP695 
predominantly in the brain, APP751/770 in non-neuronal tissues and a new APP- 
product of 70 kD, presumably derived from processing of APP, in peripheral 
tissues such as heart, liver and kidney, suggesting a role for APP during early 
development of Xenopus laevis. Since Xenopus laevis is a tetraploid organism, 
two structurally different APP-genes will likely be present in Xenopus. In chapter 
7, the cloning and sequence analysis of both gene transcripts are described, 
together with the tissue-distribution of the alternatively spliced variants of APP. 
The APP protein and its expression pattern are shown to be remarkably conserved 
throughout evolution from amphibian to mammals. In chapter 8, the expression of 
APP in the intermediate pituitary of Xenopus laevis is described. We were able to 
show a threefold up-regulation of APP at the RNA -and protein-level and a
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different intracellular localization of APP in the melanotrope cells of black- vs 
white-adapted animals, suggesting a role for APP in cell (in)activation.
Finally, in the general discussion (chapter 9) the relevance of frameshift 
mutations and internal translational initiation for the development of AD are put 
in a broader perspective. Furthermore, based on our studies in Xenopus pituitary, 
the possible physiological role of APP is discussed.
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Frameshift mutations in APP and Ubiquitin-B gene transcripts
Abstract
The cerebral cortex of Alzheimer and Down patients is characterized by the presence 
of protein deposits in neurofibrillary tangles, neuritic plaques and neuropil threads. 
Here, these structures were shown to contain COOH-terminally aberrant forms (+1 
proteins) of â amyloid precursor protein and of ubiquitin-B. The +1 proteins were not 
found in young control patients, while the presence of ubiquitin-B+' in aged controls 
may have indicated early stages of neurodegeneration. The two species o f+1 proteins 
displayed cellular colocalization, suggesting a common origin, operating at the 
transcriptional level or by posttranscriptional editing of RNA. This type of transcript 
mutation is likely to be an important factor in the widely occurring non-familial early 
and late onset forms of Alzheimer's disease.
Introduction
In Alzheimer's disease (AD) and Down's syndrome (DS) intracellular and 
extracellular deposits of proteins in tangles, neuropil threads and neuritic plaques are 
correlated with neuronal dysfunction leading to dementia (Terry, 1994). Especially the 
familial types of AD have been investigated thoroughly and are due to mutations in 
genes located on chromosome 1, 14 and 21, and the Apo-E genotype (chromosome 
19) is a risk factor (Hardy, 1997). However, at least 60% of AD patients do not have a 
family history of the disease (Van Broeckhoven, 1995; Tanzi et al., 1996). For these 
frequently occurring sporadic cases a more general mechanism must exist, ultimately 
leading to neuronal degeneration.
mRNA editing is a means of producing phenotypic variability (Sommer et al., 1991; 
Simpson and Emeson, 1996). Moreover, we have identified another type of mutation 
in vasopressin-transcripts (Evans et al., 1994). Homozygous Brattleboro rats have a 
single base deletion in the vasopressin-gene and newborn rats do not have a 
functional vasopressin-mRNA and -protein. Surprisingly, functional RNA and protein 
are found in a small but increasing proportion of hypothalamic cells as the animals 
age (Van Leeuwen et al., 1989). This apparent reversion is due to a dinucleotide 
deletion (ÄGA) within GAGAG motifs of the mutant RNA (Evans et al., 1994). Thus 
genetic information in neurons is not stable, but subject to modification through an as 
yet unknown mechanism. We surmised that the opposite process may take place in 
other neuronal genes resulting in mutant transcripts from wild-type genes and so 
looked for dinucleotide deletions in two genes associated with the pathogenesis of 
AD. The genes encoding â amyloid precursor protein (APP) and ubiquitin-B (Ubi-B)
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(Terry, 1994; Perry et al., 1989) each contain several GAGAG motifs. In this study 
we have developed and used an immunoscreening strategy to identify frameshift 
mutations near GAGAG-motifs in APP and Ubi-B gene transcripts.
Materials and Methods
Human brain material
Paraffin-embedded and frozen brain material of the cerebral cortex, that is orbitofrontal cortex 
(area 11), temporal pole (area 38) and hippocampus of non-demented control (n=12), AD 
(n=21) and DS (n=7) patients, was obtained from the Netherlands Brain Bank (coordinator 
Dr. R. Ravid). Informed consent was obtained after the nature and possible consequences of 
the studies had been explained. All brains were neuropathologically diagnosed (for details see 
www.nih.knaw.nl). The cases were matched for age, sex, postmortem delay and fixation 
duration. The Brain Bank also supplied the substantia nigra and striatum of 11 Parkinson 
patients of whom only one patient displayed AD neuropathology as well (male, 72 years).
Antibodies
The +1 peptides (Figure 2-1A) were coupled with glutaraldehyde to thyroglobulin, mixed 1:1 
with complete Freunds adjuvant and injected once both intramuscularly and subcutaneously. 
No homology was found for these peptide sequences in the EMBL database. The affinities 
were evaluated on nitrocellulose paper with antigen spots and on tissue sections.
Immunocytochemistry
Six-mm paraffin sections were deparaffinized, treated in 100% formic acid for 30 min and 
incubated overnight at 4°C with rabbit antibodies raised against APP+1 and Ubi-B+1 (Figure 2­
1). Antibodies recognizing the more NH2-terminal parts of wild-type sequences were used as 
well. These include Ubi-B 3-39 (Morishima-Kawashima et al., 1993), recognizing residues 
50-65, and APP (#22C11), recognizing residues 66-81 (Hilbich et al., 1993). Furthermore, +1 
reading frame antisera against parts of exon 14 (RSPAVAFFWG) and exon 18 
(HSSWCGGG) of APP were raised. In addition, a +2 reading frame antiserum of exon 17 
(LDSWWAVLG) was raised. The APP+1 and Ubi-B+1 antibodies were diluted 1:250 and 
1:400, respectively. The peroxidase-antiperoxidase method was followed (Jin et al., 1994). In 
some patients the APP+1 and Ubi-B+1 immunolocalizations were matched with Bodian silver, 
Alz-50 and MC-1 staining (Jicha et al., 1997).
Controls
When sections were incubated with preimmune serum and with antiserum absorbed with the 
specific antigen, no staining was seen.
Immune blotting
A small piece (~0.1 g) of frozen temporal lobe, frontal lobe or hippocampus was 
homogenized in 0.5 ml of 100% formic acid. The proteins were extracted from the dried 
samples by boiling for 10 min in 200 ì l  10% SDS. The extract was loaded on a 12.5% SDS- 
polyacrylamide gel, transferred onto nitrocellulose and, after an overnight fixation in 5%
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formaldehyde, probed with rabbit antisera generated against APP+1 and Ubi-B+1 (Figure 2-1). 
Additionally, antisera were used recognizing residues 229-252 of the N-terminus of APP 
(#3H5: Philippe et al., 1993) and residues 50-65 of Ubi-B (#3-39; Morishima-Kawashima et 
al., 1993). As a positive control wild-type of APP+1 and Ubi-B+1 proteins were expressed in 
stably transfected AtT20 cells and in bacteria (M15 (pREP4)), respectively. AtT20 cells were 
stably transfected with APP+1 pcDNA3 via electroporation at 260 V and 170 micro F. 
Resistant clones were expanded and assayed for expression of APP+1 after the formic acid 
treatment.
RT-PCR and immunoscreening o f APP and Ubi-B cDNA
Pieces of frozen human frontal and temporal cortex or hippocampus (CA1, subiculum) (~0.1 
g) were homogenized in 1 ml Trizol (GIBCO, BRL) and total RNA was isolated according to 
the manufacturer’s instructions. Two ì g of total RNA was primed with random hexamers and 
reverse transcribed with Expand reverse transcriptase. Using the Expand™ High Fidelity PCR 
system (Roche) APP cDNA was amplified (fragment 897-1405 of Y00264: 5' primer 
GCGGGATCCTGGTGATGAGGTAGAGGAAGAGGCT and 3' primer CTTACATACAA- 
GCTTAGCATATTGAACACGTGACGAGGCC and Ubi-B cDNA was amplified (fragment 
1094-1765 of X04803: 5' primer GGGGATCCGGTCAAAATG- CAGATCTTCGTGAAA 
and 3' primer AGAAGAAGCTTTTAACAGCCACCCC- TCAGG. The cycle temperature and 
timing were: APP+1 92°C, 30 sec; 62°C, 30 sec; 72°C, 40 sec (30 cycles) and Ubi-B+1, 92°C, 
30 sec, 64°C, 30 sec; 72°C, 40 sec (40 cycles). For both PCRs in the last cycle the extension 
was carried out for 7 minutes. The amplification products were digested with BamHI and 
HindIII and cloned in frame in the expression vector pQE-31. Bacterial clones were screened 
for mutant proteins with APP+1 and Ubi-B+1 antibodies (Evans et al., 1994). Immunopositive 
clones were isolated and their inserts were sequenced using Sequenase version 2.0 (USB, 
Cleveland, OH), using 35S-labeled deoxyadenosine triphosphate (dATP).
In situ hybridization
Six-mm paraffin sections were deparaffinized, rehydrated and deproteinated for 20 min with 
0.2 M HCl followed by a 15 min treatment with proteinase K. The sections were again 
dehydrated, delipidated by a 5 min treatment with chloroform, rehydrated and incubated for 
20 min in 0.1 M phosphate-buffered saline / 0.1% v/v Triton-X-100. Sections were 
prehybridized with hybridization buffer (30% formamide, 0.1 M NaCl, 5x Denhardt’s, 10 mM 
Tris/HCl, pH 7.5, 1 mM EDTA 10% dextran sulphate 50 mM DTT) containing 100 mg/ml 
ssDNA and 500 mg/ml tRNA for 1 h at room temperature. To detect the APP mutant mRNA a 
20-mer oligonucleotide complementary to the APP-mRNA containing the GA deletion in 
exon 9 at position 1130 (5'-GGGACATTCTCTCGGTGCTT-3', corresponding to nucleotides 
1123-1144) was labeled at the 3'-end using terminal deoxynucleotidyl-transferase (Roche) and 
35S-labeled dATP (NEN/Dupont, Boston, MA) to provide an average tail length of five 
nucleotides (data not shown). To detect the Ubi-B mutant mRNA a 20-mer oligonucleotide 
complementary to the Ubi-B mRNA containing the GT deletion at position 1317 (5'- 
CGCAGACTCTCCCATACGTC-3', corresponding to nucleotides 1307-1327) was similarly 
labeled. The labeled probes were applied to the sections at a concentration of 107 counts/ml 
hybridization buffer (APP+1: 30% formamide, 0.0125 M NaCl, 5x Denhardt’s, 10 mM 
Tris/HCl, pH 7.5, 1 mM EDTA, 10% dextran sulphate 50 mM DTT; Ubi-B+1: 30% 
formamide, 0.025 M NaCl, 5x Denhardt’s, 10 mM Tris/HCl, pH 7.5, 1mM EDTA, 10% 
dextran sulphate 50 mM DTT). The sections were incubated under stringent conditions
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overnight in a humid chamber; APP+1 at 38.5°C (hybridization at Tm+15°C) and Ubi-B+1 at 
40.5°C (hybridization at Tm +10°C). Slides were washed once at 55°C in 1x standard sodium 
citrate (SSC) followed by two washings at 55°C in 0.3xSSC. Sections were dehydrated in 
graded ethanols containing 300 mM ammonium acetate and after drying dipped in NTB-2 
photoemulsion (Kodak). After two weeks the sections were developed, counterstained with 
hematoxylin, dehydrated and mounted.
Genomic PCR
To check if the dinucleotide deletions in APP and Ubi-B occur in the genome or exclusively 
during transcription we pursued two strategies: I) genomic PCR with intron primers followed 
by immunoscreening and II) genomic PCR with a 5' primer that hybridizes only to the 
complementary DNA template with the mutation, and thus can discriminate between the wild 
type gene and the mutated gene. I) Genomic DNA was isolated from frozen human brain 
tissue and amplified with the Expand™ High Fidelity System (Roche) by using PCR primers 
recognizing intron sequences adjacent to exon 9 and exon 10 of APP (5' primer, exon 9, 5'- 
GCGGATCCCCTCCTTCTCTTCTACT-TTATAG-3' and 3' primer, exon 9, 5'- 
AGGGGAGC-TCGATGGAAGAGCCAGAC-TTAC-3'; 5' primer, exon 10, 5'- 
AAATTCAAGAGCTCCCT-TTATTTATTGGTC-3' and 3' primer, exon 10, 5'- 
TGTTAAGCTTGAAATGGGTTCAGGTT-TTAC-3'). The PCR products were cloned in 
frame in the BamHI and SacI sites (exon 9) or in the SacI and HindIII sites (exon 10) of the 
expression vector pQE-31. Ubi-B was amplified with a 5' primer recognizing the intron 
sequence adjacant to the startcodon (5'-AGAAGAAGCTT-TTAACAGCCACCCCTCAGG, 
corresponding to nucleotides 1765-1783) and 3' primer recognizing the exon sequence (5'- 
GGGGATCCGGTCAAAATGCAGATCTTCGT-GAAA-3'). The cycle temperature and 
timing were: APP+1 (exon 9) 92°C, 30 sec; 50°C, 30 sec; 72°C, 40 sec (40 cycles) and Ubi- 
B+1, 92°C, 30 sec; 55°C, 30 sec; 72°C, 40 sec (40 cycles). For both PCRs in the last cycle the 
extension was carried out for 7 min. The Ubi-B fragment was digested with BamHI and 
HindIII and cloned in frame in PQE31 expression vector mentioned above. Bacterial clones 
were screened for the production of recombinant proteins as described above. With this 
method we were able to detect ten copies of plasmid DNA containing the dinucleotide 
deletion of APP in of a background of 100,000 copies of wild type APP-DNA.
II) Genomic DNA isolated from frontal cortex of frozen brain material from AD, DS and 
control patients was amplified by using a 20mer primer complementary to the APP-gene 
containing a GA deletion in exon 9 at position 1135 (5' primer, 5'-AGGCCAAGCACC- 
GAGAGAAT-3', corresponding to nucleotides 1110-1138) and an intron primer (3' primer, 5'- 
CTGTGGGGAG-ACTGAGGCAG-3') hybridizing to the exon 9 adjacent intron sequence. 
For the mutant Ubi-B-gene with a GT deletion in the first repeat we have chosen an 
appropriate primer (5' primer, 5'-GGTCCTGCGTCTGAGAGGGT-3', corresponding to 
nucleotides 1300-1321) and a 3' primer hybridizing downstream to the polyA signal (3' 
primer, 5'-GCGTA-CCCACACATCACTAG-3', corresponding to nucleotides 1973-1954). 
Genomic DNA (0.5 ì g) was ampified by PCR with Goldstar DNA Polymerase (Eurogentec) 
in 0.3 M Tris-HCl, pH 9.5, 10 mM dNTPs, 35 pmol of each primer, 7.5 mM MgCl2 and 75 
mM ammonium sulfate. The cycle temperature and timing were as follows: 93°C, 1 min; 
56°C, 1.5 min (35 cycles). In the last cycle the extension was carried out for 10 min. PCR 
products were checked on a 2% agarose gel (for details see Glisic and Alavantic, 1996).
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Results and Discussion
In APP-mRNA, seven GAGAG motifs are present in regions corresponding to exons
4, 6, 9, 10 and 14. Because in exons 9 and 10 three motifs were clustered, this part of 
the transcript, encoding a putative growth-promoting domain (Jin et al., 1994), was 
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Figure 2-1
(A) Partial nucleotide and amino acid sequences of APP and Ubi-B expressed in the wild type (wt) and +1 reading 
frame (+1 protein). Boxed nucleotides represent GAGAG and CTCT motifs. Peptide sequences printed in bold italic 
were used for immunization. Against Ubi-B+1 two antibodies were raised (Y-Q and R-Q, respectively Ubi-B1  and 
Ubi-B2, indicated by lines). (B) sequence gels showing a GA deletion in APP-transcripts (exon 9 and exon 10), and a 
GT and CT deletion in Ubi-B transcripts. (C) Colocalization of Ubi-B+1 mRNA (a) in Ubi-B+1 immunoreactive cells 
(b) in the temporal cortex of an AD patient. In (a) the section was counterstained with hematoxylin. Bar = 10 ìm. 
Immunoblots showing (c) an intense immunoreactive band at 38 kDa with the APP+1 antibody in the temporal cortex 
of a DS patient, (d) the same band stained with an NH2-terminal APP-antibody (#3H5), and (e) the frontal cortex of a 
young control, in which no reaction was visible. In (d) the 38 kDa band is shown but in the absence of prior immuno- 
precipitation, degradation products of APP were detected as well.
a
I
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selected for the detection of a +1 frameshift mutation resulting in truncated APP 
(APP+1) with a novel COOH-terminus (Figure 2-1A). In two of the three repeats of 
Ubi-B mRNA a single GAGAG motif is present (Figure 2-1A). The predicted +1 
frameshift results in an aberrant COOH-terminus of Ubi-B of the first or second 
repeat (Ubi-B+'). As a result, the glycine moiety essential for multi-ubiquitinilation 
(Morishima-Kawashima et al., 1993) would be lacking. To examine the occurrence of 
the predicted +1 proteins, antibodies
against the novel COOH-terminus of APP+1 and Ubi-B+' were generated and used to 
evaluate the presence of the abnormal proteins in tissue sections of cerebral cortex of 
AD, DS and control patients by immunocytochemistry and immune blot analysis, and 
to assess reading frame mutations by selecting cDNA clones expressing +1 
immunoreactivity.
Immunoreactivity for APP+1 and Ubi-B+' was prominent in early and late onset AD 
cases and even more prominent in DS compared to controls matched for age, sex, 
postmortem delay and duration of fixation (Figure 2-2, 2-3; Table 2-1; see also 
www.nih.knaw.nl).
When the three brain areas studied are taken together, APP+1 immunoreactive 
structures were present in 71% and Ubi-B+1 in 100% of the AD patients. In young 
controls and one non-demented DS patient devoid of neuropathology in the frontal 
and temporal cortex and hippocampus, no Ubi-B+1 immunoreactivity was found.
Figure 2-2
Neuritic plaques.
APP+1 (A,B) and Ubi-B+1 (C) immunoreactivity in the frontal cortex of an AD patient is present in neuritic plaques. In 
(A) neuropil threads can be seen (arrowheads), s = sulcus. In (B) and (C) a higher magnification shows immuno- 
reactivity in dystrophic neurites and neuropil threads (arrowheads). The core of the plaques is unstained as seen in (B) 
and (C). Ubi-B+1 immunoreactivity was obtained with two different antibodies (that is Ubi-B1 and Ubi-B2) Ubi-B2  was 
most immunoreactive and used for all immunohistochemistry.
34
Frameshift mutations in APP and Ubiquitin-B gene transcripts
Figure 2-3
Neurofibrillary tangles.
Ubi-B+1 (D-F) and APP +1(G,H) immunoreactivity in tangle shaped structures in the temporal (D) and frontal (E­
G) cortex and hippocampus, CA1 area (H) of two different AD patients (D) and (E-G). Neuropil threads are 
indicated with arrowheads. Bar in A,D = 50 ì, in B,C,E-H = 20 ìm.
When Ubi-B+' immunoreactivity was found in aged non-demented controls (>72 
years), their neuropathological diagnosis revealed the presence of some plaques and 
tangles. Furthermore, no APP+1 and Ubi-B +1 immunoreactivity was found in the 
substantia nigra and striatum of11 patients suffering from Parkinson's disease, except 
for the striatum and temporal cortex of one patient with AD neuropathology. In the 
frontal and temporal cortex and the hippocampus of AD cases and DS patients, both 
APP+1 and Ubi-B+' immunoreactivity was present in neurofibrillary tangles, neuropil 
threads and dystrophic neurites (Figure 2-2, 2-3). In many cases APP+1 and Ubi-B+' 
immunoreactivities coexisted (Figure 2-4A,B) in neurons located especially in layers 
2, 3 and 5 (Figure 2-2A, 2-3A). The APP+1 or Ubi-B+' immunoreactive tangles and 
neuropil threads formed a considerable subpopulation of classical Bodian silver and 
Alz-50- or MC-1-stained neuropathological structures (Figure 2-4C-F). The presence 
of APP+1 and Ubi-B+' in a subpopulation of Alz-50 or MC1 immunoreactive neurons 
excludes the possibility that they crossreact with hyperphosphorylated tau protein. In a 
subpopulation of the wild type APP and Ubi-B immunoreactive neurons, 
accumulation of APP+1 and Ubi-B+' immunoreactivity was found in neurofibrillary 
tangles. APP +1 immunoreactivity was often found in restricted areas of the sections, 
whereas Ubi-B+1 immunoreactivity was distributed
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Table 2-1. Immunoreactivities in the human frontal and temporal cortex and hippocampus for â amyloid precursor 
protein and ubiquitin-B of which the mRNA is expressed in the +1 reading frame (resulting in APP+1 and Ubi-B+1 
protein). Tissues were obtained from controls and neuropathologically confirmed Alzheimer and Down syndrome 
cases (see ww.nih.knaw.nl). Immunoreactivity present in tangles, dystrophic neurites and neuritic plaques of 
patients is expressed as a percentage of the total number of patients studied.
Disease
frontal cortex 
(area 11)
tem poral cortex 
(area 38)
hippocam pus
APP*1 Ubi-B*1 APP*1 Ubi-B*1 APP*1 Ubi-B*
Nondemented controls* (n=12) 0 0 0 8* 0 50*
AD** (n=21) 19 80 43 95 50 95
DS (n=7) 86 86 86 86 71 86
*: Young (n=6) and elderly (n=6) nondemented controls. Controls were matched for sex, age and postmortem 
delay.
¥ in old non-demented patients with age related neuropathology (tangles, plaques)
¥¥early- (<65 years, n=10) and late-(>65 years, n=11) onset AD.
much more widely throughout the section and present in a higher percentage of AD 
patients. In the hippocampus, intense APP+1 and Ubi-B+1 immunoreactivities were 
prominent in neurofibrillary tangles present in pyramidal cells of CA1 (Figure 2-3E) 
and the subiculum, whereas in the more intensely stained cases immunoreactivity was 
frequently seen as cytoplasmic staining in CA4, CA3, CA2 and hilus. In the 
enthorhinal cortex tangle staining was often observed in the pre-á layers and 
concentrated in cellular islands (Braak et al., 1996). To characterize the 
immunoreactive products detected in immunocytochemistry by molecular size, 
immunoblots of homogenates of the temporal cortex of AD and DS patients revealed 
the presence of immunoreactive proteins with sizes (38 kDa for APP+1 (Figure 2-1C) 
and 11 kDa for Ubi-B+' ; data not shown) predicted by the open reading frames of 
transcripts with a dinucleotide deletion. In young nondemented controls, 
these +1 protein bands were absent. The eukaryotically (APP+1) or bacterially 
expressed (Ubi-B+') recombinant proteins corresponding to the +1 mutant proteins 
served as positive controls (data not shown). Antibodies directed against wild-type 
sequences of APP (Figure 2-1C) and Ubi-B located in the unaffected region NH2- 
terminally of the COOH terminus with the +1 reading frameshift revealed bands of 
the same size.
Pre-immune and solid-phase adsorbed antisera showed no reaction in paraffin sections 
or immune blots. In contrast to the APP+1 antibody against a region in exons 9 and 10, 
two APP+1 antisera directed against regions of exons 14 and 18 and an APP+2 
antiserum (part of exon 17) did not display immunocytochemical staining in any of 
the sections
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Figure 2-4
Colocalization of APP+1 (A,C,E) and Ubi-B+1 (B) immunoreactivity, and with Bodian (D) and Alz-50 (F) stained 
cell bodies (large arrowheads) and subiculum (E,F) in consecutive sections of the frontal cortex (A-D) of an AD 
patient. Note in E,F that Alz-50 stains neurons and neuropil threads more abundantly). Small arrowheads: Alz-50 
positive, APP+1 negative neurons. * = capillary. Bar in A-F = 20 ìm.
positive for APP+1 .In order to establish the nature of the mutations resulting in the 
truncated APP+1 and modified Ubi-B+: proteins, cDNAs generated by PCR were 
cloned into an expression vector. Immunoscreening of RT-PCR products generated 
from APP-cDNAs of young and aged AD and DS patients and subsequent sequencing 
of immunopositive clones revealed that in all AD and DS cases examined a GA 
deletion was present in either exon 9 or exon 10 (Figure 2-1B; Table 2-2). In exon 9 a 
higher frequency of mutations was found than in exon 10. In one AD patient GA 
deletions were found in both exon 9 and 10 in separate mRNA molecules. No 
immunopositive clones were found in nondemented young and aged control patients. 
In addition, another dinucleotide deletion (ÄGT) was found in the first repeat of Ubi- 
B. This mutation is located directly adjacent to the GAGAG motif in young, aged AD 
and DS patients (Figure 2-1B; Table 2-2). The frequency of Ubi-B+1 immunopositives 
was much higher than with APP. In a young control no immunopositive clones were 
found, whereas in the aged control displaying neuropathology and Ubi-B+: immuno­
reactivity not only a GT deletion was found in the first repeat, but also a CT deletion 
in the third repeat. A ÄCT deletion was also found in a DS patient. In four patients 
dinucleotide deletions were found in both APP and Ubi-B transcripts as
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Table 2-2. Screening of cDNA of APP and Ubiquitin B for dinucleotide deletions in the cortex and hippocampus of 
Alzheimer and Down syndrome patients and non-demented control patients.
Disease
total number 
of clones
number of 
positive clones
dinucleotide
deletion
control 1* 20,000
APP+1
0
control 2¥ 20,000 0 -
AD¥¥ 20,000 10 AGA (exon 9)
AD1¥¥° 20,000 2 A GA (exon 10)
AD2°0 20,000 5 A GA (exons 9 or 10)
AD3°0 20,000 5 A GA (exon 9)
DS1° 20,000 2 A GA (exon 9)
DS2° 20,000 12 AGA (exon 9)
control 1* 20,000
Ubi-B+1
0
control 2¥ 20,000 13 AGT or ACT
AD¥¥ 5,000 15 AGT
AD1¥¥° 1,500 138 A GT
AD2°0 2,000 32 AGT
DS1° 800 44 AGT
DS 1,000 2 AGT or ACT
DS2n 20,000 93 AGT
*young non-demented control patient; ¥elderly, nondemented control patient with age-related neuropathology; 
¥¥early onset AD (<65 years); 0  late onset AD (>65 years); a indicates patients with a dinucleotide deletion in both 
APP and Ubi-B transcripts.
expected from the colocalization of APP+1 and Ubi-B+1 (Figure 2-1C).
In order to exclude PCR and cloning artefacts as a possible explanation for the 
mutation, we confirmed the presence of mutated RNA by in situ hybridization. PCR 
artifacts were also excluded by genomic PCR (see below). The GA deletion in A P P 1 
and the GT deletion in Ubi-B+1 transcripts were both detected by stringent in situ 
hybridization with an oligoprobe discriminating between wild-type and mutant (ÄGA) 
APP and (ÄGT) Ubi-B (Figure 2-1C).
The mutations in APP and Ubi-B proteins could be caused at two different levels, 
either by a deletion in the DNA or by a transcriptional defect or editing mechanism in 
the RNA. The problem in detecting mutations in the DNA is the fact that a tissue 
sample inevitably contains not only the immunoreactive cortical layers 2, 3 and 5, but 
also the other layers and a part of the white matter. Thus, only approximately one in 
10,000 cells would carry a mutation. Hence we developed two PCR protocols that 
would be sufficiently sensitive to detect this frequency of mutation.
Assuming that the human haploid genome contains 3.109 base pairs for the RT-PCR 
and the genomic PCR for APP, an equivalent of 50,000 cells (that is 0.5 ìg  of total 
RNA and 300 ng genomic DNA, respectively) was assayed. Estimated by the 
occurrence of one immunopositive cell out of 10,000, we should have found 
approximately five out of 50,000 positive clones. Indeed, in the immunoscreening 
assay following the RT-PCR of the RNAs we found a minimum of two and a
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maximum of12 positive clones, resulting in a mean of six (Table 2-2). However, we 
were not successful in finding immunopositive clones following the genomic DNA 
PCR in two AD and two DS patients. A total of 400,000 clones were negative with 
immunoscreening, which also excluded PCR artifacts in the cDNA screening. A 
similar result was obtained with the RT-PCR and genomic PCR for Ubi-B of one of 
the DS patients: 100,000 clones were negative with immunoscreening. A comparable 
amount of RNA and genomic DNA resulted in 2-138 positive clones (Table 2-2) after 
RT-PCR compared to none after genomic PCR. In a best case estimate of the 
variables of the genomic PCR-immunoscreening approach, if screening 100,000 
colonies, we should have found five positives (for both APP and Ubi-B, based on the 
assumption of a heterozygous genotype; Van Leeuwen et al., 1989). Because we 
found no positive clones and in a worst estimated case, this method would not be 
sufficiently sensitive, we developed a more sensitive method.
A direct discrimination between mutant and wild-type DNA was based on the use of 
primers specific for the mutation. Using 5' oligonucleotides ending in the expected 
deletions and 3' oligonucleotides, which hybridize 100 bp and 674 bp downstream of 
the APP and Ubi-B mutations respectively, a detection level of ten copies of mutant 
cDNA mixed into 500 ng genomic DNA was reached (80,000 cells expressing APP 
or Ubi-B). Under the same very sensitive conditions, that is one copy of the mutant 
DNA in 8,000 cells genomic PCR was performed on human brain DNA derived from 
an AD, a DS and a control patient.
These experiments repeatedly failed to detect any amplification products neither for 
A P P 1 nor for Ubi-B+1. We repeated the PCR ten times, checking at least 5 ìg  of 
genomic DNA from each patient (that is 1.6.106 copies of APP and Ubi-B) but none 
of the PCR reactions showed a specific amplification product for the mutation. A PCR 
with oligonucleotides hybridizing to the wild-type sequences of APP and Ubi-B gave 
the expected products. Although it is difficult to base conclusions on a negative 
result, the mixing control experiments show that there is only a very small chance that 
a positive DNA amplification product was not detected. Thus, it is likely that 
frameshift mutations introduced in the transcripts and not in the DNA are responsible 
for the +1 proteins observed by immunocytochemistry.
Here, in the cerebral cortex of AD, DS and control patients, two novel APP and Ubi- 
B derived proteins generated by mutations of APP and Ubi-B transcripts were 
detected. The mutations were in all instances a dinucleotide deletion (ÄGA, ÄGT) 
occurring preferentially in or adjacent to GAGAG motifs. Since we also found a CT 
deletion in a CTCT motif of Ubi-B transcripts, it seems that other dinucleotide 
deletions in simple dinucleotide repeats occur as well. The much higher frequency of 
A P P 1 and Ubi-B+1 proteins in AD patients compared with their age- and sex-matched 
controls indicates that transcript mutation is a critical factor for initiating
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neuropathology in non-familiar forms with early and late onset AD.
The absence of these +1 proteins in patients with Parkinson's disease, except for one 
patient who also showed AD neuropathology, suggests that these +1 proteins correlate 
strongly with AD. Furthermore, the +1 proteins occur in areas known to be severely 
affected in AD (for example, CA1 and subiculum in the hippocampus; Strachan et al.,
1997). The DS patients revealed a very intense APP+1 and Ubi-B+1 immunoreactivity, 
except for one DS patient, who did not display any neurodegeneration in the three 
areas studied and did not suffer from dementia. Consistent with the idea that the 
transentorhinal cortex is an early target for neuropathological changes in AD (Braak et 
al., 1996), in the non-demented DS patient APP+1, Ubi-B +1 and Alz-50 
immunoreactivities coexisted in Bodian-stained tangles in cellular islands ofthe pre-á 
layers. The presence of Ubi-B+1 immunoreactivity in the hippocampus of non­
demented controls in an age-related manner indicates that the Ubi-B+1 peptide may 
contribute to initial stages of neurodegeneration in AD. The Ubi-B+1 protein may 
therefore be a valuable diagnostic tool for the early detection of AD.
Because enhanced transcriptional activity may be correlated with the presence o f+1 
proteins (Evans et al., 1994), it is possible that transcript mutation resulting in APP+1 
and Ubi-B+1 proteins occurred. This is illustrated best in DS, where APP-gene 
expression is much higher than expected upon trisomy 21 alone (Neve et al., 1988; 
Rumble et al., 1989; West et al., 1994). On the other hand, the lower frequency of 
APP+1 protein in AD patients (Table 2-1) is consistent with the fact that their APP- 
transcript levels are not essentially elevated (Oyama et al., 1994; Harrison et al., 
1996). The high frequency of Ubi-B+1 protein in AD and DS is in accordance with 
overexpression of the Ubi-B gene (Perry et al., 1989; Johnston et al., 1995).
The coexisting APP+1 and Ubi-B+1 proteins, but also other +1 proteins may impair 
neuronal functioning and amplify or induce neuropathology in an as yet unknown 
manner. For instance, the Ubi-B+1 molecules may be responsible for the lack of 
multiubiquitylation of the hyperphosphorylated Tau-rich neurofibrillary tangles that 
accumulate during the long period of neurodegeneration (Morishima-Kawashima et 
al., 1993). One explanation for these findings is that the Ubi-B+1 molecules are unable 
to bind to lysine residues in target molecules, because they lack the COOH-terminal 
glycine residue in the first repeat, which is essential for subsequent multiubiquityla­
tion and activation of the proteosomal machinery (Ali-Khan et al., 1992). This process 
does not seem to occur efficiently in cells with tangles in AD. Indeed no Ubi-B 
associated COOH-terminal hydrolase and 26S proteosomal immunoreactivity has 
been found in compact tangles (Lowe et al., 1990; Hilt and Wolf, 1996).
The present study shows that APP and Ubi-B transcripts can be modified by 
dinucleotide deletions (ÄGA, ÄGT or ÄCT). The GA deletion is similar to the one 
reported in vasopressin-transcripts of the homozygous Brattleboro rat (Evans et al.,
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1994). The frequently mutated motif in exon 9 of the APP-gene transcript is in fact an 
extended version of GAGAG (that is GAGAGAGA; Figure 2-1). We also addressed 
the issue whether the dinucleotide deletions occur at the transcript or at the genomic 
level. Although we used two different sensitive approaches to reveal a genomic 
mutation we failed to find any indication of a mutation at the genomic level. Support 
for the possibility of a general process of transcript mutation was provided by the 
present results showing that APP+1 and Ubi-B+1 proteins are coexpressed within the 
same neurons. In addition, in individual AD and DS patients two or three different 
dinucleotide deletions were found in two different transcripts, which makes a genomic 
event unlikely. We thus tentatively conclude that these modifications may take place 
during or after transcription. In view of the finding that frameshift mutations occur in 
multiple proteins within the same neuron, we postulate that a common denominator in 
the transcription propagating events is involved. The mechanism of transcript 
mutation (ÄGA, ÄGT or ÄCT) is, however, unclear. It is most probably not restricted 
to postmitotic cells, because we were able to show that an ectopically expressed rat 
vasopressin transgene undergoes a similar process in dividing cells (Kwak et al., 
1991).
Transcript mutation may thus be a widely occurring phenomenon. In principle, each 
transcript containing a susceptible motif, such as GAGAG, could undergo such a 
process. However, postmitotic neurons are less capable to compensate for transcript 
modifying activity, and thus particularly sensitive for the accumulation of frame- 
shifted proteins. Accumulation o f +1 proteins together with the consequent lack of 
functional proteins is probably critical for cellular functioning. Thus, during aging, 
single neurons may generate and accumulate abnormal proteins, consequently leading 
to cellular disturbances and causing degeneration. The mechanism of dinucleotide 
deletion at the transcript level may well underlie a number of neurodegenerative 
pathologies.
Acknowledgements
The authors are highly grateful for the help they received from J. Verhaagen, D.F. 
Swaab, C.W. Pool, J.J. van Heerikhuize, T.P. van der Woude, J. Wortel, A. Holtrop, 
J. Wouda, M. Kooreman, O. Pach and G. van der Meulen. We would like to thank 
R.T. Baker (John Curtin School of Medical Research, Canberra, Australia), I. 
Grundke-Iqbal (New York State Institute for Basic Research in Developmental 
Disabilities, USA), P. Davies (Albert Einstein College of Medicine, New York, 
USA), T. Hartmann (University of Heidelberg, Germany), J.M. Octave (Catholic 
University of Leuven, Brussel, Belgium) for generously providing us with plasmid 
antisera and advice. Research was supported by Het Stimuleringsfonds KNAW, an 
NWO-GPD grant, the Matty Brand Foundation and the Jan Dekker and Ludgardine 
Bouwman Foundation.
41

Chapter 3
Characterization of human 
neuroblastomas overexpressing 
the ubiquitin-B+1 protein
Wilhelmina H. van den Hurk, 
Franci A.A. Weijts, 
Rianka P.M. Vloet, 
Elly M. Hol, 
Marjon Bloemen, 
Fred W. van Leeuwen, 
Emmanuel W iertz and 
Gerard J.M. Martens

Characterization of human neuroblastomas overexpressing Ubi-B+1 protein
Abstract
Research on Alzheimer’s disease (AD) has been mainly focused on mutations in 
genes known to be involved in the familiar variants of AD. Recently, age-related 
dinucleotide deletions in gene transcripts of ubiquitin-B (Ubi-B) and ß-amyloid 
precursor protein (APP) that may underly the pathology of AD have been 
described. The dinucleotide deletion in the Ubi-B transcript results in a 
translational frameshift and a protein with an aberrant C-terminus (Ubi-B+1). Here 
we used an in vitro assay to show that the Ubi-B+1 protein is unable to 
ubiquitinilate target proteins. Furthermore, human neuroblastoma cells 
overexpressing the Ubi-B+1 protein were found to proliferate normally, but show 
impaired protein degradation via the ubiquitin-proteasomal pathway. Thus, 
frameshift mutants of ubiquitin may lead to the accumulation of proteins that have 
been destined for degradation, which eventually may affect neuronal cell 
physiology.
Introduction
The presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex 
and hippocampal brain areas are hallmarks of both Alzheimer’s disease (AD) and 
Down’s syndrome (DS) and are correlated to neuronal dysfunction and dementia 
(ref). Neurofibrillary tangles are intraneuronal lesions, mainly consisting of the 
hyperphosphorylated form of the microtubule-associated protein tau (Goedert et 
al., 1989; Grundke-Iqbal et al., 1986a-b; Kosik et al., 1986; Lee et al., 1991). An 
important constituent of the neuritic plaques is ß-amyloid (Aß), a peptide of 40-42 
amino acids that is proteolytically derived from the ß-amyloid precursor protein 
APP (Glenner and Wong, 1984a-b). Several other proteins aggregate in these 
plaques and tangles, among which mutated forms of APP and ubiquitin-B (Ubi- 
B). Mutations that underly these altered proteins are dinucleotide deletions that 
have been located to RNA molecules encoding these proteins. Following a 
dinucleotide deletion, translation of a transcript will continue in the ‘+1’ reading- 
frame, resulting in so called ‘+1 proteins’ which have aberrant C-termini (Van 
Leeuwen et al., 1998). Whether +1 proteins are a possible cause or a consequence 
of AD and DS and whether they can affect cellular physiology is not known. 
Ubiquitin exists in all eukaryotic cell types, is highly conserved among different 
species and is involved in many biological processes (Haas and Siepmann, 1997; 
Hershko and Ciechanover, 1998) because it eliminates short-lived (Ciechanover,
1991) and ‘abnormal’ proteins (Jungmann et al., 1993; Betting and Seufert, 1996).
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Translation of the wild type human Ubi-B transcript results in three mature 
ubiquitin molecules, as the transcript harbors three head-to-tail ubiquitin repeats. 
The mutated Ubi-B transcript results in only one ubiquitin molecule (Ubi-B+1) 
which has the C-terminal glycin replaced by a +1 sequence of 20 amino acids, 
before translation ends at a stopcodon in the +1 frame (Figure 3-1).
2nd repeat
wild type Ubi-B ...L V L R L R G G M Q I F V K T L T G K T I T L E V E P S D...
ubi-B mRNA ...c t g g t c c t g c g t c t g a g a g § t]3g t a t g c a g a t c t t c g t g a a g a c c c t g a c c g g c a a g a c c a t c a c c c t g g a a g t g g a g c c c a g t g a c
Ubi-B*1 ...L V L R L R G Y  A  D L R  E  D P D R  W  D H  H  P G S  G A  Q *
Figure 3-1
Nucleotide and deduced amino acid sequence o f  wild type Ubi-B and Ubi-B*1.
Amino acids o f the frameshift protein Ubi-B+' that differ from the wild type ubiquitin are indicated in bold italic 
and the deleted nucleotides are boxed. Ubiquitin nucleotide numbering is according to Baker et al. 1987 
(accession # X04803).
The C-terminal glycine of wild type ubiquitin is thought to be essential for its 
functioning and is mutated in Ubi-B+1. Ubiquitinilation starts with binding of the 
C-terminal glycin (G76) of ubiquitin to a lysin residue in a target protein. In turn, 
lysin 48 (K48) of ubiquitin can be recognized by G76 of another ubiquitin 
molecule, resulting in a di-ubiquitinilated protein and in time multi- 
ubiquitinilation (Hershko and Heller, 1985). Multi-ubiquitinilation directs 
proteins that are destined for degradation towards the 26S proteasome, a 2000kD 
multi-subunit protease (Coux et al., 1996). Yeast mutants that carry a G76A 
substitution show a ubiquitin deficient phenotype (Hodgins et al., 1992).
Here we assess the in vitro activity of the frameshifted ubiquitin-B mutant (Ubi- 
B+1) which has been detected in AD and DS patients. Overexpression of Ubi-B+1 
in neuroblastoma cells allowed us to study the effects of the mutation on cellular 
functioning in general and the ubiquitin-proteasomal degradation pathway in 
particular. Impairment of the ubiquitin-proteasomal degradation pathway in the 
brain by Ubi-B+1 could lead to accumulation of proteins that should have been 
degraded, which might result in neuronal damage.
Materials and Methods
Antibodies
Polyclonal antibody directed against wild type ubiquitin was obtained from Sigma, and 
polyclonal Ubi-B2+1 antibody has been described before (Van Leeuwen et al., 1998; 
Chapter 2).
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In vitro ubiquitinilation
Wild type ubiquitin and Ubi-B+1 were cloned in the eukaryotic expression vector pcDNA3 
and transcribed and translated in vitro using a reticulocyte lysate (TNT Quick coupled 
transcription/translation system, Promega), following the manufacturer’s instructions. In 
vitro ubiquitinilation reactions were set up in a total volume of 25 ^l in 50 mM Tris pH 
7.6, 5 mM MgCl2 and 2 mM DTT. In vitro translated 35S-wild type ubiquitin or 35S-Ubi- 
B+1 was added in equimolar amounts, together with 25 ^g protein of a fraction II 
reticulocyte lysate containing all ubiquitinilation enzymes required and also providing 
target proteins, but essentially ubiquitin-free (Affinity, UK). In ATP-suppletion reactions, 
1 mM ATP, 5 ^g creatine phosphate per reaction and 10 mM creatine phosphokinase were 
added. In ATP-depletion reactions, 1.3 ^g hexokinase per reaction and 10 mM 2- 
deoxyglucose were added. Reactions were incubated at 37°C or kept on ice for 60 min. 
before addition of sample buffer for electrophoresis. Proteins were analysed on 15% Tris- 
Tricine gels and 7.5% SDS-PAGE.
Stable transfection of neuroblastoma cells
The neuroblastoma cell line SK-N-BE was transfected with Ubi-B+1 in pcDNA3 or 
pcDNA3 alone using Fugene (Roche Biochemicals). Neomycine (1 ^g/^l) was added to 
select for stable incorporation of the plasmid. Several clones were picked and screened for 
Ubi-B+1 expression using immunofluorescence, radioimmunoassay (RIA), Western blot 
analysis and pulse labeling followed by immunoprecipitation, as has been published 
elsewhere (ref.). Briefly, 5.106 cells were pulsed for 2 h with 150 ^Ci of 35S- 
methionine/cysteine and then lysed in 1 ml lysisbuffer containing 2 mg/ml deoxycholate, 
1 mM PMSF and 100 ^g/ml trypsin inhibitor. Subsequently wild type ubiquitin and Ubi- 
B+1 were immunoprecipitated for 2 h at 4°C with a polyclonal anti-ubiquitin serum and 
polyclonal anti-Ubi-B2+1 serum, respectively. Immunocomplexes were collected using 2 
mg protein A conjugated sepharose beads. Proteins were analysed by 15% Tris-Tricine 
electrophoresis followed by exposure to a phosphor-imaging screen (BioRad).
Growth curves of different clones were determined by 3H-thymidine incorporation.
Ubiquitin-proteasome assay
Ubi-B+1 overexpressing SK-N-BE cells were infected with an adenoviral construct 
harbouring the coding sequence of the Human cytomegalovirus (HCMV)-derived US11 
protein. This protein induces destruction of the major histocompatibility complex (MHC) 
by redirecting it from the ER to the cytoplasm, where it is ubiquitinilated and degraded by 
the proteasome (Wiertz et al., 1996). After 16h of US11 infection at an m.o.i. of 20, cells 
were detached by trypsin treatment and incubated in methionine/cysteine-free RPMI for 1 
h. Subsequently 2.106 cells were pulse labeled with 100 ^Ci 35S-Met/Cys for 10 min., 
followed by a 30 min. chase in full medium. Immediately after the chase, samples were 
placed on ice and lysed. MHC was immunoprecipitated from these cells using an antibody 
recognizing assembled MHC class I molecules (W6/32) as described in an earlier section. 
Proteins were analyzed on a 12% SDS-PAGE gel.
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Results
In vitro ubiquitinilation
In vitro transcription and translation of wild type ubiquitin-B resulted in 3 times 
more mature protein than transcription and translation of the Ubi-B+' protein, due 
to the three repeats in the wild type gene and early translational termination in the 
Ubi-B+' transcript. This was corrected for in the in vitro ubiquitinilation reactions.
In reactions containing wild type ubiquitin-B, the amount of free detectable 
ubiquitin at 0°C decreased to approximately 20% at 37°C (Figure 3-2), indicating 
that ubiquitinilation did occur at this latter temperature. This was also evident 
from extra bands that appeared at 37°C, most likely representing ubiquitinilated 
target proteins from the lysate. In the reactions containing Ubi-B+', no difference 
was seen between the 0 °C and the 37 °C incubation, indicating that no 
ubiquitinilation occurred.
Analysis o f neuroblastoma cells stably transfected with Ubi-B+1 
Overexpression of Ubi-B+' in stably transfected SK-N-BE cells was checked by
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Table 3-1. RIA measurements of SK-N-BE stably transfected with Ubi-B+1 or mock. Ubi-B2+1 antibody was 
used in the RIA.
Clone # pg ubi-B+1 / 106 cells
ubi-B+1 #2 4268
ubi-B+1 #3 284
ubi-B+1 #5 517
ubi-B+1 #7 208
ubi-B+1 #9 1022
ubi-B+1 #10 85
mock #1 54
mock #3 125
mock #4 84
immunofluorescence (Figure 3-3A) and quantified by RIA (Table 3-1). The 
immunofluorescence data show the presence of Ubi-B+1 in the cytoplasm of stably
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A. Immunofluorescence on SK-N-BE cells stably transfected with UM-B+1
SK-N-BE cells were stably transfected with Ubi-B+1. Localization and expression of the protein was determined 
by immunofluorescence with Ubi-B2+1 antibody (1:500). Bar indicates 10 mm.
B. Immunoprecipitation o f  UM-B+1 produced in transfected SK-N-BE cells. SK-N-BE cells were stably 
transfected with mock or Ubi-B+1. Proteins were pulse labeled for 2 hours in the presence of 35S-Met/Cys, 
extracted, immunoprecipitated with Ubi-B2+1 antibody and analyzed on SDS-PAGE. The arrow indicates the 
migration position of the Ubi-B+1 protein. Mr represents the molecular weight marker with sizes in kD.
C. Ubi-B*1 protein in stably transfected SK-N-BE cells. SK-N-BE cells were stably transfected with mock or 
Ubi-B+1. Ubi-B+1 protein was detected at 11 kD via Western blot analysis using anti-Ubi-B2+1 antibody.
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Figure 3-4
Proliferation o f  Ubi-B+‘ overexpressing SK-N-BE cells is not affected
The proliferation o f SK-N-BE cells that were stably transfected with either mock or Ubi-B+1 was determined by 
3H-thymidine incorporation.
transfected cells (Figure 3-3A). The RIA measurements confirmed the 
predominant presence of Ubi-B+1 in clone number 2, 5 and 9 (Table 3-1). The size 
and stability of Ubi-B+1 in three clones was investigated by using Western blot 
analysis and pulse labeling followed by immunoprecipitation (Figure 3-3B-C). In 
the clones tested, Ubi-B+1 was visible as an 11 kD band, which is the expected 
size for the Ubi-B+1 protein. No bands were detected in cells overexpressing only 
pcDNA3. In the clone expressing the highest level of Ubi-B+1 (#2), the ratio 
between wild type ubiquitin and Ubi-B+1 will be approximately 9:1, based on data 
on ubiquitin content of neuronal cells from literature (Koji et al., 1996). 
Proliferation of SK-N-BE cells was not affected by Ubi-B+1 overexpression 
(Figure 3-4) and no effects were seen on the morphological level using EM 
analysis (data not shown).
To assay possible effects of the in vitro non-functional Ubi-B+1 (Figure 3-2) in 
neuronal cells, the ubiquitin-proteasomal degradation pathway was tested in the 
Ubi-B+1 overexpressing neuroblastoma cells. The HCMV-derived protein US11 
redirects newly synthesized MHC class I molecules from the ER towards the 
cytoplasm, where they are deglycosylated, ubiquitinilated and degradated by the 
proteasome (Wiertz et al., 1996). Therefore, in the presence of US11, MHC class
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Figure 3-5
Proteasomal degradation is affected in Ubi-B+1 overexpressing SK-N-BE cells
SK-N-BE cells stably transfected with either mock or Ubi-B+', were transiently infected with either mock or 
US11. After 16 hours o f infection, cells were pulse labeled for 10 minutes in the presence 35S-Met/Cys and 
chased for indicated time periods. Proteins were extracted, immunoprecipitated with anti-MHC antibody W6/32, 
and analyzed on 12 % SDS-PAGE.
I proteins can be used as markers for the activity of the ubiquitin-proteasomal 
degradation pathway. US11 infection of SK-N-BE cells stably transfected with 
mock resulted in the rapid degradation of MHC class I molecules (Figure 3-5). In 
contrast, US11-induced MHC class I degradation was decreased in SK-N-BE 
cells overexpressing Ubi-B+' (Figure 3-5), indicating that the ubiquitin- 
proteasomal degradation pathway is impaired in these cells.
&
Discussion
Here we show that a dinucleotide deletion in ubiquitin-B transcripts, that has been 
detected in the brains of AD and DS patients, results in a frameshifted elongated 
protein (Ubi-B+') that is not functional in vitro. Wild type ubiquitin and U bi-B 1 
are identical for the first 75 amino acids. Only the C-terminal glycine (G76) has 
been mutated in the Ubi-B+' protein and is replaced by a stretch of 20 amino acids 
resulting from the +1 reading frame (Figure 3-1). Importantly, G76 is pivotal for 
ubiquitinilation. Substitution of this amino acid for an alanin in yeast, results in a 
mutant protein that binds to its target irreversibly and thereby causes phenotypes 
consistent with a ubiquitin deficiency (Hodgins et al., 1992). Ubi-B+' does not 
bind target proteins, as in the in vitro ubiquitinilation experiments no decrease in 
the amount of free Ubi-B+' was detected.
The effect of the expression of this non-functional ubiquitin mutant on cellular 
physiology has been studied using human neuroblastoma cells overexpressing the
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mutant protein. These cells showed no defects in cell growth and morphology, but 
seem to have an impaired ubiquitin-proteasomal degradation pathway. This 
pathway plays an important role in the elimination of faulty proteins. Impairment 
of this pathway may result in the accumulation of aberrant proteins and neuronal 
damage. Rat neurons and glia that were exposed to proteasome inhibitors in vitro, 
showed morphological changes which accompagny some neurodegenerative 
diseases, such as aggresomes characterized by ubiquitin immunoreactivity and 
redistributed pericentriolar neurofilaments and glial fibrillary acidic protein 
(GFAP; Kopito, 2000). Indeed, dramatic increases in ubiquitin and ubiquitin- 
protein conjugates are observed in AD brain and cerebrospinal fluid (CSF) 
compared to age-matched controls (Kudo et al., 1994; Iqbal et al., 1997). 
Furthermore, immunohistochemical studies report on concominant increases of 
the proteasome and ubiquitin at sites of dystrophic neurites in AD (Ii et al., 1997). 
These observations point towards an activation of the ubiquitin-proteasomal 
degradation pathway in neurodegenerative diseases, probably in an attempt to 
clear away aggregating proteins.
The proteasome is also involved in the regulation of presenilin levels (Fraser et 
al., 1998; Steiner et al., 1998). Mutations in the presenilin genes (PS1 and PS2) 
cause most of the early-onset forms of familiar AD (reviewed by Kovacs and 
Tanzi, 1998). Intact PS1 and PS2 are cleaved into N-terminal (NTF) and C- 
terminal fragments (CTF), which form a stable complex (Capell et al., 1998; 
Thinakaran et al., 1998; Yu et al., 1998). CTF/NTF complex formation is tightly 
regulated as both intact PS1 and CTF/NTF fragments that have not been 
incorporated in the complex are unstable due to quick degradation by the 
proteasome (Steiner et al., 1998; Marambaud et al., 1998; Fraser et al., 1998; 
Honda et al., 1998). This CTF/NTF complex regulates APP cleavage and 
production of Aß (De Strooper et al., 1998; Borchelt, 1998) and it has even been 
suggested to be the actual g-secretase (Wolfe et al., 1999). Indeed, inhibition of 
proteasomal activity increases Aß levels (Marambaud, 1997). Deficiency of the 
proteasomal-degradation pathway due to Ubi-B+' mutants may therefore 
specifically increase Aß levels through disregulation of the presenilin signaling 
route. Thus, Ubi-B+'-induced inhibition of the ubiquitin-proteasomal degradation 
pathway can contribute to the accumulation of aberrant proteins, among which 
Aß. Levels of Aß may also increase as a result of decreased PS1 degradation. 
Furthermore, in its turn Aß binds to the proteasome and blocks degradation of 
ubiquitinilated proteins (Prasad et al., 1998; Gregori et al., 1995,1997). This can 
again lead to the accumulation of faulty proteins, including Ubi-B+1, making Ubi- 
B+1 both a possible cause and a possible consequence of high Aß levels.
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Age-related frame-shift mutations in RNA molecules may be only one of several 
possible failures in cell functioning due to cellular aging. We speculate that when 
cells age, they become more errorprone and that aging of a cell might be due to 
the accumulation of mutated proteins due to transcription-, translation-, 
processing- and other errors affecting cellular physiology. Many of these errors 
might stay unnoticed as a few mutant non-functional proteins will most likely not 
affect cell physiology. However, other errors may lead to dominant negative 
peptides that can block certain vital cellular pathways. The Ubi-B+1 mutation 
affects approximately one in a hundred transcripts in AD and DS brain. It is 
remarkable that especially in these two diseases the proteasomal degradation 
pathway appears to be highly activated in an attempt to clear away the 
aggregating proteins. Under these circumstances of high proteasomal demand 
even low numbers of non-functional Ubi-B+1 protein may impair the ubiquitin- 
proteasomal degradation pathway.
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Molecular misreading near short simple repeats
Abstract
In patients with Alzheimer’s disease (AD) or Down’s syndrome (DS), the 
cerebral cortex exhibits protein deposits in neurofibrillary tangles and neuritic 
plaques. Recently, the deposits have been shown to contain protein fragments of 
ubiquitin-B (Ubi-B) and amyloid precursor protein (APP) with an aberrant 
carboxy terminus resulting from frameshift mutations (dinucleotide deletions; 
AGU or AGA) in or adjacent to GAGAG motifs in their mRNAs, a process 
referred to as molecular misreading. We have now used a bacterial expression 
system with the green fluorescent protein as a reporter to screen gene transcripts 
from aged controls, AD and DS for molecular misreading. Novel frameshift 
mutations at a number of locations in the transcripts of the Ubi-B and APP genes 
were discovered (AGA, DG, AGU, AGG, ACA, AAU, DA, AAA, AC, AU, 
insertion of an A). Interestingly, most mutations were in close proximity of short 
simple repeats (GAGAG, GGUGGU, GAGACACACA, UCAUCAUCA, 
CAAACAAA, GAAGAAGAA), demonstrating that the GAGAG-motif does not 
constitute the only hotspot for transcriptional errors. Unlike the previously 
detected aberrant APP-fragments, some of the novel ones have the potential to 
generate the neurotoxic peptide ß-amyloid. We conclude that during aging 
molecular misreading is a widespread phenomenon.
*
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain and 
accounts for the most frequent form of dementia at higher age. The disease is 
characterized by the presence of neurofibrillary tangles, neuropil threads and 
neuritic plaques in the brain. A major constituent of the plaques is ß-amyloid, a 
neurotoxic peptide generated by processing of the type I transmembrane ß- 
amyloid precursor protein APP (Glenner and Wong, 1984a). Two different types 
of AD can be discriminated, namely the early-onset (familial) and the late-onset 
(sporadic) form. The sporadic form accounts for more than 60 % of all AD cases, 
but the cause of the development of these cases is unknown. A recent study 
provided a new on the mechanism that may underly aging and that in particular 
may contribute to the development of the sporadic forms of AD and Down’s 
syndrome (DS; Chapter 2; Van Leeuwen et al., 1998a; Hol et al., 1998). The new 
view is referred to as molecular misreading and is based on the finding of a novel 
type of dinucleotide deletion in or adjacent to a GAGAG-motif in the mRNA 
transcripts of two neuronal genes, encoding APP and the cytoplasmic garbage-
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protein ubiquitin-B (Ubi-B) (Chapter 2; Van Leeuwen et al., 1998a). These 
mutations were found at the RNA- and not the DNA-level, and resulted in 
frameshifts and proteins with an aberrant carboxy-terminus (Chapter 2; Van 
Leeuwen et al., 1998a; Hol et al., 1998; Van den Hurk et al., 1999). The same 
type of frameshift mutations may underlie other neuropathologies and age-related 
diseases.
To examine how widespread the phenomenon of molecular misreading is and 
whether hotspots other than GAGAG may occur, we have developed a bacterial 
expression system with the green fluorescent protein GFP as a reporter and 
successfully used this system for the screening of frameshift mutations in 
mRNAs, even when the mutational rate is low. We discovered novel frameshift 
mutations at different sites in Ubi-B and APP gene transcripts isolated from 
cortical regions of aged individuals.
Materials and Methods
Isolation o f RNA
Using a standard Trizol procedure (Gibco BRL), total RNA was extracted from cortical 
regions of aged individuals that had suffered from AD or DS (# 92-50-529, control, age
96, 9; # 92-50-692, control with plaques, 85, 9; # 94-52-312, control, 85, 9; # 95-50-665,
control, 84, 9; # 88-50-322, AD, 85, 9; # 88-52-120, AD, 83, 9; # 92-51-371, AD, 81, 9; #
95-51-242, AD, 79, '  # 95-51-014, AD, 81, 9; obtained from the Department of
Pathology, University of Nijmegen, The Netherlands; NHB # 92080, DS, 58, 9; and NHB
# 93028, DS, 67, 9; obtained from the Netherlands Brain Bank, Amsterdam, The 
Netherlands, coordinator R. Ravid).
RT-PCR
Single stranded cDNA was synthesized by using 2 mg of total RNA, randomly primed 
with hexamers and reverse transcribed with RT Superscript II (Gibco BRL). The PCR- 
reaction was performed with PWO DNA polymerase (Roche; proofreading activity). 
Initially, we experienced a technical problem in that a substantial percentage (~1%) of the 
synthesized primers was found to contain a deletion or an insertion of a nucleotide. 
Therefore, primers (Biolegio, The Netherlands) were purified on SDS-PAGE to diminish 
background signals caused by the mistakes made during primer synthesis. The primers 
used for Ubi-B mRNA analysis were 5’-ggggggggaagcttccgctatcaggtcaaaatg-3’ as forward 
and 5’-gggggtctagatcttcacgaagatctgcat-3’ as reverse primer (255 bp PCR-product). For 
APP mRNA analysis, the following primer sets were used: APP-ex9 with 5’- 
gggggaagctttgcccatttccagaaagcc-3’as forward and 5’-gggggtctagacggcggtcattgagcatggc-3’ 
as reverse primer (242 bp product); APP-BA with 5’-ggggaagctttgggttgacaaatatcaagagc-3’ 
as forward and 5’-ggggtctagattctgcatctgctcaaagaac-3’ as reverse primer (APP-BA1; 341 
bp product) or 5’-ggggtctagattttcgtagccgttctgctgc-3’ as reverse primer (APP-BA2; 312 bp 
product); APP-CT with 5’-gggggaagcttgaagaagaaacagtacaca-3’ as forward and 5’-
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ggggtctagattctgcatctgctcaaagaac-3’ as reverse primer (APP-CT1; 141 bp product) or 5’- 
ggggtctagattttcgtagccgttctgctgc-3’ as reverse primer (APP-CT2; 112 bp product).
Screening strategy
PCR-products were gel purified, digested with HindIII and XbaI, and subcloned into the 
bacterial vector pGFPuv (Clontech #6079-1; GenBank Accession #U62636; Figure 4-1).
RNA ISOLATION 
1RT-PCR
HindIII XbaI
AAGCTTNNNNNNGAGAGNNNNNNTCTAGA
TTCGAANNNNNNCTCTCNNNNNNAGATCT
t
out-of-frame
HindIII XbaI
AAGCTTNNNNNNGAGNNNNNNTCTAGA
TTCGAANNNNNNCTCNNNNNNAGATCT
SUBCLONE
cDNA
insert
H X
t TRANSFORMATION
ANALYSIS FOR FLUORESCENCE
pGFP*uv f
DNA SEQUENCE ANALYSIS
GFP
Figure 4-1 Schematic overview of the screening strategy to illuminate frameshift mutations in gene transcripts. 
Arrow in pGFP*uv-vector indicates PlacZ promoter; arrow above insert indicates the translational process; 
H=HindIII; X=XbaI.
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DNA was isolated from selected clones (Flexiprep kit, Pharmacia Amersham) and insert 
sizes were determined. During the development of this method we experienced a 
background signal caused by internal initiation of translation at the first AUG of the GFP- 
coding region. To prevent this background signal, this AUG was removed via PCR with 
5’ primer ggtcgactctagaaaaaagtaaaggagaagaacttttcactgg and 3’ primer ctcagttggaattcattatt- 
tgtagagctcatgcatgccatg. The mutated construct is referred to as pGFP*uv and was used for 
the cloning of the PCR-products to identify the frameshift mutations. DNA sequence 
analysis was performed according to the manufacturer’s protocol (Perkin Elmer; ABI 
Prism 310). The screening strategy provides different ways to detect frameshift mutations. 
The Ubi-B primers were designed in such a way that clones containing a wild type insert 
would show no fluorescence, while clones containing an insert with a dinucleotide 
deletion would generate weak fluorescence. By changing the 3’ primer one could also 
search for deletions of one nucleotide. For the detection of mutations in APP gene 
transcripts, the primers were designed in such a way that the wild type APP is in frame 
with GFP, while a frameshift would lead to non-fluorescent bacteria. However, one of the 
wild type APP PCR-fragments (generated with primers APP-BA1 and 2) was found to 
result in a non-fluorescent GFP fusion protein because of the size of the insert. 
Surprisingly, in this case a number of fluorescent bacteria were still detected, and 
sequencing of these clones revealed the presence of APP frameshift mutations. These 
frameshifts caused an early termination of translation and it is likely that reinitiation of 
translation occurred to generate a fluorescent GFP fusion protein (Figure 4-2).
A
Í pGFPuv*
lì
wild type Ubi-B pGFPuv*
1 Í i *
fram eshift Ubi-B pGFPuv*
B Í
I  mumple donmg s¡te
pGFPuv*
r ' " " ' "
----------------
*
wild type APP-BA pGFPuv*
». ». w k
* *
fram eshift APP-BA pGFPuv*
translation initiation *  translation termination translation re-initiationr*
Figure 4-2
A). Screening strategy: cloning of PCR products into pGFP*uv. Cloning of wild type Ubi-B results in a 
truncated protein lacking GFP, whereas cloning of a frameshift Ubi-B PCR-product results in a fluorescent GFP 
fusion-protein.
B). Cloning of wild type APP results in a non-fluorescent GFP-fusion protein, whereas cloning of a frameshift 
APP PCR-product leads to a fluorescent GFP-fusion protein, probably caused by translation termination and re­
initiation of translation.
*
*
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Results and discussion
Age-related frameshift mutations in gene transcripts have been shown to occur in 
Brattleboro rats (Evans et al., 1994) and in patients who had suffered from AD or 
DS (Chapter 2; Van Leeuwen et al., 1998a). These frameshift mutations are 
generated at the RNA- and not the DNA-level, and this process has been referred 
to as molecular misreading (Van Leeuwen et al., 1998b). The frameshifts were 
detected with an immunoscreening procedure implying the need for a specific 
antibody for each mutation to be investigated. To circumvent the necessity for the 
generation of an antibody for the detection of any new mutation, we developed a 
bacterial expression cloning strategy involving the use of GFP as a reporter 
protein to screen PCR fragments up to 300 nucleotides in length for the presence 
of frameshift mutations (see Materials and methods). To examine the sensitivity 
of the method and to show that the mutations are not generated as a result of a 
PCR artifact, constructs containing either wild type Ubi-B (wt) or Ubi-B with the 
dinucleotide deletion previously described (AGU; Ubi-B+1; Chapter 2; Van 
Leeuwen et al., 1998a) were used in different ratios ranging from 1:1 to 1:10000 
(wt:AGU). Even at a ratio of 1:10000 the (weakly) fluorescent clones containing 
the frameshift mutation could still be detected at the expected frequency. 
Subsequently, the validity of the procedure was checked by searching for a 
frameshift that is known to occur in Ubi-B gene transcripts isolated from human 
DS brain tissue (Chapter 2; Van Leeuwen et al., 1998a). A GU-deletion following 
a GAGAG-motif in the Ubi-B transcript identical to the one reported earlier 
(Chapter 2; Van Leeuwen et al., 1998a) was indeed found (Table 4-1). Since the 
PCR-primers corresponded to regions located in separate exons of the Ubi-B 
gene, the size of the PCR-fragment (255 bp) revealed that the mutations were 
detected at the RNA- and not the DNA-level. Interestingly, in addition to the 
AGU, we discovered several novel mutations (AGA, AG, AGG, and insertion of 
an A) (Table 4-1). These novel mutations were also located adjacent to the 
GAGAG-motif described earlier, except for the insertion of an A, which occurred 
adjacent to a GGUGGU-motif. This latter observation indicates the importance of 
simple repeats for the process of molecular misreading.
Another transcript previously shown to contain dinucleotide deletions at a 
GAGAG-motif is produced by the APP-gene (Chapter 2; Van Leeuwen et al., 
1998a). In exons 9 and 10 of the APP gene, three GAGAG-motifs are clustered. 
When applying our strategy on RNA derived from aged individuals, we were 
again able to confirm the previously observed GA-deletion in the second 
GAGAG-motif in exon 9 (Table 4-1). Furthermore, we detected a CA-deletion in 
exon 11 that, remarkably, occurred in a GAGACACACA-motif, again pointing to 
the involvement of simple repeats in molecular misreading. Molecular misreading
61
Chapter 4
Table 4-1 Frameshift mutations detected in human brain RNA o f aged individuals (controls [C] and patients that 
had suffered from AD or DS). Nucleotide numbering corresponds to Accession # X04803 (Ubi-B; Baker and 
Board, 1987) and of Accession # Y00264 (APP; Kang et al., 1987). Repeats are underlined and the mutations are 
bold.
transcript m utation region surrounding m utation Patient # (frequency)
human Ubi-B AGA (nt 1314-1315) UGCGUCUGAGAGGUGGUAU 88-50-322 (AD; 1:3400)
human Ubi-B AG (nt 1316) GUCUGAGAGGUGGUAUGCA 88-52-120 (AD; 1:6400)
human Ubi-B AGU (nt 1317-1318)* UCUGAGAGGUGGUAUGCAG
92-50-692 (C¥; 1:5000)
92-080 (DS; 1:3200)
93-048 (DS; 1: 950)
human Ubi-B AGG (nt 1319-1320) UCUGAGAGGUGGUAUGCAG 95-51-242 (AD; 1:6300) 
95-51-014 (AD; 1:8600)
human Ubi-B insertion o f A (nt 1322) GAGAGGUGGUAAUGCAGAAU 92-080 (DS; 1:6000) 
92-50-692 (C¥; 1:5800)
human APP AGA (nt 1134-1135)* AAGCACCGAGAGAGAAUGUCC 92-080 (DS; 1:1700) 
88-50-322 (AD; 1:3800)
human APP ACA (nt 1293-1294) UGGAGACACACAUGGCCAGAG 92-50-692 (C¥; 1:4800)
human APP AAU (nt1962-1963) CUGAGGUAUAGAAGUUCATCAT 92-50-529 (C; 1: 1300)
human APP AA (nt 1980) GUUCAUCAUCAAAAAUUGGUGUU
92-080 (DS; 1:1950) 
92-50-529 (C; 1:1000) 
92-50-692 (C¥; 1:2650)
human APP AAA (nt 1980-1981) GUUCAUCAUCAAAAAUUGGUGUU 92-080 (DS; 1:1950)
human APP AA (nt 2018) UUCAAACAAAGGUGCAAUCAUUC 95-50-665 (C; 1:5700)
human APP AG (nt 2023) UUCAAACAAAGGUGCAAUCAUUC 92-50-692 (C¥; 1:1750)
human APP AG (nt 2043) UUGGACUCAUGGUGGGCGGUGUU 92-50-529 (C; 1:4000)
human APP AU (nt 2075) CAGUGAUCGUCAUCACCUUGGUG 92-080 (DS; 1:5900)
human APP AG (nt 2103) GAAGAAGAAACAGUACACAUCC 92-080 (DS; 1:4500)
human APP AC (nt 2153) CCGCUGUCACCCCAGAGGAGCGC 92-080 (DS; 1:4400)
* mutations that have previously been reported by Van Leeuwen et al. (1998a; Chapter 2); ¥ indicates an aged 
control with plaques
in neither exon 9 nor exon 11 of the APP gene can, however, by itself lead to an 
increase in the production of Aß, since the APP-fragments generated by these 
frameshift mutations do not contain the Aß-peptide region (encoded by exons 16 
and 17 of the APP gene). In contrast, the occurrence of a frameshift mutation in a 
region of the mRNA corresponding to the carboxy-terminal cytoplasmic region of 
APP would lead to an aberrant protein with the potential to give rise to Aß 
(Figure 4-3). We therefore searched for mutations in the mRNA region encoding 
the carboxy-terminal part of APP and this analysis revealed a number of novel 
frameshift mutations, namely AA and AAA (both in U C AU C AU CA AAAA- 
UUGG), AA (UU C A A AC A A AGGUGCAAUCAUUC), AG (UUGGACUCA- 
UGGUGGGCGGUUGUU; UUCAAACAAAGGUGCAAUCAUUC; GAAGAA- 
GAAACAGUACACA), AU (UGAUCGUCAUCACACCU), and AC (CTGTCA- 
CCCCAGAGGAG) (Table 4-1). Some of these mutations occurred in close 
proximity of short simple repeats (UCAUCAUCA, CAAACAAA and 
GAAGAAGAA). The mutations were not only detected in mRNAs derived from
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patients who had suffered from AD or DS, but also in temporal cortex mRNAs of 
aged controls.
The aberrant proteins resulting from molecular misreading might affect cell 
physiology. For instance, the previously published Ubi-B+1 protein, lacking 
Glycine residue 76 that is essential for recognition of the target protein (Hershko 
and Heller, 1985), is no longer able to ubiquitinilate proteins in vitro (Chapter 3).
a g a
APP
wtAPP
R L E A K H R E 
AGGCTTGAGGCCAAGCACCGAGAGA(
V P G H E R M G R G R T S S K E L A *
TGTCCCAGGTCATGAGAGAATGGGAAGAGGCAGAACGTCAAGCAAAGAACTTGCCTAA- 
R L E A K H R E R M S Q V M R E W E E A E R Q A K N L P K ■
wtAPP
+.
APP-CT
■K K K Q Y T S I j H H G V V E V D A A V T P E E R 
•AAGAAGAAACAGTACACATCCATTCATCATGGTGTGGTGGAGGTTGACGCCGCTGTCACCCCAGAGGAGC 
K K K H T H P F I  M V W W R L T P L S P Q R S
AG AC
&
H L S K M Q Q N G Y E N P T Y K F F E Q M Q N * 
GCCACCTGTCCAAGATGCAGCAGAACGGCTACGAAAATCCAACCTACAAGTTCTTTGAGCAGATGCAGAACTAGA--- 
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Figure 4-3
Schematic representation of wild type APP and APP-fragments resulting from frameshift mutations. APP+1, 
APP-fragment resulting from a AGU dinucleotide frameshift mutation previously identified and lacking the Aß­
region (2). APP-CT+2, APP-fragment containing the Aß-region and due to a frameshift mutation in the 
cytoplasmic tail of APP resulting in a protein with a tail lacking one (in case of AC) or both (AG) 
localization/targeting signals that are boxed in wild type APP (wtAPP); APP-CT+2 has the potential to generate 
Aß. SP= signal peptide, TM= transmembrane region.
B  ß-amyloid (Aß); □  , □ :  aberrant carboxy-terminal regions resulting from frameshift mutations.
+i
The above-mentioned novel frameshift mutations in the Ubi-B gene transcripts 
probably also result in ubiquitin molecules unable to function properly.
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Concerning the APP protein one should consider its cytoplasmic tail that contains 
two sorting signals (YTSI and YENPTY) characterized as internalization and 
endosomal/lysosomal targeting signals, and necessary for intracellular trafficking 
of APP. Deleting or mutating these signals indeed affects APP routing (Chen et 
al., 1990; De Strooper et al., 1993; Haass et al., 1993; Jacobsen et al., 1994; Lai et 
al., 1995; Ono et al., 1997). The frameshift deletions AG at nucleotide 2103 and 
AC at nucleotide 2153, in the part of the APP transcript encoding the cytoplasmic 
region, result in proteins with an aberrant and elongated cytoplasmic tail lacking 
one or both of the targeting-signals of APP (Figure 4-3). Since an affected APP 
routing may lead to an increased production of Aß (Selkoe, 1994), the novel APP 
proteins with the aberrant tails may give rise to this neurotoxic peptide.
Although the frameshift mutations were found at a relatively low rate (1:950 to 
1:8600 transcripts; Table 4-1), at the single cell level the frequency may be 
considerably higher. Immunocytochemical analysis has revealed that only a small 
percentage of cells contain the aberrant frameshift proteins, indicating that 
molecular misreading is indeed restricted to a minority of neuronal cells (Chapter 
2; Van Leeuwen et al., 1998a). In an affected cell, the percentage of mutated 
transcripts may thus well be relatively high which could significantly contribute 
to the malfunctioning of such a cell, possibly eventually even promoting its 
degeneration.
We conclude that during aging molecular misreading is a widespread event 
occurring at a variety of short simple repeats.
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Intracellular fate of the A4CT-peptide
Abstract
ß-Amyloid (Aß) is generally accepted as a key peptide in the development of 
Alzheimer's disease and is generated by processing of the ß-amyloid precursor 
protein APP. To study the generation of Aß by the enzyme g-secretase, the ß- 
secretase carboxy-terminal cleavage product of APP (C99, also known as A4CT) 
can be used. Since the A4CT product might also be the result of internal initiation 
of translation at Met596 of the APP protein, we have first studied the occurrence of 
internal initiation of translation in the APP mRNA molecule. Transfection studies 
with the green fluorescent protein as a reporter gene showed the occurrence of 
internal initiation of translation in a region corresponding to exon 9 of the APP 
gene, indicating that this process indeed occurs. We next examined the 
intracellular fate of the internal APP translational initiation product A4CT. 
Expression of A4CT in COS7 cells revealed that this signal peptide lacking 
A4CT-protein is packaged in vesicular structures. Furthermore, in a pulse-chase 
experiment we detected the generation of an A ß-like peptide and found that this 
cleavage was inhibited by the g-secretase inhibitor MW-I-167, showing the 
involvement of an enzyme with g-secretase characteristics. The results show that 
A4CT is expressed in vesicular structures and processed to the toxic Aß-peptide, 
and that this protein can be valuable for testing therapeutic compounds that 
interfere with g-secretase activity.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative age-related disorder, 
characterized by the presence of neuritic plaques and neurofibrillary tangles in the 
brain. The major constituent of the neuritic plaques is the ß-amyloid peptide (Aß; 
Glenner and Wong, 1984; Selkoe, 1994). Aß is derived from the large 
transmembrane amyloid precursor protein (APP) via proteolytic cleavage by the 
enzymes ß- and g-secretase. a-Secretase cleavage of APP effectively prevents 
formation of Aß and results in the production of a secreted form of APP (APPas) 
and a 83-amino acid membrane-associated carboxy-terminal fragment (Palmert et 
al., 1989; Weidemann et al., 1989; Esch et al., 1990; Kametani et al., 1990; Wang 
et al., 1991). For the generation of Aß, APP has first to be cleaved by ß-secretase, 
leading to the release of secreted forms of APP (APPßs) and leaving intact Aß 
behind in a 99-amino acids membrane-associated carboxy-terminal fragment of 
APP (C99, alternatively named A4CT). Then the A4CT protein has to be further
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processed by g-secretase to produce Aß (Estus et al., 1992; Selkoe, 1993; Higaki 
et al., 1995; Knops et al., 1995). Another possibility to generate A4CT involves 
internal initiation of translation at Met596 of the APP protein. However, no 
evidence for this phenomenon has been reported (Citron et al., 1993). To release 
Aß, the product generated by either internal (re)initiation or ß-secretase 
processing still needs to be cleaved by g-secretase. The A4CT protein, the 
production of which does not necessitate ß-secretase, has been used to investigate 
and characterize g-secretase activity (Dyrks et al., 1988; Busciglio et al., 1993; 
Higaki et al., 1995). A4CT may be cleaved either directly by g-secretase or first 
by a- and then by g-secretase, generating Aß and p3, respectively. Most 
investigators have used SPA4CT, in which the signal peptide (SP) of APP was 
fused via the dipeptide leucine-glutamic acid (LE) to the N-terminus of A4CT to 
ensure correct insertion of the protein into the membrane of the endoplasmic 
reticulum (Dyrks et al., 1993). Cleavage of this fusion protein by signal peptidase 
results in A4CT with two additional amino acids at the N-terminus (Dyrks et al.,
1992). Recently, LE was substituted for aspartic acid and alanine (DA) resulting 
in an A4CT protein identified as the APP-fragment derived from processing of 
APP by ß-secretase (Lichtenthaler et al., 1999). Recent research has provided 
insight into the identity of the a - and ß-secretases (reviewed by Sinha and 
Lieberburg, 1999). The g-secretase enzyme has not been identified, although the 
polytopic transmembrane protein presenilin 1 (PS1) has recently been suggested 
to either directly influence the g-secretase or to be the g-secretase itself (Wolfe et 
al., 1999; De Strooper et al., 1999; Li et al., 2000; Russo et al., 2000).
As mentioned above, A4CT is proteolytically derived from APP via processing 
either by ß-secretase or via internal initiation of translation at Met596 that would 
not necessitate the involvement of ß-secretase. Citron et al. (1993) have used an in 
vitro assay to investigate this latter event, but they could not find evidence for 
internal translational initiation at Met596 of APP, possibly because the distance 
between the start codon and the Met596 codon is too long. Recently, a dinucleotide 
deletion at the RNA level in the region corresponding to exon 9 of the APP gene 
has been described, resulting in a truncated APP protein (Van Leeuwen et al., 
1998). We now would like to raise the hypothesis that the occurrence of a 
frameshift within APP-mRNA might allow internal reinitiation of translation to 
occur. To test this hypothesis, we have cloned exon 9 of the APP gene in three 
different frames in front of the green fluorescent protein GFP. We were able to 
show that an AUG in exon 9 can be used as internal initiation site. Furthermore, 
transfection of COS7 cells with A4CT revealed that Met596 can be used as an 
initiation site for translation. The A4CT protein is localized to vesicular structures 
and is processed to Aß by a g-secretase-like enzyme.
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Materials and Methods
Plasmid construction
Construct APP695/pcDNA3 was generated by cloning into pcDNA3 the 2740 bp HindIII- 
fragment of construct APP695/pSg5 (B. De Strooper; Center for Human Genetics, Leuven, 
Belgium). Construct pcDNA3/A4CT was obtained by subcloning the 1084 bp BglII/XhoI 
fragment of the APP695/pSG5 clone into the BamHI and XhoI sites of pcDNA3. The 
resulting plasmid includes the coding sequence for Met596 of APP695 as initiation codon, 
the complete Aß sequence and the entire carboxy-terminal domain of APP.
Exon 9 of the APP gene was amplified via PCR using human APP695-pSG5 cDNA as a 
template. The sequence of the 5’ primer was 5’-gggggggctagcgcttccggtcgccaccatggttccta- 
caacagcagccagtacc-3’, synthesized with an NheI-site. Three 3’-primers were used to 
generate different constructs and were synthesized with an AgeI-site: DGA-APPex9 5’- 
gggggggaccggtgggacattctctcggtgcttggcctcaag-3’ (= wt-frame), wtAPPex9 5’-ggggggcgac- 
cggtgggacattctctctcggtgcttggc-3’ (= +2-frame) and +1ntAPPex9 5’-ggggggaccggtggacatt- 
ctctctcggtgctt-3’ (= +1-frame). PCR was performed for 1 min at 94°C, 1 min at 55 °C and 
1 min at 72°C for 35 cycles. The PCR-products were digested and cloned into pEGFP-C1 
(Clontech #6084-1).
Antibodies
Polyclonal antibody C87 was generated by immunizing a rabbit with a synthetic peptide 
corresponding to the last 12 amino acids of human APP (NPTYKFFEQMQN). 
Monoclonal anti-Aß antibody (directed against the first 16 amino acids of human Aß) was 
purchased from BioSource (# 44-352).
Mutagenesis.
Mutagenesis was performed via Quick Change site directed mutagenesis (Stratagene) with 
primer mut1 5’-agtacccctggcgccgttgacaagt-3’ and mut2 5’-tatctcgagacacctggggcgagagc- 
gaacgcgcccatttccagaaa and removal of the ATG from pEGFP-C1 was performed by 
mutagenesis with primer 5’-ccgggatccatcgtgagcaagggcgaggagc-3’.
Tissue Culture
COS7 cells were grown in DMEM containing 10% fetal calf serum (FCS) and 1% 
penicillin/streptomycin (Gibco, Brl) at 37 °C and 5.5% CO2. COS7 cells were split at a 
1:8 ratio twice a week.
Transfection
Cells were cultured in a petridish (0  3.2 cm) or on a coverslip (0  24 mm) to 60% 
confluence and transiently transfected with 1 mg DNA using 3 ml Fugene (Roche). Cells 
were analyzed 24 hours after transfection.
Western blot analysis
For Western blot analysis, cells were lysed in lysis buffer (10 mM Hepes pH 7.4, 140 mM 
NaCl, 0.1 % Triton X-100, 0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF) and 1 mM soybean trypsin inhibitor). Cell lysates
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were denatured in Laemmli sample buffer at 95 °C for 5 min, separated on 12.5 % SDS- 
PAGE and transferred to nitrocellulose membranes (Protran, Schleicher and Schuell). The 
blot was incubated with APP-antibody C87, followed by reaction with peroxidase 
conjugated secondary antibody. The signal was detected using Lumilight (Roche) and 
quantified by using the BioRad Fluor-S-Max.
Immunofluorescence
Cells were fixed in 2% paraformaldehyde/PBS pH 7.4 for 1 hour, rinsed in PBS, 
incubated in 100 mM glycin/PBS for 30 min and permeabilized by three 5 min washes in 
0.1 % Tween/PBS (PbS-T). Antibody incubations were performed for 1 hour in PBS-T 
containing 2% (w/v) BSA (PBS-TB). Texas red-conjugated goat anti-rabbit antibodies 
(1:200; Jackson’s laboratories) and FITC-conjugated goat anti-mouse (1:200; Jackson’s 
laboratories) were used to visualize the antibody-antigen complex. Finally, coverslips 
were mounted in Mowiol (10% w/v Mowiol (Calbiochem) 15 % glycerol, 100 mM Tris- 
HCl pH 8.5 and 2.5 % NaN3) and analyzed with a Leica fluorescence microscope.
Metabolic cell labeling and immunoprecipitation
Twenty-four hours after transfection, cells were incubated for at least 30 minutes in 
methionine-free DMEM containing 10 % dialysed fetal bovine serum (FBS). The cells 
were pulse labeled for 30 minutes in the presence of 400 mCi/ml 35S-Met/Cys (Promix, 
Amersham) or pulse labeled and chased for 1 or 3 hours in regular DMEM with 10 % 
FBS and in the presence or absence of g-secretase inhibitor (20 mM MW-I-167; 
M.S.Wolfe). Following labeling, the cells were lysed on ice in 50 mM Hepes pH 7.4, 140 
mM NaCl, 0.5 % NP-40, 0.1 % deoxycholate, 0.1 % Triton X-100, 5 mM EDTA, 1 mM 
PMSF and 0.1 mg/ml soybean trypsin inhibitor. Lysates were cleared by centrifugation 
(10,000 x g, 3 min, 4 °C) and the supernatants were incubated overnight at 4 °C with 
antibody C87 (1:1000) or Aß 1-16 (1:1000). Immunocomplexes were precipitated with 2 
mg protein A sepharose and analyzed by applying to 12.5 % SDS-PAGE or 10-20% tris- 
tricine gels (Novex). The gels were exposed to a phosphor-imaging screen (BioRad 
Personal FX).
Results
Internal initiation o f translation in an mRNA region corresponding to exon 9 of 
the APP gene
Constructs containing exon 9 of the human APP gene in three different frames (in 
frame, lacking GA at positions 1136-1137; +2, wild type sequence; +1, deletion 
of G at position 1144; numbering according to wild type APP695, Kang et al.
1987) in front of GFP were transfected into COS7 cells. For the construct 
containing exon 9-DGA in frame with GFP, Western blot analysis with anti-GFP 
antibody on the cell lysates revealed the presence of a product of ~32 kD (Figure 
5-1). Western blot analysis on lysates containing the construct with exon 9 in the 
+2-frame in front of GFP (wild type) resulted in a small amount of ~27 kD,
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Figure 5-1
Internal initiation o f  translation in a construct containing exon 9 o f  the APP gene
Western blot analysis o f lysates o f COS7 cells transiently transfected with exon 9 APP-pEGFP constructs, which 
are schematically represented. In frame = exon 9 lacking GA1136.1137, in frame with pEGFP; +1 = exon 9 in +1- 
frame (lacks G1144) in front o f pEGFP; +2 = wild type exon 9 in +2-frame in front o f pEGFP; in mut 1 and mut2 
respectively one and three AUGs in exon 9 have been mutated. The arrow indicates the translational initiation 
site; asterisks indicate the translational termination site; - : COS7 cells; + : cells transfected with pEGFP.
migrating at the same height as GFP-immunoreactive product in cell lysates of 
cells transfected only with empty pEGFP. Remarkably, in the +1-transfected cells 
an extra product of ~30 kD was detected (Figure 5-1). To identify whether this 
product was derived from internal initiation of translation at an AUG in exon 9, 
mutagenesis was performed to remove the different AUGs. Removal of the AUG 
at nucleotides 1040-1042 (mut1) had no influence on the ~30 kD product, 
whereas removal of the hree AUGs (mut2) that are clustered between nucleotides 
1073-1087 (numbering according to APP695), the band of ~30 kD disappeared 
(Figure 5-1). Thus, one of the AUGs between nucleotides 1073-1087 was used as 
internal translational initiation site.
Expression and intracellular localization o f A4CT in COS7 cells 
The SPA4CT-DA protein, in which the signal peptide of APP was fused to the C- 
terminal 99 residues of APP (A4CT, C99) via the dipeptide Asp and Ala, has 
been reported to be a useful substrate for analyzing the enzyme g-secretase 
(Lichtenthaler et al., 1999a), because of it is expressed as the genuine A4CT.
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Here, we investigated by transfection studied in COS7 cells the production, 
routing and processing of the A4CT protein without a signal peptide. Western blot 
analysis with the anti-APP antibody C87 revealed the expression levels of A4CT 
and of the intact APP protein in the transfected COS7 cells (Figure 5-2). We have 
noticed that the amount of A4CT produced in the transfected cells is lower than
110 kD A PP  
100 kD A PP
Figure 5-2
A4CT-production in transfected COS7 cells 
Western blot analysis o f intact APP695 and A4CT 
produced in transiently transfected COS7 cells 
using anti-APP antibody C87. Lanes 1, 2 and 3 are 
lysates o f cells transfected with intact APP695, 
A4CT and mock, respectively. Molecular masses 
(Mr) of proteins are indicated in kD.
17 kD A4CT 
14 kD C83
that of intact wild type APP695. Figure 5-2 shows that A4CT is expressed and 
present in the lysate as a protein of ~17 kD, and that intact APP695 is processed to 
a product of ~14.5 kD, presumably by cleavage of a-secretase. A small amount of 
APP is endogenously expressed in COS7 cells as can be concluded from the 
mock-transfected sample.
Immunofluorescence was used to study the localization of A4CT within the COS 
cell. Since the construct lacks a signal peptide, the protein was expected to be 
localized in the cytoplasm. Remarkably, staining with C87 revealed that A4CT is 
located within vesicular structures (Figure 5-3).
Processing o f A4CT in COS7 cells
To gain more insight into the trafficking and the possible processing of A4CT to 
Aß, the biosynthesis of A4CT was investigated by pulse-chase analysis. COS7 
cells were transfected with either A4CT, APP695 or empty vector (mock). The 
transfected cells were pulse-labeled only or pulse labeled and chased, and the 
newly synthesized proteins were extracted and immunoprecipitated using C87 or 
an anti-APP antibody directed against Aß. Following a 30-min pulse, A4CT was 
again detected in the lysate as a protein of ~17 kD (Figure 5-4). During a
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Figure 5-3
The A4CT protein is localized in vesicular structures in transfected COS7 cells
Immunofluorescence of A4CT-transfected COS7 cells with anti-APP antibody C87. N  = nucleus. The bar 
indicates 10 mm.
subsequent chase this protein was processed to Aß, that was detected in the 
medium by immunoprecipitation analysis with the anti-Aß antibody. APP695 is 
synthesized as a protein of ~110 kD, part of which is subsequently processed to a 
~14 kD protein that is also immunoprecipitated by C87 from the lysates (Figure 
5-4). Following a 3 hours chase, the amount of this product in the lysates was 
reduced, but no Aß-related protein could be detected in the medium. Mock- 
transfected cells revealed the endogenously expressed APP751/770 protein, that is 
migrating as a ~125 kD protein, and also processed to a ~14 kD protein; again, no 
Aß was detectable in the medium (Figure 5-4).
Effect o f the g-secretase inhibitor MW-I-167on A4CT biosynthesis 
To investigate whether Aß was generated from A4CT by the g-secretase enzyme 
known to be involved in the production of Aß from intact APP, the effect of the g- 
secretase inhibitor MW-I-167 was studied. COS7 cells were transfected with 
either A4CT, APP695 or mock. The transfected cells were pulse labeled only or 
pulse labeled and chased in the presence or absence of MW-I-167, and the newly 
synthesized proteins were extracted and immunoprecipitated using the anti-Aß 
antibody. Following the 30-min pulse, A4CT could be detected in the lysates 
(Figure 5-4). During a subsequent chase the ~17 kD A4CT protein was processed 
to Aß, which was found in the medium of 1 hour chase. Addition of the g-
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Figure 5-4
In transfected COS7 cells, the A4CT protein is processed to Aß by an enzyme with characteristics o f  g- 
secretase
COS7 cells were transfected with either mock (A-B), APP695 or A4CT (C-D) and pulse labeled in the presence of 
35S-Met/Cys or pulse labeled and chased. Proteins were extracted from cells and media, and APP and its 
derivatives were immunoprecipitated with either anti-APP antibody C87 (lysates; A-C) or anti-Aß antibody 
(media; B-D). + and — indicate the presence or absence of the g-secretase inhibitor MW-I-167, respectively. 
Molecular masses (Mr) of proteins are indicated in kD.
8
+ ++
+ +
0 0
secretase inhibitor prevented the conversion of A4CT to Aß since the amount of 
A4CT in the lysates was increased and a reduced amount of Aß was found in the 
medium (Figure 5-4). MW-I-167 also prevented the processing of the ~14 kD 
APP-derived C83-product, since after addition of the g-secretase inhibitor the 
amount of this product had also increased in the lysates of cells transfected with 
APP6 9 5  or mock. Again, no Aß could be detected in the media of these cells 
(Figure 5-4).
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Discussion
A possible treatment of AD may involve the inhibition or modulation of g- 
secretase, the enzyme responsible for the processing of the APP-derived protein 
A4CT at the C-terminus of the Aß-region within the transmembrane domain. 
Inhibitors for g-secretase activity, such as the compound MW-I-167, have been 
successfully used to study the characteristics of the enzyme (Citron et al., 1996; 
Higaki et al., 1995; Klafki et al., 1996; Wolfe et al., 1998; Yamazaki et al., 1997). 
These inhibitor studies, together with molecular modeling and mutagenesis of the 
g-secretase cleavage site of APP, suggest that g-secretases are aspartyl proteases 
that catalyze a novel intramembranous proteolysis, which also requires the 
presenilins (Annaert et al., 1999; Kimberly et al., 2000; Li et al., 2000; Russo et 
al., 2000; Wolfe et al., 1999a-b). Presenilin-1 has been proposed to either only 
influence this cleavage or to be the responsible enzyme itself (Wolfe et al., 1999; 
De Strooper et al., 1999; Li et al., 2000; Russo et al., 2000). Transfection studies, 
in which the conversion of A4CT to Aß is examined, may give some clues about 
the activity and specificity of g-secretase. Transfection of A4CT in COS7 cells 
resulted in the production of a protein of ~17 kD that could be detected by 
Western blot and immunoprecipitation analysis of cell lysates. No additional 
bands were observed. Previous research has shown that A4CT can aggregate, 
resulting in a ladder of bands on a Western blot, whereas insertion of A4CT into 
the membrane prevents aggregation of this protein, on a Western blot leading to a 
single band (Dyrks et al., 1992). This indicates that our transfected A4CT is 
presumably integrated in the membrane. It is remarkable that A4CT, that lacks a 
signal peptide, was found in vesicular structures. Previously, researchers also 
noticed a strong interaction of in vitro translated A4CT with microsomal 
membranes (Dyrks et al., 1992), indicating that the hydrophobic transmembrane 
region is sufficient for translocation across a membrane. The presence of Aß in 
the medium indicates that A4CT ends up in vesicles that can fuse with the plasma 
membrane.
In our studies, COS7 cells processed intact APP mostly to C83, indicating that a- 
secretase is active and more predominantly present than ß-secretase, and only a 
small amount of Aß was produced. Whereas other groups have also found a 
predominant cleavage of intact APP by a-secretase in cells (Iizuka et al., 1996; 
Koike et al., 1999), Lichtenthaler et al. (1997) found the generation of an 
appreciable amount of Aß after transfection of intact APP into these cells. The 
fact that endogenously COS7 cells hardly produce Aß, make A4CT-transfected 
COS7 cells a good model to study g-secretase activity, since the production of the 
A4CT-protein does not involve the need for a ß-secretase cleavage.
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Compared to the results obtained by the transfection of A4CT into SY5Y cells 
(Dyrks et al., 1993), the production of A4CT and Aß in our transfected COS7 
cells is high. This might indicate that COS7 cells can use Met596, the initiation-site 
for A4CT, more efficiently than SY5Y cells. The fact that A4CT is produced 
indicates that the Met596 codon can be used as an initiation site for translation. 
Internal initiation of translation at this methionine may provide an alternative 
pathway for the production of Aß, i.e. without the initial production of intact APP 
and independent of ß-secretase activity. Citron et al. (1993) used an in vitro assay 
to investigate internal translational initiation at Met596 of APP. They engineered 
frameshift mutations in APP6 9 5  cDNA by inserting or deleting a single nucleotide, 
10 or 5 nucleotides in front of the codon for Met596. For this construct, only 
internal initiation of translation at Met5 9 6  would lead to Aß-production. However, 
no Aß was detected and thus no evidence for internal translational initiation was 
found (Citron et al., 1993). In our present study, we have shown that internal 
translational initiation in APP can occur, possibly also involving the process of 
frameshift mutations in that molecular misreading of the APP gene would lead to 
early termination (Van Leeuwen et al., 1998; Hol et al., 1999), which may allow 
translational reinitiation at Met596.
Finally, the inhibition of g-secretase activity with compound MW-I-167 led to 
reduced processing, not only of A4CT, but also of C83, the carboxy-terminal part 
of APP generated by a-secretase. This would suggest that proteins with similar 
enzymatic characteristics are responsible for the production of Aß and p3, and 
that the signal peptide deficient A4CT-protein is present in g-secretase-containing 
vesicles. Together, our results indicate that A4CT is a useful protein to study the 
enzymatic characteristics of g-secretase.
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Het leven van een Xenopus
Een oöcyt in een schaaltje 
Een rondzwemmende spermatozo 
Als ze elkaar bevruchten 
Ontstaat er een embryo
Het embryo gaat groeien 
Een dikke kop, een lange staart 
Met zijn bolle ogen 
Wordt het tot kikkervis verklaard
Daarna wordt hij slanker 
En met pootjes getooid 
Hij kan nu gaan springen 
De metamorfose is voltooid
Ziijn huid kan verkleuren 
En eenmaal goed geadapteerd 
Eindigt het kikkerleven 
En wordt hij gedecapiteerd
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Developmental expression of APP in Xenopus laevis
Abstract
The ß-amyloid precursor protein APP is a transmembrane protein that is highly 
conserved from mammals to the amphibian Xenopus laevis. During Xenopus 
development splicing patterns of APP mRNA have previously been investigated 
at the RNA level in oocytes, gastrula and stage 42 embryos. Here we examined at 
both the RNA and protein level the APP expression patterns of the different 
isoforms in many developmental stages of Xenopus laevis. APP is maternally 
inherited as APP695, whereas the zygotic onset starts around stage 20 resulting in 
the production of the three splicing variants of APP. In the brains of embryos 
from stage 42 onwards, APP6 9 5  is produced predominantly, showing that already 
during early development this APP isoform is preferentially expressed. In non­
neuronal tissues, APP751/7 70 are the major isoforms expressed. Furthermore, we 
identified in stage 38 and subsequent stages a novel APP-related product of ~70 
kD. We conclude that during early development of Xenopus laevis initially 
APP695, but subsequently all three forms of APP are expressed in a manner 
suggesting that these forms have different developmental roles.
Introduction
The ß-amyloid precursor protein APP has been identified as the precursor for ß- 
amyloid, a peptide of 40-42 amino acids that is present in the neuritic plaques of 
patients with Alzheimer’s disease (AD) or Down’s syndrome (DS) (Glenner and 
Wong, 1984a-b). APP exists in three major forms of 695, 751 and 770 amino 
acids, which are resulting from alternative splicing. APP has been identified in 
human (Kang et al., 1987; Kitaguchi et al., 1988; Ponte et al. 1988; Tanzi et al.,
1988), mouse (Yamada et al., 1987; Yamada et al., 1989), rat (Kang et al., 1989; 
Shivers et al., 1988) and Xenopus laevis (Okado and Okamoto, 1992/1995). In 
addition to the alternatively spliced variants, several APP-related proteins have 
been identified (that, together with APP, form the APP superfamily), including 
human APP-like protein-1 (APLP1) and APLP2 (Wasco et al., 1993; Sprecher et 
al., 1993), mouse APLP1 (Wasco et al., 1992), Drosophila APPL (Rosen et al.,
1989) and C. elegans APL-1 (Daigle and Li, 1993). Within the members of the 
APP family, three main regions of amino acid sequence identity have been 
identified, namely extracellular domains 1 and 2 (designated E1 and E2, 
respectively), and one region in the cytoplasmic domain. E1 contains twelve 
conserved cysteines, E2 contains a large number of negatively charged residues 
and N-linked glycosylation sites, whereas the cytoplasmic domain contains the
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NPXY-sequence implicated in clathrin-coated vesicle targeting (Chen et al.,
1990). The strong structural conservation within the superfamily indicates an 
important function for APP and the APP-like proteins.
Expression of the Drosophila APPL is restricted to the nervous system (Martin- 
Morris and White, 1990) and neuronal overexpression has been shown to disrupt 
axonal transport (Torroja et al., 1999), suggesting a role for APPL during 
development. Mouse APLP2 (initially described as a DNA-binding protein under 
the name Cdebp; Vidal et al., 1992; Hanes et al., 1993) has been shown to be 
required for correct genomic segregation in dividing mouse cells (Rassoulzadegan 
et al., 1998) and a possible role in pre-implantation development has been 
suggested for this protein (Blangy et al., 1991/1995). Analysis of APP expression 
in developmental stages of mouse has revealed the presence of APP throughout 
all stages examined, although there were changes in the ratios of the splicing 
forms in the different stages (Fisher et al., 1991). The relevance of the occurrence 
of these different ratios remains to be established. APP has also been identified in 
the non-mammalian clawed toad Xenopus laevis and its splicing patterns during 
development have been investigated at the RNA level in a limited number of 
developmental stages, namely only in oocytes, gastrula and stage 42 embryos 
(Okado and Okamoto, 1992). Here we used the well-defined developmental 
stages of Xenopus laevis to study APP expression during Xenopus development in 
more detail at both the RNA-and protein-level. We reveal the presence of APP in 
all developmental stages examined and show, by analyzing the brains of stage 42 
embryos and subsequent stages, that APP6 9 5  is predominantly expressed in neural 
tissues. Furthermore, we discovered a novel ~70 kD APP-raleted product in 
peripheral tissues. The overall expression pattern of APP in the various 
developmental stages suggests an important role for APP during Xenopus 
development.
Materials and Methods
Xenopus laevis embryos
Xenopus laevis embryos were obtained by in vitro fertilization as described (Harland and 
Sive, 1993) and were allowed to develop in 0.1 x MMR (0.5 mM Hepes pH 7.5, 10 mM 
NaCl, 0.2 mM KCl, 0.1 mM MgSO4, 0.15 mM CaCl2, 0.01 mM EDTA) at 16°C until the 
desired stages. The embryonic stages are numbered according to Nieuwkoop and Faber 
(1967).
Antibodies
Polyclonal antibody C87 and J58 were generated by immunizing a rabbit with a synthetic 
peptide corresponding to the C-terminal 12 amino acids among all known APP-proteins
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(NPTYKFFEQMQN) and amino acid 1-12 of Xenopus Aß (DSEYRHDAAYEV), 
respectively.
RT-PCR for determining splicing pattern in different tissues
Using Trizol (Gibco Brl; standard protocol), total RNA was extracted from different 
tissues of Xenopus laevis that were adapted to a black background. Different 
concentrations of total RNA, varying from 0.2-2 mg, and random priming were used for 
the production of single stranded cDNA. For analysis of APP mRNA, RT-PCR with sense 
primer 5 ’ -CTTTGGATCCCGAGGAACCCTATGAAGAAG-3 ’ (S1; nt 794-815 
according to Okado and Okamoto, 1992)) and antisense primer 5’- 
CCTCTCCTTTGCTTTCA-3 ’ (A1; nt 1139-1155) was performed. Different 
concentrations of RT material were used for amplification. Amplification was performed 
at 94 °C for 1 min, 55 °C for 1 min. and 72 °C for 1 min. for 30 cycles. A final additional 
extension step of 10 min. at 72 °C was performed. PCR-products were applied to a 2.0 % 
agarose gel.
Western blot analysis
Embryos were homogenized in lysis buffer (10 mM Hepes pH 7.3, 140 mM NaCl, 0.1 % 
Triton, 0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride (PMSF) and 1 mM soybean trypsin inhibitor). Cell lysates 
were denatured in Laemmli sample buffer at 95 °C for 5 min, separated on 12.5 % SDS- 
PAGE and transferred to nitrocellulose membranes (Protran, Schleicher and Schuell). The 
blot was incubated with antibody C87, followed by reaction with peroxidase conjugated 
secondary antibody. The signal was detected using Lumilight (Roche) and quantified with 
Fluor-S-Max (BioRad).
Metabolic cell labeling and immunoprecipitation
Neurointermediate lobes from adult Xenopus laevis and whole brains from stage 48 
Xenopus embryos were dissected, incubated for at least 30 minutes in methionine-free 
XL15 (XL15: 67 % Leibovitz’s L15 medium; Gibco BRL) containing 10 % fetal bovine 
serum (FBS), and pulse labeled overnight in the presence of 5 mCi/ml 35S-Met/ Cys 
(Promix; Amersham). Following labeling, the cells were lysed on ice in lysis buffer (50 
mM Hepes pH 7.4, 140 mM NaCl, 0.5 % NP-40, 0.1 % deoxycholate, 0.1 % Triton X- 
100, 5 mM EDTA, 1 mM PMSF and 0.1 mg/ml soybean trypsin inhibitor). Lysates were 
cleared by centrifugation (10,000 x g, 3 min, 4 °C) and the supernatants were incubated 
o/n at 4 °C with antibody C87 (1:1000) or Aß 1-16 (1:1000). Immunocomplexes were 
precipitated with 2 mg protein A sepharose and analyzed on a 12.5 % SDS-PAGE or 10­
20% tris-tricine gel (Novex). The gels were exposed to a phosphor-imaging screen 
(Personal FX; BioRad).
Results and Discussion
The developmental expression of Xenopus APP has been studied before, but only 
at the RNA-level and only in oocytes, gastrula and stage 42 embryos (Okado and
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Okamoto, 1992). Here we analyzed both APP-RNA and-protein expression in the 
oocyte and in many developmental stages up to stage 54 Xenopus embryos.
Expression of APP-mRNA splicing variants during Xenopus laevis development 
APP-mRNA was present in all stages of Xenopus laevis development analyzed, 
but the ratios of the splicing variants differed among the stages (Figure 6-1). In 
the oocyte, APP695 mRNA is predominantly present, whereas in stage 20 and 
subsequent stages also APP751/7 70 mRNA is expressed (Figure 6-1). As it is in 
adult brain, in the brain of the developing Xenopus, APP6 9 5  mRNA is the
A
B
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Figure 6-1
A. RT-PCR analysis o f  alternatively spliced variants o f  APP-mRNA in developmental stages o f  Xenopus 
laevis
The PCR-band of 215 nt lacks the KPI and the OX-2 domain of APP. The band of 383 nt contains only KPI and 
the band of 440 nt contains both the KPI and the OX-2 domain. The stages are numbered according to 
Nieuwkoop and Faber (1994). H=head; B=brain; T=tail (embryo minus head/brain).
B. Ratios o f  APP-mRNA splicing form s in developmental stages o f  Xenopus laevis
The ratios o f APP695, APP751 and APP770 were calculated in arbitrary units o f optical density from the intensities 
of the bands in the RT-PCR analysis shown in A. The total amounts of AU per developmental stage were set to 
100 % to determine the ratios o f the alternatively spliced variants. The numbers shown are the mean of five 
independent experiments. All stages are numbered according to Nieuwkoop and Faber (1994).
predominant splicing variant (Chapter 7). Therefore, we separated from stage 42 
onwards the head/brain from the rest of the embryo to investigate during 
development the zygotic onset of APP6 9 5  in brain. The early presence of APP6 9 5  
points to a possible role for this variant during development, as has been shown 
for the APP family members Drosophila APPL (Torroja et al. 1999) and mouse
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APLP2 (Blangy et al., 1991,1995; Vidal et al., 1992; Hanes et al., 1993; 
Rassoulzadegan et al., 1998). The expression of the APP splice variants 
throughout all developmental stages indicates a potential function for these forms 
during development. This potential importance of APP in organogenesis, 
neurulation and other embryological events has also been suggested on the basis 
of the results of similar research in mouse embryos from embryonic day 0 to 10.5 
(Fisher et al., 1991). Fisher et al. (1991) concluded that the tissue-specific pre- 
mRNA splicing is clearly acquired later in development since all three major 
variants are present at even the earliest stages examined. In mouse, they already 
show a difference between the splicing ratios in the oocyte and the 2-cell stage 
embryo. The ratio difference of the splicing variants can more easily be explained 
by differences in alternative splicing rather than by differential degradation of 
maternal mRNAs. The APP gene from the mouse embryonic genome may thus be 
transcribed earlier than we have observed for the Xenopus, where zygotic onset 
starts around stage 12. At that later stage (later than stage 12) the three germlayers 
(endoderm, mesoderm and ectoderm) have been determined, opening the 
possibility that APP splice variants are restricted or enriched in a specific germ 
layer (for instance APP695 in the ectoderm).
The presence of APP-mRNA already in the oocyte shows that it is maternally 
inherited, as has been suggested previously for Xenopus and mouse (Fisher et al., 
1991; Okado and Okamoto, 1992). Compared to the internal control ODC, the 
level of APP mRNA decreases from stage 4 to stage 12 and increases in stage 20, 
indicating that the zygotic onset of APP-expression is likely to be around stage 
20. This can also be concluded from the observation that APP751-RNA is present 
in stage 20 embryos, a transcript that is not found in the oocyte.
Expression o f different isoforms o f the APP-protein during Xenopus laevis 
development
The fact that APP-mRNA is expressed in all developmental stages of Xenopus 
laevis examined does not imply that it is translated into protein. We therefore 
analyzed the presence of the APP-protein in the various stages by Western blot
Developmental expression of APP in Xenopus laevis
42 44 46 48 50 52 54
Figure 6-2
Expression o f  the APP-protein during Xenopus laevis development
Western blot analysis with anti-APP antibody C87 on lysates of different developmental stages of Xenopus 
laevis. Stages are numbered according to Nieuwkoop and Faber (1994).
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analysis with anti-APP antibody C87; the different isoforms of the APP protein 
(~ 110 kD, ~125 kD, ~135 kD) could be separated on the gel used (Figure 6-2). 
The APP-protein was detected in oocytes as a product of ~110 kD, which 
corresponds to the glycosylated form of APP695 (Pâhlsson et al., 1992; Páhlsson 
and Spitalnik, 1996; Tomita et al., 1998; Yazaki et al., 1996; Chapter 8). In stages 
4 to 12, only a small amount of the APP-protein was detected, but from stage 20 
onwards the ~110 kD protein was clearly produced again (Figure 6-2). In all 
stages, APP6 9 5  could be detected, both at the RNA and the protein level, although 
the amount differs between the various stages. In the isolated brains, ~110 kD 
APP695 was the major APP-protein present. In stage 48 brains, the ~110 kD 
APP695-protein was also a newly synthesized protein, co-migrating with 
immunoprecipitated newly synthesized APP from the neurointermediate lobe
110 kD APP
Figure 6-3
APP is present as an ~110 kD protein in brains o f  stage 48 
embryos o f  Xenopus laevis
Brains from stage 48 embryos and neurointermediate lobes of 
adult Xenopus laevis were isolated and newly synthesized 
proteins were labeled overnight with 35S-Met/Cys. APP was 
precipitated from the lysates with antibody Aß7/9, C87 or GID 
and applied to a precast 10-20% Tris-Tricine gel (NuPage, 
Novex). The signal was detected by phosphor-imaging 
(BioRad, Personal FX).
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(NIL) of the pituitary of adult Xenopus laevis (Figure 6-3). It is remarkable that 
the larger APP isoforms (~120 kD; APP751/7 70) are only detected from stage 46 in 
the embryo lacking the brain, whereas the corresponding RNA is already present 
in stage 20. Remarkably, an APP-related product of ~70 kD was found to be 
present in stage 38 and subsequent stages, but not in brain lysates (Figure 6-2). 
This product was not detected with preimmune serum nor with an N-terminal 
anti-APP antibody (data not shown). This would suggest that APP-70 is present in 
peripheral tissues and arises either through alternative pre-mRNA splicing or via 
processing of an intact APP protein. Previously, Northern blot analysis has 
revealed that APP-mRNA is ubiquitously expressed and that the size of the APP- 
transcript detected in for instance heart, liver, kidney and spleen resembles the
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size of the APP-transcript in brain (Tanzi et al., 1987). Western blot analysis of 
such (adult) Xenopus tissues revealed also the presence of a 70 kD protein (data 
not shown), even more suggesting that during tissue differentiation APP is present 
as a ~70 kD protein. The fact that both an anti-APP C-terminal and an anti-Aß 
antibody recognized the ~70 kD product, suggests that these regions are present in 
this product. Further studies are necessary to characterize this APP-related protein 
including pulse-chase analysis.
In conclusion, we have shown that APP is expressed during normal development 
in all stages of Xenopus laevis. The expression pattern of the different isoforms in 
the various tissues indicates a physiological role for APP during early 
development.
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The ß-amyloid precursor protein in Xenopus laevis
Abstract
The ß-amyloid precursor protein APP is generally accepted to be directly or 
indirectly involved in the neurodegenerative disorder Alzheimer’s disease and has 
been extensively studied in a number of mammalian systems. Its normal function 
remains, however, still elusive. We have used the clawed toad Xenopus laevis to 
study the first non-mammalian APP protein. Screening of a Xenopus laevis 
intermediate pituitary cDNA library led to the identification of two structurally 
different APP gene transcripts presumably resulting from duplicated genes. 
Sequence comparison between the Xenopus and human APP proteins revealed at 
the amino acid sequence level an identity of 92 %. Both Xenopus genes were found 
to be expressed in all tissues examined, but their expression levels differed among 
tissues. In addition, as in mammals, alternative splicing was observed and the 
alternatively spliced APP6 9 5  mRNA variant was expressed predominantly in the 
brain and the oocyte, while the longer isoforms (APP751_7 70) were predominant in the 
other tissues examined. Of interest is the finding that, like human but unlike mouse 
or rat ß-amyloid (Aß), the Xenopus peptide contains all amino acid residues 
implicated in amyloidogenesis. We conclude that Xenopus APP mRNA is 
ubiquitously expressed and alternatively spliced, and that the highly conserved 
Xenopus APP protein contains an Aß peptide with amyloidogenic potency.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the 
presence of neurofibrillary tangles and senile plaques in the brain. A major 
constituent of the plaques is ß-amyloid (Aß), a peptide produced by processing ol 
the type I transmembrane ß -Amyloid Precursor Protein (APP) through ß- and g- 
secretase (Glenner and Wong, 1984a). Normal cleavage of APP by a-secretase 
effectively prevents formation of Aß and results in the production of a form of APP 
that can be secreted (APPas) and a membrane-associated 83 amino acids carboxy- 
terminal fragment (Palmert et al., 1989; Weidemann et al., 1989; Esch et al., 1990; 
Kametani et al., 1990; Wang et al., 1991). ß-secretase cleavage of APP leads to the 
release of secreted forms of APP (APPßs) and leaves intact Aß behind in a 
membrane-associated 99 amino acids carboxy-terminal fragment of APP (C99; 
A4CT). This fragment can be further processed by g-secretase to release the toxic 
Aß (Estus et al., 1992; Selkoe, 1993; Higaki et al., 1995; Knops et al., 1995). APP 
exists in three major forms of 695, 751 and 770 amino acids, resulting from
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alternative pre-mRNA splicing (Kang et al., 1987; Tanzi et al., 1988; Kitaguchi et 
al., 1988). In addition to the alternatively spliced variants, several members have 
been identified within the APP superfamily, including human APP-like protein-1 
(APLP1) and APLP2 (Wasco et al., 1993; Sprecher et al., 1993), mouse APLP1 
(Wasco et al., 1992), Drosophila APPL (Rosen et al., 1989) and C. elegans APL-1 
(Daigle and Li, 1993). Three main regions of amino acid sequence identity have 
been identified among these members, namely two regions in the extracellular 
domain (designated as E1 and E2), and one region in the cytoplasmic domain. E1 
contains the twelve conserved cysteines, E2 has a large number of negatively 
charged residues and N-linked glycosylation-sites, whereas the cytoplasmic domain 
contains the NPXY-sequence implicated in clathrin-coated vesicle targeting (Chen 
et al., 1990). The strong structural conservation within the superfamily indicates an 
important function for APP and APP-like proteins (Coulson et al., 2000).
In mammals, the APP protein is expressed in all tissues examined, but there are 
differences in the expression levels of the splicing variants. Neuronal cells 
predominantly express APP695 (Bendotti et al., 1988; Goedert, 1987; Shivers et al., 
1988), whereas the APP751/7 70 form is mainly expressed in non-neuronal tissues such 
as heart, lung, liver, kidney, muscle and spleen (Forloni et al., 1992; Mattson, 1997; 
Sandbrink et al., 1994; Tanzi et al., 1987; Zimmermann et al., 1988). Although the 
APP gene is already known for more than 15 years, its function remains elusive. 
Initially, a function as cell surface receptor was proposed, based on the topology of 
the protein (Kang et al., 1987). However, the cytoplasmic part of APP does not 
contain an amino acid sequence similar to signal-transducing domains in any known 
receptor. Moreover, no ligand for APP has been identified and APP has not been 
linked to an intracellular signal transduction pathway, although it can activate G0 
(Nishimoto et al., 1993). Other functions, such as a heparan sulfate proteoglycan 
core protein (Schubert et al., 1988), a modulator of cell-cell adhesion (Shivers et al.,
1988), and a membrane cargo receptor for kinesin-1 (Kamal et al., 2000) have been 
proposed. Moreover, several regulatory functions have been suggested for the 
fragments that are proteolytically derived from APP. All studies on the 
physiological role of APP involved the overexpression of APP in cell lines and in 
mice, or were performed with in vitro assays (for review see Mattson 1997). We 
decided to use a lower vertebrate, namely the South-African clawed toad Xenopus 
laevis, as a model system to study APP.
Here we describe the complete cDNA sequences of two Xenopus laevis APP-gene 
transcripts. Furthermore, we have examined the distribution and occurrence of 
alternatively spliced variants of Xenopus APP mRNA in different tissues. Our 
results suggest that Xenopus laevis can serve as a powerful animal model for further 
studies on the function of APP.
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Materials and methods
Animals
South-African clawed toads, Xenopus laevis, were bred and reared in the aquarium facility 
of the Department of Animal Physiology at the University of Nijmegen. Animals were 
adapted to a black background under constant illumination at 22 °C for at least three weeks.
Screening o f Xenopus intermediate pituitary cDNA library
The amplified unidirectional cDNA library (5 x 108 pfu/ml) of neurointermediate pituitaries 
of black-adapted Xenopus laevis (Kuiper et al., 2000) was hybridized (250 mM 
Na2HPO4-2H2O, 0.17 % fosforic acid, 7 % SDS, 1 mM EDTA) overnight at 65 °C with a 
Xenopus APP PCR-product (nt. 493-1156, numbering according to Okado and Okamoto
1992) labeled with 32P-dCTP by random-priming (Gibco BRL). Filters were washed twice 
for 10 minutes each in 40 mM Na2HPO4-2H2O, 0.03 % phosphoric acid, 0.1 % SDS, 1 mM 
EDTA at 65 °C and then exposed to Kodak XR films. Hybridization-positive phages were 
purified and the pBluescript SK-phagemids were rescued from the IZAPII clones by in vivo 
excision according to the manufacturers instructions (Stratagene). The insert sizes of the 
positive clones were determined and the clones were sequenced (ABI prism 310, Perkin 
Elmer).
RNase protection assay
The RNase protection assay was performed according to the manufacturer’s protocol (RPA 
III kit, Ambion). Briefly, X-APP-A (nt. 1-581) and Xenopus ornithine decarboxylase (ODC) 
were randomly labeled with 32P-dUTP (Maxiscript T7, Ambion). After gel purification of 
the probe, 4x 104 cpm were added to 5 mg of total RNA. Hybridization was performed 
overnight at 56 ° C, and the RNA was digested with RNase A/T1. Protected fragments were 
analyzed on a 5 % polyacrylamide gel and the gel was exposed to a phosphor-imaging 
screen (BioRad, Personal FX). Quality and amount of RNA was checked by hybridizing 
samples to antisense RNA probe against the Xenopus housekeeping ornithine-decarboxylase 
(ODC) transcript.
Using Trizol (Gibco Brl; standard protocol), total RNA was extracted from different tissues 
of Xenopus laevis that were adapted to a black background. Different concentrations of total 
RNA, varying from 0.2-2 mg, and random priming were used for the production of single 
stranded cDNA. To check for the exponential phase of the PCR, different concentrations of 
cDNA were used in the PCR-reaction. The sequence of the sense primer was: 5’- 
CTTTGGATCCCGAGGAACCCTATGAAGAAG-3’ (S1; nt 794-815, numbering 
according to Okado and Okamoto, 1992). The sequence of the antisense primer was: 5’- 
CCTCTCCTTTGCTTTCA-3’ (A1; nt 1139-1155). For amplification of Xenopus ODC, 5’- 
GTCAATGATGGAGTGTATGGATC-3 ’ was used as sense and 5’- 
TCCATTCCGCTCTCCTGAGCAC-3’as antisense primer. Amplification was performed at 
94 °C for 1 min, 55 °C for 1 min. and 72 °C for 1 min. for 30 cycles. An extra extension 
step of 10 min. at 72 °C was performed. PCR-products were applied to a 1.4 % agarose gel.
RNA isolation and RT-PCR analysis
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For analyzing the ratio between APP-A and APP-B, the PCR-products were completely 
digested with HindIII (cleaves only within APP-A) before applying the products to the gel.
Results and discussion
Cloning and sequence analysis o f Xenopus APP-A and -B cDNAs 
A unidirectional cDNA library, generated from neurointermediate lobe mRNA of 
black-adapted Xenopus laevis, was screened with a 32P-labeled probe corresponding 
to nucleotides 493-1155 of Xenopus APP mRNA (numbering according to Okado 
and Okamoto 1992). Out of 400,000 plaques, all 24 hybridization-positive clones 
contained APP6 9 5 -cDNA, nine of which were full length clones (one of the full 
length clones was designated X-APP-A). Comparison of the nucleotide sequence of 
X-APP-A with the previously published Xenopus APP-cDNA revealed a 98.7% 
identity in the coding region, probably caused by polymorphism within the Xenopus 
species (Figure 7-1). Compared to the known Xenopus APP mRNA sequence (with 
a 3’-untranslated region, 3’UTR, of 716 nt), clone X-APP-A contained a short 3’ 
UTR of ~107 nucleotides with 98,4 % nucleotide sequence identity, pointing to 
alternative oligo-dT priming during library construction or alternative poly- 
adenylation during APP gene transcription.
Two full length clones (one designated X-APP-B; Figure 7-1) were found to be 
structurally different from X-APP-A, with 94,3 % nucleotide sequence identity to 
the previously published Xenopus APP mRNA sequence, suggesting that these were 
analogues of the Xenopus APP-A sequence and derived from a duplicated gene; 
Xenopus laevis is a tetraploid organism with a duplicated genome (Bisbee et al., 
1977). For several genes, such as those coding for proenkephalin (Martens and 
Herbert, 1984), serum albumin (Westley et al., 1981), POMC (Martens 1986), D2 
dopamine receptor (Martens et al., 1993) and PC2 (Braks et al., 1992), the existence 
of two transcripts has also been reported.
At the nucleotide sequence level the identity between X-APP-A and X-APP-B in 
the coding part is 95.4 %. Like for X-APP-A, the 3’ UTR of X-APP-B (~ 563 
nucleotides) is shorter than the size of the 3’UTR of the previously published 
Xenopus APP mRNA, and the nucleotide sequence identity with the previously 
published 3’-UTR sequence is only 63.3 % (Figure 7-1). Thus, X-APP-A 
corresponds to the previously published, and X-APP-B to the second Xenopus APP 
gene transcript.
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Figure 7-1.
Alignment o f Xenopus laevis cDNA sequences encoding the APP proteins A and B with the previously published 
Xenopus laevis APP-cDNA-sequence (Okado and Okamoto, 1992; EMBL # S52417).
Conserved nucleotides are boxed. The arrow indicates the translational start codon and the asterisk denotes the 
translational termination codon (Accession #AJ298150 corresponds to X-APP-A and #AJ298151 to X-APP-B).
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IGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLS KMQQNGYENPTYKFFEQMQN
IGLMVGGVVIATVIVITLVMLKKKQYTTIHHGVVEVDAAVTPEERHLTKMQQNGYENPTYKFFEQMQN
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*
Figure 7-2.
Comparison o f the amino acid sequences o f the Xenopus laevis (A and B), human, rat and mouse APP proteins.
The one-letter amino acid notation is used and conserved amino acids are boxed. The signal peptide is represented 
by a dashed line and the transmembrane domain by a bold line; dots represent the conserved cysteines and asterisks 
indicate potential N-linked glycosylation sites. The human (# Y00264), rat (# X07648) and mouse (# X59379) APP 
sequences were obtained from the EMBL database.
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Comparison of the Xenopus and mammalian APP sequences
The degree of identity between the nucleotide sequences in the protein-coding 
regions of the Xenopus-A/B mRNAs and the corresponding regions in human, rat 
and mouse APP 695 mRNAs is ~78 %, whereas the overall degree of amino acid 
sequence identity is 86-87 % (Figure 7-2), and the similarity is 92-93 %. The degree 
of evolutionary conservation of APP is thus very high, pointing to an important 
function for the APP protein. Remarkably, all sites in mammalian APP known to be 
used for post-translational modifications are conserved in Xenopus APP. The 
conservation of the twelve cysteines in the extracellular domain, that are also 
conserved in the Drosophila APPL and C. elegans APL-1 proteins (Rosen et al., 
1989; Daigle and Li 1993), indicates a functional importance for these residues. 
Furthermore, the O-linked glycosylation sites S124 and L172 (Tomita et al., 1998), 
as well as the N-linked glycosylation sites N467 and N496 (Kang et al., 1987) are 
conserved. Since the cytoplasmic part of APP is identical between Xenopus and 
mammals, a further potential O-linked glycosylation site, namely a cytoplasmic 
serine or threonine residues (Griffith et al., 1995) is also present in Xenopus APP. 
Several potential phosphorylation sites (S198, S206, S655 and T668) are present in 
human APP and have been shown to be indeed phosphorylated in cell lines by 
protein kinase C (S655; Suzuki et al., 1992), calcium/calmodulin dependent (cdc) 
protein kinase II (S655; Gandy et al., 1993; T668; Suzuki et al., 1994), and casein 
kinase (CK)-1 and CK-2 (S198 and S206; Walter et al., 1997). These sites are 
conserved in Xenopus laevis APP, except for S655, that is conservatively 
substituted by threonine, also resulting in a potential phosphorylation site.
The cytoplasmic tail of mammalian APP contains two sorting signals (GYENPTY 
and YTSI) characterized as internalization and endosomal/lysosomal targeting 
signals, and necessary for intracellular trafficking of APP. The NPXY-sequence is 
the signal that is required for coated-pit mediated internalization of the low density 
lipoprotein receptor (Chen et al., 1990), and is known to be involved in the 
internalization and routing of APP (De Strooper et al., 1993; Haass et al., 1993; 
Jacobsen et al., 1994; Lai et al., 1995; Ono et al., 1997). YTSI conforms to the 4- 
residue tyrosine-based internalization signal consensus sequence (Trowbridge et al.,
1993), but its relevance for APP trafficking has been found to be less critical than 
the NPXY sequence (Jacobsen et al., 1994; Lai et al., 1995). The YTSI-signal is 
present in Xenopus as YTTI (conservative S/T substitution), while the GYENPTY- 
sequence is fully conserved not only in Xenopus, but even in Drosophila and C. 
elegans (Rosen et al., 1989; Daigle and Li 1993).
Interestingly, the amino acid sequence of the Xenopus Aß peptide is nearly identical 
to the human Aß-sequence; the few amino acid substitutions found in the Xenopus 
Aß sequence are conservative changes (Figure 7-3). Aß-residues
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Human
Dog
P o la r  Bear
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Sheep
Pig
Guinea p ig
Mouse
Rat
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVVIAT
Xenopus-A DSEYRHDTAYEVHHQKLVFFAEEVGSNKGAIIGLMVGGVVIAT 
Xenopus-B DSEYRHDAAYEVHHQKLVFFADEVGSNKGAIIGLMVGGVVIAT
Figure 7-3.
Alignment o f the amino acid sequences o f human, dog, polar bear, rabbit, cow, sheep, pig, guinea pig, mouse, 
rat, Xenopus-A and Xenopus-B ß-amyloid.
Amino acid residues that differ from the human sequence are bold and underlined. Numbering refers to human 
APP695 sequence (Kang et al., 1987). Residues implicated in amyloidogenesis are indicated with asterisks.
Arg601, Tyr606 and His609, which are not present in rodent Aß, may underly the 
tendency for its aggregation (Dyrks et al., 1993; Johnstone et al., 1991). Especially 
Arg601 has been shown to be crucial for amyloidogenesis (De Strooper et al., 
1995). These amino acids are all conserved in Xenopus laevis. Furthermore, amino 
acid residues 16-24 of Aß (KLVFFAEDV), which are also conserved in the toad, 
are thought to be essential for fibril formation (Wood et al., 1995). Thus, in contrast 
to the rodent peptide, the Aß sequence of Xenopus laevis might have the same 
amyloidogenic characteristics as human A ß.
Expression o f Xenopus APP-mRNA
The expression pattern of APP mRNA in different Xenopus tissues was determined 
with an RNase protection assay (Figure 7-4). APP mRNA was found to be present 
in all Xenopus tissues examined (Table 7-1). This expression
C1 C2 Br He Lu Li Ki Sp Mu Oo Ov Te In
Figure 7-4.
RNase protection analysis o f APP mRNA in Xenopus tissues.
Radiolabeled anti-sense RNA (nt 1-591 of X-APP-A) was transcribed from Xenopus APP-cDNA and hybridized to 
5 mg of total RNA extracted from brain (Br), heart (He), lung (Lu), liver (Li), kidney (Ki), spleen (Sp), muscle 
(Mu), oocyte (Oo), ovary (Ov), testis (Te), and intestine (In). Following RNase treatment, samples were loaded 
onto a denaturing polyacrylamide gel and the dried gel was analyzed with a phosphor-imager (BioRad). Undigested 
probe (C1) or probe hybridized to 20 mg yeast tRNA prior to digestion (C2) served as controls for the specificity of 
the protected fragments.
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Table 7-1.
Relative amounts (compared to ODC) o f APP-mRNA in Xenopus laevis tissues and the ratios o f the amounts o f  
Xenopus-APP-A and X-APP-B mRNAs.
Tissue Major APP isoform mRNA X-APP-A: X-APP-B
Brain APP695 ++++ 5.2
Heart APP751 +++ 3
Lung APP751 +++++ 3.7
Liver APP751 ++ 2 . 8
Kidney APP751 +++ 3
Spleen APP751 + 2 . 8
Muscle APP751 ++++ 6.4
Oocyte APP695 +++ 6.3
Ovary APP751 + 2.6
Testis APP751 ++ 2.5
Intestine APP751 + 4.8
pattem, namely the presence of Xenopus APP mRNA in all neuronal and non­
neuronal tissues examined, is comparable to that in other species (Bahmanyar et al., 
1987; Goedert, 1987; Tanzi et al., 1987; Shivers et al., 1988; Zimmermann et al., 
1988; Fisher et al., 1991; Sandbrink et al., 1994). The possible occurrence of 
alternative splicing of Xenopus APP pre-mRNA was investigated by RT-PCR 
analysis of RNA isolated from a number of Xenopus tissues. We used primers 
flanking exons 7 and 8 to detect all three major splice variants in one sample, and 
the relative amounts of the amplified fragments will indicate the levels of the 
isoforms. In brain and oocyte, APP695 mRNA was found as the main isoform, 
whereas in all other tissues examined the APP751 form was predominantly present 
(Figure 7-5). This is consistent with previous findings of the tissue distribution of 
APP mRNA expression in the rat (although rat oocytes were not included; 
Sandbrink et al., 1994). Previous developmental studies in the mouse and Xenopus 
revealed also that in the oocyte APP is predominantly present as a mRNA coding 
for a protein of 695 amino acids. APP695 mRNA is probably from maternal origin, 
since during development and onset of zygotic expression the ratio was favored 
towards APP751/770 (Fisher et al., 1991; Okado and Okamoto, 1992).
To get a better insight into the biosynthesis and physiological role of APP and its 
relation to AD, the availability of a proper model system may be crucial. Since 
Xenopus APP is highly conserved with respect to its sequence, tissue distribution 
and isoforms, and contains an Aß peptide with potential amyloidogenic potency, the 
clawed toad Xenopus laevis may represent an interesting model system to unravel 
the long-standing problem of the function of APP.
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Figure 7-5.
APP mRNA splicing variants in Xenopus laevis tissues
A. RT-PCR analysis o f alternatively spliced variants o f APP mRNA in Xenopus laevis tissues.
The PCR-band of 215 nt lacks the APP coding region of the KPI and the OX-2 domains, the band of 383 nt 
contains only the KPI region, and the band of 440 nt contains both the KPI and the OX-2 regions.
B. Ratios o f APP-mRNA splicing forms in Xenopus laevis tissues. The ratios were calculated in arbitrary units (AU) 
o f optical density based on the intensities o f the bands in the RT-PCR analysis shown in A. The total amounts of 
AU per tissue were set to 100 % to determine the ratios o f the alternatively spliced variants. The numbers shown 
are the mean of five independent experiments. Tissues examined were brain (Br), heart (He), lung (Lu), liver (Li), 
kidney (Ki), spleen (Sp), muscle (Mu), oocyte (Oo), ovary (Ov), testis (Te), and intestine (In; duodenum).
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Abstract
Amyloid precursor protein APP is generally accepted to be involved in 
Alzheimer's disease, but its function remains elusive. We decided to investigate 
the expression and intracellular localization of APP in a non-mammalian, 
physiologically inducible neuroendocrine system, namely in the melanotrope cells 
of the intermediate pituitary of the clawed toad Xenopus laevis. The biosynthetic 
activity of these cells can be manipulated by changing the background color of the 
animal. Interestingly, we have found that APP is threefold induced at the RNA 
and protein level in the intermediate pituitary cells of animals on a black vs white 
background, indicating that APP-expression is increased in activated cells. 
Furthermore, we demonstrate that APP is phosphorylated early and N-linked 
glycosylated later in the secretory pathway of the Xenopus melanotrope cells, 
since brefeldin A treatment did not prevent phosphorylation but abolished 
glycosylation; remarkably, phosphorylated APP does not become glycosylated. 
No processing of APP was observed, indicating that in the melanotrope cells APP 
performs its function as an intact protein. Immunofluorescence and subcellular 
fractionation analysis revealed that in the melanotrope cells of black-adapted 
animals APP is localized to the endoplasmic reticulum-Golgi region, whereas in 
the cells of white animals it is predominantly localized to the plasma membrane. 
Together, our results illuminate interesting novel aspects of APP biosynthesis and 
show that in Xenopus intermediate pituitary the intracellular localization of APP 
depends on the biosynthetic activity of the cell, suggesting a physiological role for 
this protein in cell (in)activation.
Introduction
Alzheimer’s disease (AD) is a more and more common, age-related 
neurodegenerative disorder characterized by the presence of neurofibrillary 
tangles and senile plaques in the brain. A major constituent of the plaques is ß- 
amyloid (Aß), a peptide produced by processing of the type I transmembrane ß- 
amyloid precursor protein (APP; Glenner and Wong, 1984). It is generally 
thought that the cause of AD is directly or indirectly linked to APP. Progress in 
AD-research has been severely hampered by the fact that, despite that APP is 
known for almost 15 years, its normal physiological function in the cell remains 
elusive. The APP protein has been identified in a number of mammalian species 
(Glenner and Wong, 1984; Selkoe et al., 1987; Yamada et al., 1987; Shivers et al., 
1988; Johnstone et al., 1991) and in one non-mammalian species, namely the
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clawed toad Xenopus laevis (Okado and Okamoto, 1992; Chapter 7). 
Furthermore, APP-like proteins have been identified in mammals (Wasco et al., 
1992, 1993; Sprecher et al., 1993), Drosophila (Rosen et al., 1989) and C. elegans 
(Daigle and Li 1993). The APP-proteins are highly conserved throughout 
evolution pointing to an important physiological function. Initially, a role as a cell 
surface receptor was suggested, based on the topology of the protein (Kang et al., 
1987), but also functions as a heparan sulfate proteoglycan core protein (Schubert 
et al., 1988) and as a modulator of cell-cell adhesion (Shivers et al., 1988) have 
been proposed. Furthermore, APP has been shown to have neuroprotective 
functions (Mattson et al., 1993; Smith-Swintosky et al., 1994), adhesive 
properties (Shivers et al., 1988; Beyreuther et al., 1996; Storey et al., 1996) and 
synaptic functions (Scott et al., 1991). Moreover, several regulatory functions for 
the fragments that are proteolytically derived from APP have been suggested (for 
review see Mattson, 1997). Neuronal APP has been shown to be up-regulated 
after various traumatic and ischaemic insults (Siman et al., 1989; Kawarabayashi 
et al., 1991; Otsuka et al., 1991; Scott et al., 1991; Pierce et al., 1996; Bramlett et 
al., 1997; Wallace et al., 1997a-b), indicating that the protein may play an 
important role in the response of the brain to injury (Van den Heuvel et al., 1999). 
An increase in APP might enhance the production of Aß, leading to deposition of 
diffuse Aß plaques resulting in AD (Roberts et al., 1991, 1994; Gentleman et al., 
1993; Graham et al., 1995).
During trafficking of APP through the secretory pathway, a number of post- 
translational modifications of the protein have been shown to occur in mammals, 
such as O-linked glycosylation at sites S124 and L172 (Tomita et al., 1998; 
numbering according to Kang et al., 1987) and N-linked glycosylation at sites 
N467 and N496 (Kang et al., 1987; Pâhlsson et al., 1992; Pâhlsson and Spitalnik, 
1996; Yazaki et al., 1996). Additional potential O-linked glycosylation sites have 
been proposed for cytoplasmic serine or threonine residues in human APP 
(Griffith et al., 1995). Furthermore, several potential phosphorylation sites (S198, 
S206, S655 and T668) have been identified that in cell lines have been shown to 
be indeed phosphorylated by protein kinase C and calcium/calmodulin dependent 
(cdc) protein kinase II (S655; Suzuki et al., 1992; Gandy et al., 1993; T668; 
Suzuki et al., 1994), and casein kinase (CK)-1 and CK-2 (S198 and S206; Walter 
et al., 1997). These post-translational modifications may influence trafficking, 
targeting and processing of APP (Caporaso et al., 1992; Buxbaum et al., 1993; 
Gabuzda et al., 1993; Gandy and Greengard, 1994; Hung and Selkoe, 1994; 
Graebert et al., 1995; Tomita et al., 1998). All of these sites for post- translational 
modifications are conserved in Xenopus laevis APP, except for S655 that is 
conservatively substituted for a threonine (Okado and Okamoto, 1992; Chapter 
7), still resulting in a potential phosphorylation site. Until now, no physiological
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endocrine system has been used to study the transport, biosynthesis and post- 
translational modifications of APP. Therefore, we decided to study the APP 
protein in Xenopus laevis. This amphibian contains a homogeneous population of 
melanotrope cells in the intermediate pituitary, the activity of which can be 
physiologically manipulated through adaptation of the color of the skin of the 
animal to the background. When adapted to a black background, the melanotrope 
cells are highly active in producing the prohormone proopiomelanocortin 
(POMC), while the cells are in an inactive state during adaptation to a white 
background (Jenks et al., 1993). POMC is the prohormone for a-melanophore- 
stimulating hormone (a-MSH), the hormone that stimulates the dispersion of the 
black pigment melanin in the skin melanophores causing a darkening of the 
animal. The difference in biosynthetic activity is accompanied by extensive 
morphological changes (Hopkins, 1970; De Rijk et al., 1990; Roubos and Berghs,
1993).
In this report, we studied the biosynthesis of APP in the melanotrope cells of the 
Xenopus intermediate pituitary. We find that during black background adaptation 
APP is up-regulated at the RNA and protein level, and that its intracellular 
localization differs between melanotrope cells of black- and white-adapted 
animals, suggesting a role for APP in cell (in)activation.
Materials and methods 
Animals
South African clawed toads Xenopus laevis were bred and reared in the aquarium facility 
of the Department of Animal Physiology at the University of Nijmegen. Animals were 
adapted to a black or white background under constant illumination at 22 °C for at least 
three weeks.
RNA isolation
Using the Trizol method (Gibco BRL; standard protocol), total RNA was extracted from 
different tissues of Xenopus laevis that were adapted to a black or white background.
Antibodies
Polyclonal antibodies C87 and J58 were generated by immunizing rabbits with synthetic 
peptides corresponding to the last 12 amino acids of APP (NPTYKFFEQMQN) and 
amino acid 1-12 of Xenopus Aß (DSEYRHDAAYEV), respectively. Polyclonal guinea 
pig anti-POMC antibody St62 has been described previously (Berghs et al., 1997).
RNase protection assay
RNase protection analysis was performed according to the manufacturer’s protocol (RPA 
III kit, Ambion). Briefly, X-APP cDNA (nt. 1-581; accession# AJ298150) and Xenopus
109
Chapter 8
ornithine decarboxylase cDNA (ODC; Isaacs et al., 1992) were randomly labeled with 
32P-dUTP (Maxiscript T7, Ambion), gel purified and 4x 104 cpm of labeled cDNA was 
added to 5 mg total RNA. Hybridization was performed overnight at 56 °C, followed by 
digestion with RNase A/T1. Protected fragments were analyzed on a 5 % polyacrylamide 
gel and the gel was exposed to a phosphor-imaging screen (BioRad, Personal FX).
RT-PCR analysis
A sense primer (5’-ATCTGGATCCTGCAGTGAGAAGAGCATGAG-3’; S1: nt 493-512 
according to Okado and Okamoto, 1992) and an antisense primer (5’- cctctcctttgctttca-3’; 
A1: nt 1139-1155) were used for amplifying APP-cDNA. For amplification of the internal 
control ODC (Isaacs et al., 1992), 5’-GTCAATGATGGAGTGTATGGATC-3’ was used 
as sense and 5’-TCCATTCCGCTCTCCTGAGCAC-3’as antisense primer. Different 
concentrations, varying from 0.2-2 mg, of total RNA were reverse transcribed by using 
hexamers and RT Superscript (Gibco) to construct single stranded cDNA. Amplification 
of different concentrations of the cDNA was performed at 94 °C for 1 min, 55 °C for 1 
min. and 72 °C for 1 min. for 30 cycles, and an extension step of 10 min. at 72 °C. PCR- 
products were separated on a 1.4 % agarose gel.
Western blot analysis
For Western blot analysis, cells were lysed in lysis buffer (10 mM Hepes pH 7.3, 140 mM 
NaCl, 0.1 % Triton, 0.1 % deoxycholate, 0.5 % NP-40, 5 mM EDTA, 1 mM 
phenylmethylsulfonylfluoride [PMSF] and 1 mM soybean trypsin inhibitor) and lysates 
were denatured in Laemmli sample buffer at 95 °C for 5 min, separated on 12.5 % SDS- 
PAGE and transferred to nitrocellulose membranes (Protran, Schleicher and Schuell). The 
blot was incubated with anti-APP antibody C87 and subsequently with peroxidase 
conjugated secondary antibody. The signal was detected using Lumilight (Roche). A 
coomassie-stained gel revealed that equal amounts of proteins from anterior (AL) and 
neurointermediate lobes (NILs) of black- and white-adapted animals were applied onto 
the gel.
Metabolic cell labeling and immunoprecipitation analysis
NILs and Als of black- or white-adapted Xenopus laevis were dissected and incubated in 
methionine/ cysteine-free XL15-medium at 22°C for 30 minutes. In case lobes of white- 
adapted toads were used, 10-7 M neuropeptide Y was added to the medium in order to 
keep the melanotrope cells inactive. In some experiments, lobes were preincubated 
overnight in the presence of 10 mg/ml tunicamycin or 2 hours with 5 mg/ml brefeldin A 
(BFA) in normal XL 15 medium. Pulse labeling of newly synthesized proteins was 
performed by incubating lobes in methionine/cysteine-free XL 15 (in the presence or 
absence of 5 mg/ml BFA or 10 mg/ml tunicamycin) containing 5 mCi/ml 35S-Met/Cys 
(Promix; Amersham) for the indicated time periods at 22 °C. For pulse-chase analysis, 
lobes were labeled for 1 hour followed by either direct homogenization or by chase 
incubations in normal XL15 for the indicated periods. For phosphorylation experiments, 
Ringer’s medium (112 mM NaCl, 2 mM KCl, 2 mM CaCl2, 15 mM Hepes pH 7.4, 0.3 
mg/ml BSA and 2 mg/ml glucose) was used instead of XL15 and lobes were labeled in the 
presence of 8.5 mCi/ml 32P ortho-phosphate (Amersham).
For immunoprecipitation analysis, the NILs were lysed on ice in 50 mM Hepes pH 7.4, 
140 mM NaCl, 0.5 % NP-40, 0.1 % deoxycholate, 0.1 % Triton X-100, 5 mM EDTA, 1
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mM PMSF and 0.1 mg/ml soybean trypsin inhibitor. Lysates were cleared by 
centrifugation (10,000 x g, 3 min, 4 °C) and the supernatants were incubated overnight at 
4 °C with antibody C87 (1:1000). Immunocomplexes were precipitated with 2 mg protein 
A sepharose and analyzed by applying to SDS-PAGE. The gels were exposed to a 
phosphor-imaging screen (Biorad molecular imaging personal FX). For the 
phosphorylation experiments, phosphatase inhibitors were added during lysis and 
immunoprecipitation (1 mM ocadaic acid, 20 mM pyro-phosphate, 30 mM NaF, 2 mM 
EGTA, 5 mM EDTA).
Primary culture o f  Xenopus melanotrope cells
For the preparation of primary cell cultures, NILs of Xenopus laevis that were adapted to a 
black or white background for at least three weeks were used. NILs were dissected, 
washed several times in sterile Xenopus culture medium (XL15: 67 % Leibovitz’s L15 
medium; Gibco BRL) and transferred to Ringer’s solution (112 mM NaCl, 2 mM KCl, 2 
mM CaCl2, 15 mM Hepes pH 7.4, 2 mg/ml glucose and 0.3 mg/ml bovine serum albumin 
(BSA)) containing 0.25 % (w/v) trypsin. Following incubation of the cells for 45 min at 
20 °C, trypsin activity was blocked by adding XL15 medium supplemented with 10 % 
(v/v) fetal calf serum (FCS). The lobes were triturated, transferred to a syringe and filtered 
through a nylon filter (pore size 30 mm). Cells were collected by centrifugation, 
resuspended in a small volume of serum-free XL15 medium and seeded on poly-L-lysine 
coated coverslips. After 1 hour, XL15/10 % FCS was added and the cells were cultured 
overnight at 22 °C.
Immunofluorescence microscopy
For immunofluorescence microscopy, cells were fixed in 2% paraformaldehyde/XPBS pH 
7.4 (XPBS = 67% PBS) for 1 hour, rinsed in XPBS, incubated in 100 mM glycin/XPBS 
for 30 min and permeabilized by three 5 min washes in 0.1 % Triton X-100/XPBS 
(XPBS-T). Antibody incubations were performed for 1 hour in XPBS-T containing 2% 
(w/v) BSA (XPBS-TB). Texas red-conjugated donkey anti-rabbit antibodies (1:500; 
Jackson’s laboratories) and FITC-conjugated donkey anti-guinea pig (1:300; Jackson’s 
laboratories) were used to visualize the antibody-antigen complex. Finally, coverslips 
were mounted in Mowiol (10% w/v Mowiol (Calbiochem), 15 % glycerol, 100 mM Tris- 
HCl pH 8.5 and 2.5 % NaN3) and analyzed with a Leica fluorescence microscope. Digital 
images were obtained with a CoolSNAPTM color CCD-camera (Roper Scientific; located 
at the Dept. General Instrumentation, University of Nijmegen).
Subcellular fractionation o f organelles from  Xenopus intermediate pituitary 
Organelle fractionation of Xenopus intermediate pituitary was performed using a 10-30% 
linear iodixanol gradient (OptiprepTM, Nycomed Pharma AS, Oslo, Norway) according to 
the manufacturer’s protocol. Twenty-five NILs were homogenized in 200 ml 
homogenization buffer (0.25 M sucrose, 1 mM EDTA, 10 mM Hepes pH 7.4) in a glass- 
glass homogenizer (10 mm inner space), and the homogenate was centrifuged at 3,000 g 
for 10 minutes at 4 °C. After rehomogenization of the pellet in 300 ml homogenization 
buffer and centrifugation (3,000 g for 10 minutes at 4 °C), supernatants were pooled and 
loaded on top of a preformed 11 ml 10-30% iodixonal gradient and centrifuged for 1.5 
hours at 26,000 g in an SW40-rotor (Beckman Instruments). One-ml fractions were 
collected and analyzed by enzymatic assays, Western blot analysis, or ELISA. For the
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identification of the endoplasmic reticulum (ER) in the gradient fractions, Western blot 
analysis with anti-PDI antibody (John et al., 1993) (kindly provided by Dr. N. Bulleid, 
University of Manchester, UK) and an enzyme assay for glucose-6-phosphatase acitivity 
(Graham, 1993) were used. To determine the migration positions of the intermediate 
compartment (IC), Western blot analysis with anti-Sec23p antibody (kindly provided by 
Dr. R. Schekman, University of California, USA) and anti-58 antibody (Nakamura et al., 
1995) (kindly provided by Dr. J. Saraste, University of Bergen, Norway) was used. 
Fractions containing Golgi or trans-Golgi network (TGN) were identified with an enzyme 
assay for a-mannosidase II activity and Western blot analysis with anti-a/gCOP antibody 
(Gerich et al., 1995) (kindly provided by Dr. F. Wieland, EMBL, Heidelberg, Germany).
Results
Induction of APP-expression at the mRNA and protein level in Xenopus 
laevis intermediate pituitary cells during black background adaptation
We have used the homogeneous population of melanotrope cells of the 
intermediate pituitary of Xenopus laevis as a model system to study the 
biosynthesis of APP. RNase protection analysis of RNA isolated from pituitaries 
of black- and white-adapted animals exhibited a threefold up-regulation of APP 
mRNA in NILs of black compared to white animals (Figure 8-1). The level of 
APP mRNA present in the AL of the pituitary is similar in black- and white- 
adapted animals. These results reveal a specific induction of APP mRNA 
expression in the intermediate pituitary cells of black-adapted Xenopus. Similar 
results (a threefold induction of APP mRNA) were obtained via RT-PCR analysis 
of RNA derived from intermediate pituitaries of black- and white-adapted animals 
with ODC as internal control for the amount of applied RNA (Figure 8-1B). With 
the PCR primers used, the three major alternatively spliced variants of APP 
mRNA, namely APP695, APP751 and APP770, can be discriminated. In Xenopus 
pituitary, the APP695 mRNA variant is predominantly present. To investigate 
whether the induction also occurs at the protein level, we used anti-APP antibody 
C87 to perform Western blot analysis of intermediate and anterior pituitary 
lysates derived from black- and white-adapted animals. A threefold induction of 
APP protein expression was observed in NILs of black- vs white-adapted toads, 
whereas no difference was detected in the AL (Figure 8-2A). APP was present as 
an intact protein of ~110 kD and no proteolytic cleavage fragment was found.
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Figure 8-1
Differential expression o f  APP-mRNA in the intermediate pituitary o f  Xenopus laevis
A. RNase protection assay o f APP transcripts in Xenopus laevis pituitary. Radiolabeled antisense RNA was 
hybridized to total RNA extracted from two neurointermediate lobes (NILs) and two anterior lobes (ALs) o f the 
pituitary of black (B) and white (W) adapted Xenopus. Samples were digested with RNase A and T1, loaded 
onto denaturing polyacrylamide gels, exposed to phosphorimaging screens and quantified by Quantity One 
(BioRad Personal FX). C1: undigested RNA probe; C2: RNA probe hybridized to yeast tRNA before digestion.
B. RT-PCR analysis o f APP transcripts in Xenopus laevis pituitary. RT-PCR was performed on total RNA of 
NILs and ALs of black (B) and white (W) adapted Xenopus. Different concentrations o f RNA and cDNA were 
used to check for the exponential phase of the PCR. The 215-bp PCR-product lacks the KPI and the OX-2 
domain (APP695), the 383-bp product lacks only OX-2 (APP75i), while the 440-bp product contains both the KPI 
and the OX-2 domain (APP770). RT-PCR with ornithine-decarboxylase (ODC) primers was used as an internal 
standard for the amount o f RNA analyzed. Signals were quantified by Molecular Analyst (BioRad).
Biosynthesis of APP in intermediate pituitary cells of Xenopus laevis 
Since Western blot analysis shows steady-state levels of a protein, metabolic cell 
labeling combined with immunoprecipitation analysis of newly synthesized 
proteins was performed to investigate the biosynthesis of APP. Following a 6- 
hour radiolabeling with 35S-Met/Cys, the Xenopus neurointermediate and anterior 
pituitaries were lysed, and newly synthesized proteins were immunoprecipitated 
with the C87 antibody and separated by SDS-PAGE (Figure 8-2B). Again a 
protein of ~110 kD was recognized in both NIL and AL lysates. Also at the level 
of newly synthesized proteins, the APP protein is produced at threefold higher 
levels in NILs derived from black-adapted compared to that in white-adapted
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Figure 8-2
Differential expression o f  APP-protein in the intermediate pituitary o f  Xenopus laevis
A. Western blot analysis o f APP in Xenopus laevis pituitary. Proteins were extracted from neurointermediate 
(NIL) and anterior (AL) lobes of black (B) and white (W) adapted Xenopus, separated with SDS-PAGE and 
analyzed on Western blot with anti-APP antibody C87. Asterisk represents a 10 times dilution of the lysates. 
Protein molecular mass markers (Mr) are indicated on the right (in kD).
B. Immunoprecipitation o f newly synthesized APP produced by Xenopus laevis pituitary. NILs and ALs of black 
(B) and white (W) adapted animals were pulsed for 6 hours in the presence of 35S-Met and radiolabeled proteins 
were immunoprecipitated from lobe extracts (two lobes per lane) with anti-APP-J58 antibody. Protein molecular 
mass markers (Mr) are indicated on the left (in kD).
animals (Figure 8-2B). To examine the biosynthesis and processing of APP 
during transport through the secretory pathway, a pulse-chase analysis of newly 
synthesized proteins produced by the Xenopus intermediate pituitary cells was 
performed. Following a one-hour pulse, the POMC protein is present in the total 
lysate as a 37 kD protein, and during a chase-period of three hours this 
prohormone is processed to 14-18 kD products that are released into the medium 
(data not shown). Immunoprecipitation of APP from the one-hour pulse lysates 
revealed a protein of ~92 kD and a weaker band corresponding to a protein of 
~110 kD. During subsequent chase-periods, most of the ~92 kD APP protein 
(~90%) was converted to the ~110 kD protein, indicating that APP is post-
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translationally modified (Figure 8-3). Intact APP is still present after 3 hours 
chase (and even after 6 hours chase; data not shown), demonstrating that the 
turnover-rate of the protein is rather low. Indeed, in the lysates no APP- 
processing product could be immunoprecipitated with antibodies recognizing the 
C-terminus, soluble APP (APPs) or Aß (data not shown) further indicating that 
APP is not processed in the NIL of Xenopus laevis. With the same antibodies no 
APP or APP-fragments were detected in the medium (Figure 8-3).
lobe medium
1 2 3 4 5 6
110 kD APP 
92 kD APP
Figure 8-3
Biosynthesis o f  APP in neurointermediate lobes of 
Xenopus laevis
Neurointermediate lobes o f Xenopus pituitaries were 
incubated in the presence o f 35S-Met/Cys for 60 minutes 
(pulse) and chased for 0, 60 or 180 minutes. Newly 
synthesized proteins were extracted and lobe-extracts 
(lanes 1-3) and media (lanes 4-6) were immunoprecipitated 
with anti-APP antibody C87, resolved by SDS-PAGE and 
visualized by phosphor-imaging.
0 60 180 0 60 180 
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Post-translational modifications of APP in intermediate pituitary cells of
Xenopus laevis
Xenopus APP contains a number of potential phosphorylation sites (S198, S206, 
S655 and T668; Gandy et al., 1993; Suzuki et al., 1992, 1994; Walter et al., 1997) 
and glycosylation sites (S124, L1172, N467 and N496; Kang et al., 1987; 
Pâhlsson et al., 1992; Pâhlsson and Spitalnik, 1996; Yazaki et al., 1996; Tomita et 
al., 1998). To investigate whether the conversion of newly synthesized APP from 
~92 to ~110 kD was caused by post-translational phosphorylation, intermediate 
pituitaries of Xenopus laevis were incubated in the presence of radiolabeled 
phosphate (Figure 8-4A). Following a 30-min pulse, a ~92 kD APP protein was 
immunoprecipitated with antibody C87. The amount of the phosphorylated ~92
4'
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Figure 8-4
APP is phosphorylated and glycosylated in neurointermediate lobes o f  Xenopus laevis
Neurointermediate lobes (NILs) of Xenopus pituitaries were incubated in the presence of 32PO4 (A-B) or 35S- 
Met/Cys (C) for 30 minutes (pulse) and chased for 0, 60 or 180 minutes. When indicated lobes were 
preincubated for 2 hours and pulse-chased in the presence o f brefeldin A (BFA). Newly synthesized proteins 
were extracted and immunoprecipitated with anti-APP antibody C87, resolved by SDS-PAGE and visualized by 
phosphor-imaging. (A) Lanes 1-3, lobes were pulse-incubated and chased for the indicated time-periods and (B) 
in presence (+) or absence (-) BFA. (C) NILs of Xenopus pituitaries were incubated in the presence of 35S- 
Met/Cys for 5 hours and when indicated preincubated with tunicamycin (Tun) or BFA. P-APP = phosphorylated 
APP, G-APP = glycosylated APP and U-APP = unglycosylated APP. Protein molecular mass markers (Mr) are 
indicated on the right (in kD).
kD APP did not change after 3 hours chase, showing the stability of newly 
synthesized and phosphorylated APP, and demonstrating that phosphorylated ~92 
kD APP is not post-translationally modified to the ~110 kD protein. In the pulse- 
chase experiment with 35S-Met/Cys, about 90 % of ~92 kD APP was converted to
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a ~110 kD protein (Figure 8-3), indicating that at most approximately 10 % of 
newly synthesized APP becomes phosphorylated. The process of phosphorylation 
was not affected by an incubation of intermediate pituitaries in the presence of 
BFA (which blocks transport from endoplasmic reticulum (ER) to Golgi) (Figure 
8-4B) and no phosphorylated APP or APP-fragments could be detected in the 
media (data not shown). A post-translational modification besides 
phosphorylation is likely responsible for the conversion of the ~92 kD protein into 
the ~110 kD form. To determine whether APP is glycosylated, intermediate 
pituitaries were preincubated with tunicamycin (which prevents N-linked 
glycosylation), followed by a pulse labeling in the presence of 35S-Met/Cys 
(Figure 8-4C). In a 5 hour pulse labeling under control conditions, APP- 
immunoreactive products in the molecular weight range of ~92 to ~110 kD were 
found (Figure 8-4C). Tunicamycin treatment (preventing only N-linked 
glycosylation) resulted in a shift to ~92-100 kD forms of APP, indicating that the 
~110 kD product is N-glycosylated. In the presence of BFA only the ~92 kD APP 
was produced, demonstrating that a block of ER to Golgi transport prevents the 
post-translational modifications leading to APP proteins larger than 92 kD.
Localization of APP in Xenopus laevis melanotrope cells
Having demonstrated an induction of APP expression in NILs from Xenopus 
laevis that were adapted to a black background, we examined the localization of 
APP in the melanotrope cells of black- and white-adapted animals by 
immunofluorescence on primary cultures of melanotropes. The major function of 
the melanotrope cells is to produce POMC and a-MSH, the peptide hormone 
responsible for melanin dispersion in Xenopus skin melanophores (Martens et al., 
1987; Ayoubi et al., 1992; Jenks et al., 1993). POMC is known to traffic through 
the secretory pathway from ER to Golgi and via the TGN to secretory granules 
where it is processed to bioactive products that are released upon stimulation of 
the cell during black background adaptation of the animal (Smith and Funder, 
1988; Seidah et al., 1990; Smeekens and Steiner, 1990; Thomas et al., 1991). 
Since APP is a protein that also enters the secretory pathway, the localizations of 
APP and POMC were studied by immunofluorescence (Figure 8-5). Staining of 
melanotropes derived from black-adapted animals with antibody C87 revealed a 
perinuclear staining, indicating a localization of APP to the ER-Golgi. POMC was 
found to localize to the ER-Golgi and partially colocalized with APP (Figure 8-5). 
The localization of APP in melanotropes of white-adapted toads clearly differs 
from that in black-adapted animals. Although some perinuclear staining is 
observed, most of the signal in the inactive cells of white-adapted animals is 
located in close vicinity of the plasma membrane (Figure 8-5). Within the 
population of melanotrope cells of white animals ~5-10 % is active (De Rijk et
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Figure 8-5
Immunofluorescence analysis o f  APP in the intermediate pituitary cells o f  black-and white-adapted Xenopus 
laevis.
Immunofluorescence on primary cultures of white- (WA) and black-adapted (BA) melanotrope cells was 
performed with anti-APP and anti-POMC antibodies. In A) an overview of positive cells is shown, whereas in 
panel B) one cell is shown in more detail. The arrows indicate sites of colocalization, whereas the arrowheads 
show distinct localizations of APP and POMC. N= nucleus.
al., 1990) and, interestingly, these active cells that are strongly positive for POMC 
are also more intensely stained for APP than the less active (POMC-negative) 
cells.
Subcellular fractionation of Xenopus laevis intermediate pituitary cells to 
localize APP
To establish the distribution of the APP-protein in the melanotrope cells of white- 
and black-adapted Xenopus laevis, we performed subcellular fractionation. The 
fractionation was accomplished with an iodixanol density gradient and the 
migrations of the various organelles in the gradient were determined with
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enzymatic and immunological assays. Two ER-immunoreactive pools were 
detected in the gradient, namely in fractions 2-5 and 7-10, whereas markers for 
the ER-Golgi intermediate compartment (IC) were found in fractions 2-5. Golgi 
and lysosomes migrated to fractions 1 and 2, while fractions 7-10 were found to 
contain trans-Golgi network (TGN). Secretory granules migrated to fractions 7­
10 and fraction 13, and mitochondria were detected in fractions 2 and 3. The 
migration positions of the various organelles in the gradient are indicated in 
Figure 8-6. Western blot analysis was used to determine the migration of the APP 
mito
Golgi/lys 
1 2
ER/IC
3
BA NIL 
WA NIL
4 5
ER/TGN/sg 
6 7 8 9 10 11 12
Figure 8-6
Subcellular fractionation o f neurointermediate lobes o f Xenopus laevis in a 10-30 % iodixanol gradient.
Neurointermediate lobes (NILs) of pituitary glands of 20 animals were used for fractionation as described in 
Material and Methods. Fractions were analyzed by Western blotting with anti-APP antibody C87. The migration 
positions of endoplasmic reticulum (ER), intermediate compartment (IC), Golgi, trans-Golgi network (TGN), 
secretory granules (sg), mitochondria (mito) and lysosomes (lys) are indicated.
protein in the gradient. A different distribution of APP-immunoreactivity in the 
gradients of organelles extracted from intermediate pituitary cells of black- vs 
white-adapted animals was found (Figure 8-6). APP-immunoreactivity in the 
gradient of intermediate pituitary cells of black-adapted animals was present 
predominantly in fractions 2-5 (ER, IC and Golgi). In the gradient of the inactive 
melanotrope cells of white-adapted animals, the APP protein was present in 
fraction 2 (Golgi/lysosomes). Together, the results indicate that in the less active 
secretory cells (from white-adapted animals), the APP protein has a restricted 
steady-state localization, whereas in the biosynthetically active intermediate 
pituitary cells of black-adapted animals APP is distributed over a much broader 
range of subcompartments of the early secretory pathway.
Discussion
Although APP is known for more than a decade and is probably one of the most 
studied proteins in molecular neurobiology, the role of APP remains largely 
hidden in a forest of speculative interpretations. We decided to use a well-defined, 
physiological non-mammalian model system, namely the clawed toad Xenopus
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laevis, for studying APP biosynthesis. The melanotropes of black-adapted 
Xenopus display ultrastructural features of cells with high biosynthetic and 
secretory activities, including an enlarged cell nucleus, extensively elaborated ER 
and Golgi complexes, and a low amount of storage granules (Hopkins, 1970; De 
Rijk et al., 1990). Conversely, the melanotropes of white-adapted animals 
resemble inactive storage cells with a poorly developed synthetic apparatus and a 
high content of storage granules. Hence, the biosynthetic and secretory activity of 
Xenopus laevis melanotropes can be manipulated at the physiological level simply 
by changing the background color of the animal. By comparing the expression 
levels of APP in neurointermediate and anterior pituitary cells derived from 
black- vs white-adapted Xenopus laevis, we surprisingly found in the intermediate 
but not anterior cells a threefold induction of APP at the RNA and protein level. 
Previous research has revealed that other transcripts, whose products are mostly 
found in the secretory pathway, are also up-regulated in the neurointermediate 
and not in the anterior pituitary cells (Holthuis et al., 1995). The local induction of 
APP in the early secretory pathway of the intermediate pituitary cells of black- 
adapted animals might even be higher, since the intracellular localization of the 
APP protein was found to differ between melanotrope cells of black and white 
animals. Our immunofluorescence and subcellular fractionation studies revealed 
the presence of APP throughout the ER and Golgi region in the melanotrope cells 
of black-adapted animals, whereas in cells of white-adapted animals APP was 
predominantly found at the plasma membrane. Hence, in the ER/Golgi-region the 
degree of up-regulation appears to be more pronounced suggesting that, like the 
other proteins that have been shown to be induced (Holthuis et al., 1995), APP is 
involved in the biosynthetic and secretory processes in the melanotrope cells 
during black background adaptation. Up-regulation of APP has previously been 
linked to brain trauma and injury (Siman et al., 1989; Abe et al., 1991; 
Kawarabayashi et al., 1991; Otsuka et al., 1991; Scott et al., 1991; Pierce et al., 
1996; Bramlett et al., 1997; Wallace et al., 1997a-b; Van den Heuvel et al., 1999), 
also pointing to an involvement of APP in cell activation, either for neuronal cell 
recovery (in case of brain injury) or for increased peptide hormone synthesis 
(background adaptation).
Metabolic cell labeling experiments with the Xenopus intermediate pituitary cells 
revealed that APP is post-translationally modified during its trafficking through 
the secretory pathway. Previous biosynthetic studies by others involved the use of 
transfected cell lines to examine glycosylation and phosphorylation of newly 
synthesized APP (Griffith et al.,1995; Gandy et al., 1993; Kang et al., 1987; 
Pâhlsson and Spitalnik, 1996; Pâhlsson et al., 1992; Suzuki et al., 1992, 1994; 
Tomita et al., 1998; Walter et al., 1997; Yazaki et al., 1996). Here we demonstrate 
the phosphorylation and N-linked glycosylation of newly synthesized APP in
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primary cultures of neurointermediate lobes. Xenopus APP is produced as a ~92 
kD protein, of which a relatively small portion of becomes phosphorylated, while 
most of the remainder becomes glycosylated, indicating that phosphorylated APP 
is not glycosylated and vice versa. In vivo phosphorylation of APP in the 
melanotrope cells of Xenopus laevis was not prevented by BFA treatment, 
showing that APP phosphorylation occurs rapidly after entering of the protein in 
the secretory pathway. In transfected human embryonic kidney 293 cells, BFA 
treatment either did (Walter et al., 1997) or did not (Knops et al., 1993) abolish 
phosphorylation of APP and thus from these overexpression studies it is not clear 
whether APP is phosphorylated early or late in the secretory pathway of 
mammalian cells. It remains to be established what the significance is of the 
finding of two ‘pools’ of the Xenopus APP protein (phosphorylated and 
glycosylated). Recently, the existence of ‘pools’ of APP has been proposed. One 
‘pool’ of APP would function as a cargo membrane receptor for kinesin-1 in post- 
Golgi and axonal transport, whereas the other ‘pool’ is no longer associated with 
kinesin-1 and therefore not in the actively transported compartment (Kamal et al., 
2000). In the melanotrope cells, the APP protein has a low turnover rate, since 
after 6 hours chase the amount of protein was essentially the same as following 
the pulse incubation. Furthermore, no processing products could be observed, 
indicating that APP performs its role as an intact protein.
Of special interest is the finding that APP is localized to the ER-Golgi region in 
the melanotrope cells of black-adapted animals, while in white-adapted animals 
this transmembrane protein is predominantly present at the plasma membrane. 
Thus, APP could be involved in the inactivation of the melanotrope cell by acting 
at the membrane as a modulator of cell-cell communication. Alternatively, the 
higher expression and different intracellular localization of APP in the active cells 
compared to that in the inactive cells may indicate an involvement of this protein 
in the regulation of melanotrope cell activity, in particular in protein biosynthesis 
and transport. In this connection, the aforementioned report proposing a role for 
APP as a membrane cargo receptor for the microtubule-dependent motor protein 
kinesin-1 is intriguing (Kamal et al., 2000). Whatever its exact role may be, in the 
Xenopus melanotrope cells APP most likely has an intracellular function and acts 
as an intact protein, since we did not observe processed or released forms of this 
protein.
Together, our results demonstrate that the clawed toad Xenopus laevis is a useful 
model system to study the biosynthesis of APP under physiological conditions. 
The differential expression and intracellular localization of APP in the 
melanotropes of black- vs white-adapted animals suggests an involvement of APP 
in neuroendocrine cell (in)activation during background adaptation. Future
121
Chapter 8
functional studies in this non-mammalian system might elucidate the long­
standing problem of the physiological role of APP.
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General Discussion
To protect their cells, humans have developed cellular mechanisms that provide 
defensive capacity, e.g. against environmental stress. As these mechanisms and 
their backups gradually give up, the cells lose this capacity, leading to aging and 
eventually death. An example of an age-related disease is Alzheimer’s disease 
(AD), a more and more common, neurodegenerative disorder and the most 
frequent form of dementia at higher age. In this thesis, several aspects of proteins 
thought to be involved in the development of AD have been investigated, and in 
this final chapter the findings will be discussed and put in a broader perspective.
Frameshift mutations, Alzheimer’s disease and aging
A few years ago, an exciting new view on the cause of the development of age- 
related diseases has been proposed. This view was based on an observation in 
adult di/di Brattleboro rats (i.e. rats suffering from diabetes insipidus caused by a 
single-base deletion in the vasopressin (VP) gene). Surprisingly, in these rats rare 
neurons immunoreactive for wild-type VP and an age-related reversion to a 
hemizygous wild-type VP-peptide phenotype were found (Richards et al., 1985; 
Van Leeuwen et al., 1989). Analysis of polymerase chain reaction (PCR) products 
generated from hypothalamic cDNA led to an explanation of the revertant peptide 
phenotypes, namely an age-related dinucleotide deletion in the VP-gene transcript 
(Evans et al., 1994; 1995). This mutation restored the normal reading frame, 
resulting in the production of wild type VP in solitary neurons. The deletion 
(AGA) occurred at the mRNA level at two specific hotspots within GAGAG 
motifs that were downstream of the initial one-base deletion in the gene. The 
mutation was also found in a small percentage of the wild type VP-transcripts, 
generating a truncated protein with an altered carboxy-terminal region, so-called 
+1-protein. On the basis of these findings the hypothesis was postulated that this 
kind of mutation (referred to as molecular misreading) might also play a role in 
human aging and age-related diseases. To test this hypothesis, two proteins linked 
to AD and Down’s syndrome (DS) were investigated, namely APP and the brain- 
specific, cytoplasmic garbage-disposal protein ubiquitin-B (Ubi-B) that associates 
with misfolded proteins and targets the faulty proteins to the proteosomal pathway 
for degradation. With an immunoscreening strategy, dinucleotide deletions were 
indeed detected in APP and Ubi-B mRNAs in or adjacent to GAGAG-motifs 
(Van Leeuwen et al., 1998a; Chapter 2). These mutations were not the result of 
PCR or cloning artifacts, since they did not occur in the brains of age-matched 
non-demented persons. Moreover, the presence of mutated Ubi-B mRNA was 
confirmed by stringent in situ hybridization, using an oligonucleotide probe that
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Figure 9-1
Schematic of the process of molecular misreading
Mistakes during gene transcription lead to frameshift mutations near short simple repeats in a subset o f mRNA 
molecules, resulting in the generation of aberrant proteins (+1/+2-proteins). This process has been referred to as 
molecular misreading.
could distinguish between mutant and wild type mRNA. The in situ signal indeed 
colocalized with the Ubi-B+' immunoreactivity. To test whether other hotspots for
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molecular misreading occur, we developed and successfully used a bacterial 
expression system with the green fluorescent protein GFP as a reporter protein 
(Chapter 4). Several novel mutations near short simple repeats were detected in 
brain-mRNAs of aged individuals. These data indicate that age-related mutations 
occur in close proximity of short simple repeats (GAGAG, GGUGGU, 
GAGACACACA, UCAUCAUCA, CAAACAAA, GAAGAAGAA), demon­
strating that the GAGAG-motif does not constitute the only hotspot for 
transcriptional errors (Figure 9-1). The frequencies found with the GFP bacterial 
expression system are not as high as those found with the immunoscreening 
strategy. The frequency of the occurrence of molecular misreading is however 
influenced by the heterogeneity and the origin (temporal cortex, hippocampus etc) 
of tissue used for RT-PCR, since not all cells show immunostaining with the +1- 
antibodies (Van Leeuwen et al., 1998a; Chapter 2). This can be an explanation for 
the finding that in the same DS patient a frequency of 1:50 mutations was found 
in the hippocampus with the immunoscreening approach as described in Chapter 
2, while only 1:1000 mutations were found in the temporal median lobe by the 
bacterial GFP-expression system (Chapter 4).
Thus far, simple repeats were known to be hotspots for mutations at the DNA 
level. However, since enzymes involved in DNA replication and repair may also 
be part of the transcriptional machinery (reviewed by Hanawalt, 1994), mutations 
may occur at simple repeats during transcription as well, with the DNA remaining 
unaffected. Furthermore, cellular stress may cause a distorded local 
microenvironment, leading to inaccurate gene transcription.
The process of molecular misreading is not restricted to non-dividing neuronal 
cells. Van Leeuwen et al. (2000) generated mice transgenic for a rat VP minigene 
that specifically expresses VP in epithelial cells of secretory organs and found by 
in situ hybridization and immunocytochemistry not only wild type but also the 
frameshifted transcript. This observation shows that molecular misreading is a 
general phenomenon and may thus be widely involved in cellular derangements. 
The mechanism underlying molecular misreading remains unclear. Age-related 
frameshift mutations in RNA molecules may be only one of several possible 
failures in cell functioning due to cellular aging. Aging has been defined as ‘the 
accumulation of changes responsible for the sequential alterations that accompany 
advancing age and the associated progressive increase in the chance of death and 
disease’ (Harman, 1991). We speculate that when cells age, they become more 
error prone and that aging of a cell might be the accumulation of aberrant proteins 
due to transcriptional-, translational-, processing- and other errors affecting 
cellular physiology. Many of these errors might remain unnoticed since most of 
the mutated proteins are probably efficiently removed (the proteasomal 
degradation pathway appears to be highly activated in AD and DS brains (Ii et al.,
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1997), probably in an attempt to clear away the abnormal proteins) and because 
sufficient functional proteins are still present to allow proper cell functioning. 
Possibly, we therefore found only minor effects on cell growth, morphology, and 
physiology in the human neuroblastomas overexpressing Ubi-B+' (Chapter 3), and 
expression of extremely high levels of this aberrant protein is necessary to distort 
the cell. However, it is well possible that some errors may lead to toxic proteins or 
to dominant negative peptides that can affect certain viable cellular pathways. 
Molecular misreading is not the only example of variability in gene transcripts. 
Alternative splicing is used to generate different transcripts with the splicing 
machinery recognizing AG-GU sequences. Under some circumstances transcripts 
are produced by cleavage and ligation using cryptic sites (still obeying the AG- 
GU rule), resulting in aberrant mRNAs. In EAAT2 transcripts, encoding a protein 
involved in the sporadic form of ‘amyotrophic lateral sclerosis’, another form of 
aberrant splicing has been observed. In this case exons are skipped and introns are 
retained. Furthermore, a completely new aberrant splicing variant of EAAT2 
transcripts was found, namely resulting from the fact that the pre-mRNAs were 
not cleaved and ligated according to the AG-GU rule but a variety of 
dinucleotides was used as a signal for the formation of the EAAT2 mRNAs (Lin 
et al., 1998; review Bai and Lipton, 1998). Thus, this is another example of the 
generation of aberrant mRNA products, with the DNA still being intact. Aberrant 
RNA processing, either as a primary defect as in spinal muscle atrophy or 
secondary to other cellular defects, could constitute an important mechanism 
leading to neurodegenerative diseases. Whether the cause of this phenomenon lies 
in damage of the DNA encoding RNA processing enzymes or of the enzymes 
themselves is at present unclear. In addition, proteins involved in repair 
mechanisms may not function optimally, resulting in mutations at the DNA level 
or at the transcriptional level.
Molecular misreading has been defined as ‘the inaccurate conversion of genomic 
information into nonsense mRNA’ (Van Leeuwen et al., 1998b). This implies that 
these mutations occur only at the RNA- and not the DNA-level. However, it is 
difficult to exclude the possibility that the mutations are also present at the DNA- 
level since only in a subset of cells the mutations are detected, so only a minor 
percentage of DNA-molecules might be affected. Van Leeuwen et al. (1998a; 
Chapter 2) have tried to exclude this possibility by using two PCR protocols that 
would be sufficiently sensitive to detect this frequency of mutation. These 
experiments repeatedly failed to detect mutations at the DNA-level. Moreover, 
since we find many different mutations at the RNA-level (Chapter 4), it is very 
unlikely that all of these mutations would also be present at the DNA-level (this 
would imply that many DNA mutations occur in non-dividing cells). 
Nevertheless, this is a problem that is difficult to tackle since in case a frameshift
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at the DNA-level is not detected, one could always argue that not enough 
recombinants have been generated and analyzed.
Altogether, we conclude that molecular misreading is a widespread phenomenon 
that can occur in neuronal as well as non-neuronal cells, but the mechanism 
underlying the frameshift mutations and whether it is the cause or the 
consequence of aging remains unclear.
Internal reinitiation of translation
As mentioned above, the phenomenon of molecular misreading seems to occur 
only in a subset of cells (not all cells are immunoreactive with +1-antibodies). 
One can speculate that in these cells not only the transcriptional machinery is 
affected, but also the mRNA decay pathway, normally taking care of the 
clearance of aberrant mRNAs, and even the translational machinery, which might 
result in initiation of translation at various, normally not used, potential initiation 
sites. In Chapter 5, we show that internal translational initiation in an mRNA 
region corresponding to exon 9 of the APP--gene can indeed occur. We have 
further investigated whether reinitiation of translation takes place in combination 
with frameshift mutations. Our studies involving the transfection of the APP 
molecule into cell lines did not show this phenomenon. This observation does not 
exclude the possibility that reinitiation of translation occurs in the in vivo situation 
in aging brains, but this will be difficult to establish, since molecular misreading 
seems to be restricted to a subset of cells. A methionine-residue within the APP- 
protein that is of interest to study with respect to internal translational initiation is 
Met596. The nucleotide sequence surrounding the Met596 codon (GAAAGATGG) 
conforms to Kozak’s rule (CAg/aAGATGG; Kozak, 1989). Initiation of 
translation at this methionine will result in the production of C99/A4CT that can 
be further processed to release Aß. Citron et al. (1993) did not observe internal 
translational initiation at this site with an in vitro assay. It will be of great interest 
to examine whether internal translational reinitiation at Met596 might occur at a 
higher frequency in combination with molecular misreading. This constitutes 
another protein that will be difficult to investigate since initiation of translation at 
Met596 will result in A4CT, a processing product of APP that is also normally 
produced in the brain. However, the A4CT-protein produced via internal 
translational initiation might be cleaved by g-secretase in a different manner and 
in a different subcellular compartment than A4CT generated by APP-cleavage. 
One could envision that an abnormal cleavage of A4CT may lead to Aß42, only 
slightly larger than the more commonly produced Aß40 but with a drastic change
131
Chapter 9
in the amyloidogenic properties (Roher et al., 1993; Iwatsubo et al., 1994; 
Gravina et al., 1995; Scheuner et al., 1996).
Xenopus laevis as a model system to study the APP-protein
To study the (developmental) expression of APP, we have used the amphibian 
Xenopus laevis, the first and thus far only non-mammalian species in which APP 
has been identified. In all developmental stages, APP-mRNA and protein was 
present, although the ratio between the three major isoforms differed (Chapter 6). 
APP is maternally inherited as APP695, whereas the zygotic onset of expression 
starts around stage 20 resulting in all three splicing variants of APP-mRNA. In 
the brains of stage 42 embryos, APP6 9 5  is produced predominantly, showing 
already during early development preferential expression of the APP-isoforms, 
suggesting separate developmental functions for the isoforms. In non-neuronal 
tissues, APP751/770 are the major isoforms expressed. The early presence of APP695 
points to a possible role for APP in neurogenesis. Neuronal overexpression of 
Drosophila APP-like protein APPL led to a disruption of axonal transport 
(Torroja et al., 1999). Mouse APP-like protein 2 (APLP2; initially described 
under the name Cdebp, a DNA-binding protein; Vidal et al., 1992; Hanes et al., 
1993) has been shown to be required for correct genomic segregation in dividing 
mouse cells (Rassoulzadegan et al., 1998) and a possible role in pre-implantation 
development has been suggested (Blangy et al., 1991/1995). The expression of 
APP throughout all developmental stages of Xenopus indicates a potential role for 
this protein in organogenesis, neurulation or some other embryological event. 
Such a function has also been suggested on the basis of results of similar research 
in mouse embryos (Fisher et al., 1991). The ratios of the splicing variants found in 
mouse resemble those in Xenopus laevis. However, Fisher et al. (1991) concluded 
that the tissue-specific splicing of APP-pre-mRNA is clearly acquired later in 
mouse development, since all three major isoforms are present at even the earliest 
stages examined. This does not hold for Xenopus laevis, since in the earliest 
stages predominantly APP6 9 5  is present and only from stage 12 onwards (the time 
of zygotic onset of expression) the other isoforms are being produced. The 
significance of the production of the three Xenopus isoforms, the time of zygotic 
onset of gene expression for the determination in Xenopus embryos of the three 
germ layers (endoderm, mesoderm and ectoderm) is at present unclear. Overall, 
the possibility arises that the various APP isoforms may play a pivotal role during 
early development of Xenopus laevis.
Other AD-linked proteins that are worth investigating during development of 
Xenopus laevis are the presenilins. The expression of these proteins has been
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shown to be essential for the intramembranous cleavage of not only APP, but also 
of other transmembrane proteins such as Ire1p (Niwa et al., 1999) and Notch (De 
Strooper et al., 1999). Notch is a large type I membrane protein that is involved in 
complex cell-fate decisions (Artavanis-Tsakonas et al., 1999). Ligand binding by 
Notch induces the release of its cytoplasmic domain by proteolysis at a site in or 
close to the transmembrane domain (Schroeter et al., 1998). The cytoplasmic 
portion of Notch functions as a signaling factor, that is transported to the nucleus 
as a complex with DNA-binding proteins. In this way, Notch can control the 
expression of genes involved in myogenesis, neuronal differentiation and 
hematopoiesis (Artavanis-Tsakonas et al., 1999). Presenilin-deficient Drosophila 
and C. elegans show Notch phenotypes (Levitan and Greenwald, 1995; 
Baumeister et al., 1997; Struhl and Greenwald, 1999; Ye et al., 1999). This can be 
explained by the need for presenilins to cleave the cytoplasmic domain of Notch 
(De Strooper et al., 1999; Song et al., 1999; Struhl and Greenwald, 1999). 
Interesting parallels exist between the Notch signaling pathway and APP 
processing, in both of which presenilins seem to participate. It will be of great 
interest to investigate whether APP is processed during development and what the 
function of a possible cytoplasmic processing product is. We identified in 
developmental stage 38 and subsequent stages a novel APP-derived product of 
~70 kD, that was only detected with C-terminally directed anti-APP antibodies, 
suggesting processing of APP in the N-terminal region. The identity and role of 
this ~70 kD APP immunoreactive product remain to be investigated.
In Xenopus laevis, two structurally different gene transcripts of APP were 
characterized showing that both genes are active, although the ratios between the 
two transcripts differ among tissues (Chapter 7). The significance of the 
occurrence of the two transcripts is not clear. The ubiquitous expression pattern of 
Xenopus APP and the phenomenon of alternative splicing, resulting in three 
different isoforms (APP695 predominantly in neural and APP751/770 in non-neuronal 
tissues), have also been found in other species, such as mouse, human and rat 
((Bahmanyar et al., 1987; Fisher et al., 1991; Goedert, 1987; Sandbrink et al., 
1994; Shivers et al., 1988; Tanzi et al., 1987; Zimmermann et al., 1988). These 
findings together with the strong conservation of the APP protein sequence 
throughout evolution, suggest an important function for this protein. Interestingly, 
the amino acid sequence of the Xenopus Aß-peptide is nearly identical to the 
human Aß-sequence. Aß-residues Arg601, Tyr606 and His609, conserved 
between Xenopus and human but not in rodent Aß, may underly the tendency for 
its aggregation (Dyrks et al., 1993; Johnstone et al., 1991); especially Arg601 has 
been shown to be crucial for amyloidogenesis (De Strooper et al., 1995). 
Furthermore, amino acid residues 16-24 of Aß (KLVFFAEDV), which are fully
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conserved between mammals and Xenopus, are thought to be essential for fibril 
formation (Wood et al., 1995). Thus, in contrast to the rodent peptide, the Aß­
peptide of Xenopus laevis might have the same amyloidogenic characteristics as 
human A ß.
In Xenopus APP, all known sites for post-translational modification are 
conserved. In Chapter 8, we have shown that in vivo Xenopus APP is indeed N- 
glycosylated and phosphorylated, although the exact sites remain to be identified 
(APP contains several potential glycosylation and phosphorylation sites; Kang et 
al., 1987; Pâhlsson et al., 1992; Suzuki et al., 1992/1994; Gandy et al., 1993; 
Griffith et al., 1995; Pâhlsson and Spitalnik, 1996; Yazaki et al., 1996; Walter et 
al., 1997; Tomita et al., 1998).
In the melanotrope cells of Xenopus laevis, we have found a threefold induction 
of APP-mRNA and protein in black- vs white-adapted animals, i.e. in active vs 
inactive cells (Chapter 8). The local induction of APP in the early secretory 
pathway of the melanotropes of black-adapted animals might even be higher, 
since the intracellular localization of the APP-protein was found to differ between 
black and white animals. Induction of APP at the mRNA level has been described 
previously in mammalian cells. In human lymphoblastoid cells, APP-mRNA was 
found to be induced following a heat shock, indicating a relationship between 
cellular stress and the expression levels of APP (Abe et al., 1991b). Furthermore, 
several researchers have shown that neuronal APP is up-regulated after various 
traumatic (Bramlett et al. 1997; Kawarabayashi et al., 1991; Otsuka et al., 1991; 
Pierce et al., 1996; Scott et al., 1991) and ischaemic insults (Siman et al., 1989; 
Wallace et al., 1997a; Wallace et al., 1997b), indicating that the protein might 
play an important role in the response of the brain to injury (Van den Heuvel et 
al., 1999). Of interest is our finding that APP is localized to the endoplasmic 
reticulum (ER)-Golgi in the highly active cells. Recently, cellular stress at the 
ER-level has been implicated in Aß-production, and with the involvement of 
caspases and apoptosis (Nakagawa et al., 2000). This ER-specific apoptosis is 
triggered by caspase-12, a protein localized to the ER. ER stress, such as the 
disruption of ER calcium homeostasis or the accumulation of excess proteins in 
the ER, causes the activation of this caspase, and caspase-12 deficient cortical 
neurons are defective in apoptosis induced by Aß (Nakagawa et al., 2000). 
Stressing the melanotrope cells of Xenopus laevis might give more insight into the 
relationship between APP-processing and ER-specific apoptosis. Furthermore, the 
significance of the so-called unfolded protein response (UPR), an intracellular 
signaling pathway that connects the ER with the nucleus, for APP-biosynthesis 
should be considered. Accumulation of unfolded proteins in the lumen of the ER 
leads to the transcription of a set of genes involved in protein folding, such as
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genes encoding the molecular chaperones BiP (or GRP78), GRP94, calreticulin, 
and protein disulfide isomerase. As such, the UPR adjusts the protein folding 
capacity of the ER according to its need in the cell (reviewed by Shamu et al., 
1994; Chapman et al, 1998). Ire1p, a bifunctional ER transmembrane protein 
with both serine/threonine kinase and endoribonuclease activities, is the initiator 
of UPR signaling (Cox et al., 1993; Mori et al., 1993; Welihinda and Kaufman, 
1996; Sidrauski and Walter, 1997). Ire1p is a single-spanning ER membrane 
protein directed with its N-terminal part inside the ER lumen, and its C-terminal 
part, which contains both the kinase and nuclease domain, in the cytoplasm. The 
substrate of Ire1p is the pre-mRNA encoding the UPR-specific transcription 
factor Hac1p that, upon cleavage by Ire1p at both intron-exon junctions and 
ligation of the two liberated exons by tRNA ligase (Sidrauski et al., 1996; 
Gonzalez et al., 1999), binds to unfolded protein response elements (UPRE) in the 
promoters of direct target genes of the pathway (Cox and Walter, 1996; Mori et 
al., 1996; Nikawa et al., 1996). Surprisingly, the UPR leads to proteolytic 
cleavage of Ire1, releasing fragments containing the kinase and nuclease domains 
that accumulate in the nucleus (Niwa et al., 1999). Mutations in presenilin-1 
(PS1) affect the UPR, which normally responds to the increased amount of 
unfolded proteins that accumulate in the ER under conditions that cause ER stress 
(Katayama et al., 1999). Furthermore, the nuclear localization of Ire1 fragments 
and the induction of the UPR are reduced in PS1 knockout cells (Niwa et al., 
1999), suggesting that PS1 controls Ire1p proteolysis. Remarkably, like for the 
potential PS1 substrates APP and Notch, the cleavage of Ire1p presumably occurs 
within its transmembrane domain.
A number of investigators has proposed that aberrant trafficking or processing of 
APP may play a causative role in the development of AD (reviewed by Selkoe, 
1999; Sinha and Lieberburg, 1999; De Strooper and Annaert, 2000). Gaining 
more insight into the normal biosynthesis and transport of APP is thus essential to 
elucidate how APP is participating in AD-development. In neurons, APP is 
transported by fast anterograde transport from the neuronal cell bodies to the 
distal nerve terminals (Koo et al., 1990; Sisodia et al., 1993). The trafficking of 
APP through the neuronal cells appears to be mediated by its direct binding to the 
kinesin light chain subunit of kinesin-1 (Kamal et al., 2000). APP is therefore 
considered to be a membrane cargo receptor for kinesin-1. Furthermore, 
depending on the activity of transportation along the microtubules the existence of 
different pools of APP has been proposed. In the actively transported neuronal 
compartments, APP would exist in a transport complex with kinesin-1, whereas in 
the whole brain there may be pools of APP that are not transported and therefore 
not associated with kinesin-1 (Kamal et al., 2000). The melanotrope cells of
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Figure 9-2
APP in the melanotrope cells o f black- and white-adapted Xenopus laevis
A schematic of a melanotrope cell o f black-adapted (BA) Xenopus laevis and of a cell o f white- adapted (WA) 
Xenopus is presented. In the active melanotrope (BA), APP (indicated in red) is localized to the endoplasmic 
reticulum (ER) and Golgi, where it interacts with kinesin-1 and participates in active vesicular transport, whereas 
in the inactive melanotrope (WA), APP is predominantly localized at the plasma membrane, where it no longer 
interacts with kinesin-1 and is not involved in active transport anymore.
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black-adapted Xenopus are highly active cells with respect to the biosynthesis and 
transport of newly synthesized proteins, whereas the cells of white-adapted 
animals are in an inactive state. Therefore, the findings of Kamal et al. (2000) and 
the observed differences in expression level and intracellular localization of 
Xenopus APP are intriguing. On the basis of these results, we would like to 
hypothesize that in the melanotrope cells of black-adapted Xenopus, APP is 
predominantly localized to the early secretory pathway (ER-Golgi), associated 
with kinesin-1, and functioning as a membrane cargo receptor, while in the 
melanotrope cells of white-adapted animals APP is predominantly localized at the 
plasma membrane (not actively transported) and no longer associated with 
kinesin-1 (Figure 9-2). Although in the latter case APP might function as a 
modulator of cell-cell communication to keep the melanotrope cell inactive, we 
favor the view that under this physiological condition it is in a transport-inactive 
state waiting for cell activation.
In conclusion, APP in the Xenopus melanotrope cells offers a unique model 
system to study various aspects of APP, including its biosynthesis, its role in 
intracellular transport processes, its function during embryonic development and 
the involvement of related proteins such as the presenilins and secretases.
Future prospects
The recent studies on molecular misreading have confirmed that this process is 
occurring in neuronal and non-neuronal cells, and is very likely linked to the 
process of aging. A number of questions concerning molecular misreading 
remain: what is the actual mechanism underlying these mutations?; can the 
affected cells be isolated for more detailed research?; is it a cause or the 
consequence of AD or other age-related diseases?; does it occur in all cells?; are 
the aberrant mRNAs and proteins present because they are no longer degraded 
during aging? Since molecular misreading occurs only in a subset of cells and at a 
relatively low frequency, further research on this topic will be technically 
difficult.
The observed similarities between the expression of APP in mammalian species 
and that in Xenopus leavis provides a good argument to perform a study on the 
physiological role of APP in this amphibian during development and in the adult 
frog. Remarkable is the finding of a ~70 kD APP-immunoreactive product in 
stage 38 and subsequent stages, which demands for further characterization of this 
protein, including its developmental expression in different organs. Sense and
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antisense APP-RNA injection experiments with fertilized Xenopus eggs will be 
useful to study an early embryonic role of APP.
The overall amino acid sequence identity between mammalian and Xenopus APP 
is another indication that APP might fulfill an important function. The potential 
amyloidogenic properties of the Xenopus Aß-peptide need to be investigated by, 
for instance, in vitro fibril formation assays or by adding the Xenopus peptide to 
cell lines to examine its toxicity. Furthermore, it will be of interest to investigate 
whether in aged toads deposits of Aß can be detected in the brain. Assuming that 
such plaques exist in Xenopus, then these animals can also be used to see whether 
immunisation of young animals with Aß42 (vaccination) might reduce plaque 
formation. Such a vaccination has recently been shown to reduce behavioral 
impairment and plaques in transgenic mice overexpressing a human APP-mutant 
(Schenk et al., 1999; Chen et al., 2000; Janus et al., 2000; Morgan et al., 2000). 
Another interesting question is whether APLP exists in Xenopus. The presence of 
only APLP (but not APP) in invertebrates, and both APP and APLP in mammals, 
suggests that APP has its origin later in evolution. Until now, Xenopus laevis is 
the only non-mammalian species in which APP has been identified and this may 
imply that also APLPs exist in Xenopus. On the basis of a possible involvement of 
APPL in development of Drosophila (Torroja et al., 1999) and APLP2 during 
mouse development (Rassoulzadegan et al., 1998; Blangy et al., 1991/1995), 
identifying Xenopus APLPs will be of great interest.
A further intriguing aspect concerns the possible presence of two ‘pools’ of 
Xenopus APP, namely a phosphorylated and a glycosylated pool, in the 
melanotrope cells of black-adapted Xenopus. It will be interesting to see where 
exactly within the cell the phosphorylated and glycosylated forms act, and if both 
of these forms are also present in the melanotrope cells of white-adapted animals. 
Furthermore, the determination of the expression levels and intracellular 
localization of the presenilins in the melanotrope cells in relation to background 
adaptation needs further work. Presenilin proteins have been localized to the ER 
and the Golgi (De Strooper et al., 1997; Kovacs et al., 1996; Walter et al., 1996), 
and recently also to the endosomes (Lah and Levy, 2000). It has been proposed 
that presenilins either only modulate the activity of g-secretase or are the g- 
secretases themselves (De Strooper et al., 1999; Kimberly et al., 2000; Li et al., 
2000; Russo et al., 2000; Wolfe et al., 1999a-1999c). Presenilin knockout mice 
result in a technical knockout for Aß with accumulation of C83 and C99, the 
substrates for g-secretase, indicating that presenilin influences g-secretase activity 
(De Strooper et al., 1998). Since no cleavage of APP has been observed in the 
melanotrope cells of Xenopus, any presenilin expressed in these cells would be 
inactive, not the actual g-secretase, or only involved in the proper transport or
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folding of APP. Presenilins have been shown to be important during the 
development of C. elegans (Levitan and Greenwald, 1995/1998), Drosophila 
(Struhl and Greenwald, 1999; Ye et al., 1999), and mouse (Wong et al., 1997; De 
Strooper et al., 1999) by influencing the Notch/delta pathway. As mentioned 
above, Notch undergoes proteolytic cleavages that resemble those involved in 
APP processing, including a step that takes place in or near the plasma membrane 
(Schroeter et al., 1998). Therefore, an investigation of presenilin expression in 
relation to APP expression during development of Xenopus is of interest.
The difference in localization of APP in the melanotrope cells of black- vs white- 
adapted Xenopus is intriguing and this finding offers possibilities for further 
research. Immunoelectron microscopic studies on melanotrope cells of black and 
white animals with anti-APP and anti-kinesin-1 antibodies will learn whether 
APP is present in vesicles that are transported by kinesin-1 along microtubules. 
Furthermore, coimmunoprecipitation studies with these antibodies might give 
insight into the physical interaction between APP and kinesin-1 in the Xenopus 
melanotrope cells. Mutagenesis experiments may reveal which amino acid 
residues in the cytoplasmic part of APP are involved in its interaction with the 
tetra-trico peptide repeat (TPR-domain; Gindhart and Goldstein, 1996) of kinesin- 
1 (Kamal et al., 2000). Mutated APP, as found in familial AD forms, may 
influence the intracellular routing of vesicles, possibly causing the APP-protein to 
encounter the g-secretase, with resulting increased Aß-production.
An attractive possibility to study the physiological function of APP involves the 
recently introduced technique of stable transgenesis of Xenopus laevis (Kroll and 
Amaya, 1996; Amaya and Kroll, 1999) or of Xenopus tropicalis (Amaya et al.,
1998), a related species with a diploid genome and a shorter generation time than 
Xenopus laevis (6-8 months vs 2 years). In this way, the spatial and temporal 
expression of APP (or of related proteins such as presenilins) can be manipulated 
by using specific gene promoters (for example the Xenopus POMC-promoter 
which is active primarily in the intermediate pituitary), and sense or antisense 
DNA constructs (including constructs resulting in RNA interference, RNAi; 
Nakano et al., 2000). Although APP is probably one of the most studied proteins 
in molecular neurobiology, the role of the intact protein and its various proteolytic 
fragments remains largely hidden in a forest of speculative interpretations. Future 
functional studies, including the application of Xenopus transgenesis, may shed 
light on this interesting problem. Elucidation of the function of APP and related 
proteins may help in our understanding of AD-development and as such may be 
of great importance to our rapidly aging society.
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Summary
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that was 
first described in 1907 by Alois Alzheimer. It is the most common form of 
dementia in the elderly. Two different types of AD can be discriminated: the 
early-onset (familial; onset below the age of 60-65) and the late-onset (sporadic) 
forms. The familial forms have been investigated thoroughly and mutations in 
three genes, namely in those encoding the ß-amyloid precursor protein APP, 
presenilin 1 (PS1) and PS2, account for almost all known cases of early-onset 
AD. Less attention has been given to the sporadic form of AD, possibly because 
no genomic mutation underlies its onset, although this form accounts for more 
than 80 % of AD patients. Both forms of AD are characterized by the presence of 
neurofibrillary tangles, neuropil threads and neuritic plaques in the brain. The 
major component of the neuritic plaques is the ß-amyloid (Aß) peptide. This 
peptide of 39-43 amino acid residues is produced via proteolytic cleavage of the 
APP-protein. APP is a type I transmembrane protein that is ubiquitously 
expressed. Three major forms of APP are produced via alternative splicing 
(involving exons 7 and 8 of the APP-gene), resulting in proteins of 695, 751 and 
770 amino acids. In mammals, the tissue-distribution of these three splice variants 
has been investigated. In the brain, APP695-mRNA (lacking exons 7 and 8) is 
expressed predominantly, whereas in non-neuronal tissues APP75i/77 o are the 
major forms. The APP-protein can be processed by a number of enzymes. The 
general idea is that under non-pathological conditions the major portion of APP is 
processed by a-secretase to release a soluble APP-fragment (APPsa) and a 
cytoplasmic fragment of 83 amino acids (C83). This latter fragment can be further 
processed by g-secretase to a peptide of 3 kD (p3) and a short cytoplasmic 
product. The cleavage by a-secretase effectively prevents the formation of the Aß 
peptide. Under pathological conditions APP is first processed by ß-secretase, 
resulting in a soluble APPsß product and a cytoplasmic fragment of 99 amino 
acids (C99 or A4CT). The A4CT-protein can be processed by g-secretase to the 
neurotoxic 4 kD Aß peptide and a short cytoplasmic product. Remarkably, the 
cleavage-site of the g-secretase is within the transmembrane region of the APP- 
protein. Since this cleavage leads to the production of Aß, the g-secretase has 
received a lot of attention. Despite many attempts, the identity of the enzyme 
responsible for the intramembranous cleavage has still not been established. The 
above-mentioned PS1 protein has been shown to be involved in this cleavage and 
it might even be the actual g-secretase enzyme.
The purpose of the research described in this thesis was to provide more insight
• • • • • into the molecular and cell biological events underlying the neurodegenerative 
disorder AD. This was attempted by approaching the problem from different 
points of view. The introductory Chapter 1 provides background information on
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previously performed research on AD. In Chapter 2, a novel perspective on a 
molecular event that might contribute to the process of aging is presented. Recent 
research in Brattleboro rats has shown that dinucleotide deletions could occur at 
the RNA-level, leaving the DNA unaffected, a process referred to as molecular 
misreading. These mutations were present in an age-related frequency and at 
specific hotspots, namely at GAGAG-sequence-motifs. We therefore postulated 
the hypothesis that these frameshift mutations might underlie the sporadic variant 
of AD as well. Indeed, dinucleotide deletions were detected at GAGAG-motifs in 
gene transcripts of AD and Down’s syndrome (DS) patients encoding the APP- 
protein and the cytoplasmic garbage-disposal protein ubiquitin-B (Ubi-B). These 
mutated gene transcripts result in the production of proteins with an aberrant 
carboxy-terminal region, the so-called +1-proteins (APP+1 and Ubi-B+1, 
respectively). To investigate whether expression of the Ubi-B+' protein might 
influence the normal ubiquitinilation properties and proteasome function of a cell, 
we further investigated the Ubi-B+' protein (Chapter 3). We were able to show 
that in vitro U bi-B 1 is unable to ubiquitinilate proteins. However, human 
neuroblastoma cells stably transfected with Ubi-B+' showed no effect on cell 
proliferation and morphology, and only a minor effect on protein degradation via 
the ubiquitin-proteosomal pathway was detected. Then the question arose whether 
the GAGAG-motifs constitute the only repeats in the near vicinity of which 
molecular misreading might occur. In Chapter 4, we therefore developed and used 
a sensitive bacterial expression system to illuminate frameshift mutations in AD- 
related transcripts at locations other than the GAGAG-motif. We were indeed 
able to detect deletions and insertions at a number of different short simple 
repeats, such as GGUGGU, CACACA, GAAGAAGAA, UCAUCAUCA, 
showing that molecular misreading is a widespread phenomenon occurring in 
close proximity of short simple repeats.
Chapter 5 describes an investigation of the process of internal translational 
initiation in APP-transcripts. The green fluorescent protein was used as a marker 
for the occurrence of internal translational initiation. We found that in an mRNA 
region corresponding to exon 9 of the APP-gene a methionine can be used as 
initiation site. Internal translational initiation within the APP-transcript is of 
interest, since it can be an alternative way to generate the neurotoxic Aß, namely 
via initiation at the Met596 codon which results in the production of A4CT. We 
performed transfection studies to investigate the biosynthesis of the A4CT- 
product. We were able to show that A4CT is intracellulary localized to vesicular 
structures, is recognized by g-secretase and can indeed be processed to Aß. These 
results suggest that when internal translational initiation at Met596 would occur, 
indeed Aß can be produced, in spite of the fact that the A4CT-product lacks a 
signal peptide.
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Although the APP-protein has received a lot of attention of researchers all over 
the world, its function is still elusive. We therefore decided to use an animal 
model system to study the expression, tissue distribution and biosynthesis of APP. 
We used the first non-mammalian animal in which the APP-gene has been shown 
to exist, namely the clawed toad Xenopus laevis. In Chapter 6, we describe the 
expression patterns of the three alternatively spliced variants of APP-mRNA 
during the development of Xenopus laevis. APP was present throughout all 
developmental stages, showing expression of APP6 9 5  predominantly in the brain, 
APP751/770 in non-neuronal tissues and a novel APP-product of ~70 kD 
(presumably produced via APP-processing) in peripheral tissues such as heart, 
kidney and liver. These results suggest a role for APP during early development 
of Xenopus.
Since Xenopus laevis is a tetraploid animal, two structurally different APP-genes 
will likely be present. We have cloned and sequenced both gene transcripts, and 
examined in adult animals the tissue distribution of the alternatively spliced 
variants of APP-mRNA (Chapter 7). The expression pattern of APP-mRNA 
shows a remarkable conservation throughout evolution from amphibian to 
mammals. Remarkable is that, like in human but unlike rodent Aß, the Xenopus 
Aß-peptide contains all amino acid residues that are implicated in 
amyloidogenesis.
Xenopus laevis is capable of adapting its skin color to the background. When 
placed on a black background, the melanotrope cells in the intermediate lobe of 
the Xenopus pituitary will produce large amounts of a-melanophore stimulating 
hormone (a-MSH). This hormone is secreted into the blood and travels to the 
melanophores in the skin, where it causes the spreading of black pigment, 
resulting in a darkening of the skin. When placed on a white background, the 
melanotrope cells become inactive and no a-MSH is produced or secreted into the 
blood. This provides us with a physiological model system in which the 
biosynthetic and secretory activities of the cells can be manipulated. To examine 
whether APP is involved in cell (in)activation, we investigated the expression of 
APP-mRNA and -protein in the neurointermediate lobe (NIL) and anterior lobe 
(AL) of the Xenopus pituitary (Chapter 8). In the NIL, a threefold induction of 
both APP-mRNA and -protein was detected, when comparing black- and white- 
adapted animals, whereas in the AL of black and white animals no difference in 
APP-expression levels was found. Furthermore, we have studied the biosynthesis 
of APP and revealed that the APP-protein undergoes phosphorylation and N- 
linked glycosylation. Remarkably, the portion of APP-molecules that becomes 
phosphorylated is not glycosylated and vice versa. We have also examined the 
intracellular localization of the APP-protein in the melanotrope cells of black- and
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white-adapted animals by immunofluorescence and organelle separation. In the 
melanotrope cells of black toads, the APP-protein is localized to the ER-Golgi 
region, whereas in cells of white animals APP is localized predominantly to the 
plasma membrane. These differences in localization suggest a role for APP in cell 
(in)activation.
In conclusion, the investigations described in this thesis have provided more 
insight into the process of molecular misreading in ubiquitin-B and APP-gene 
transcripts in neuronal cells, the biosynthesis and intracellular localization of 
APP, and the use of the amphibian Xenopus laevis as a model system for studying 
the physiological role of APP during development as well as in the adult. As such, 
the results may contribute to a better understanding of the molecular and cell 
biological mechanisms underlying AD and related disorders.
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Bij de ziekte van Alzheimer (AD) functioneren de zenuwcellen in de hersenen, de 
zogenaamde neuronen, minder goed. AD is een verouderingsziekte en is een van 
de meest voorkomende vormen van dementie. Er bestaan twee vormen van AD: 
een familiaire variant die reeds op een leeftijd beneden de 60 jaar toeslaat 
(familiaire AD; FAD) en een variant die zich pas boven de 60 jaar openbaart 
(seniele of sporadische AD; SAD). Zoals de naam FAD al aangeeft, komt deze 
vorm van AD vaak voor in bepaalde families, doordat hij veroorzaakt wordt door 
een foutje in het genetisch materiaal van deze mensen. Dit heeft tot gevolg dat 
deze variant van de ziekte kan worden doorgegeven aan het nageslacht en daarom 
familiair of erfelijk wordt genoemd. Meer dan 80 % van de AD patiënten heeft de 
andere vorm van AD (SAD). De oorzaak van het ontstaan van SAD is 
onduidelijk. Wat wel duidelijk is, is dat er in het genetisch materiaal van deze 
patiënten geen afwijkingen te vinden zijn.
AD wordt gekenmerkt door de aanwezigheid van ophopingen van eiwitten ín 
neuronen, de zogenaamde neurofibrillaire “tangles”, en van neerslagen van 
eiwitten tússen de neuronen, de zogenaamde neuritische “plaques”. De neuritische 
“plaques” bestaan voor het merendeel uit een neerslag van het zogenoemde ß- 
amyloïde (Aß) peptide. Dit peptide wordt gevormd doordat het ß-amyloi'de 
voorloper eiwit APP in stukjes wordt geknipt door twee enzymen, genaamd 
secretase-ß en -g. Het Aß heeft als vervelende eigenschap dat het onder bepaalde 
omstandigheden heel gemakkelijk neerslaat en ophoopt. De gedachte is dat er in 
cellen onder normale omstandigheden maar heel weinig van dit Aß-peptide wordt 
gevormd. Echter tijdens het verouderen van cellen wordt er meer Aß 
geproduceerd, wat resulteert in de neerslag tussen neuronen. Hierdoor kunnen de 
zenuwcellen minder goed met elkaar communiceren, kan de informatie minder 
goed of helemaal niet op de plaats van bestemming komen, en zullen de cellen 
niet meer optimaal kunnen functioneren.
In het genetisch materiaal, het DNA, ligt alle informatie opgeslagen om een cel 
goed te laten functioneren. Om deze informatie te kunnen gebruiken moet dit 
DNA worden afgelezen en omgezet worden (via het zogenaamde proces van 
trancriptie) in boodschapper-RNA (mRNA). Het mRNA is een keten bestaande 
uit vier verschillende bouwstenen, nucleotiden genaamd (en wel de nucleotiden 
A, C, G en U). Alleen van de genetische informatie die nodig is voor het 
functioneren van een cel wordt mRNA gemaakt. Deze mRNA moleculen worden 
vervolgens (met behulp van het translatie-proces) vertaald in eiwit, een snoer met 
als bouwstenen de zogenaamde aminozuren. Hierbij worden steeds drie 
opeenvolgende nucleotiden van het mRNA omgezet in één aminozuur. Doordat 
steeds drie nucleotiden gebruikt worden voor de codering van één aminozuur, 
ontstaat er een soort leesraam in het mRNA, een “frame” genaamd. De drie ÆL 
bouwstenen van het mRNA worden een “codon” genoemd. Er bestaan twee
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speciale codons. Eén ervan is het startcodon, dat er voor zorgt dat vanaf die plek 
de omzetting van mRNA naar eiwit begint. Dit codon bepaalt dan ook meteen wat 
het “frame” is. Het andere speciale codon is het zogenaamde stopcodon. Dit 
codon bepaalt wanneer de vertaling van mRNA naar eiwit moet worden 
beëindigd. Een volledig mRNA bevat altijd zowel een startcodon als een 
stopcodon, zodat het de code bevat voor een volledig eiwit. Doordat het mRNA is 
opgebouwd uit vier verschillende soorten nucleotiden, ontstaan er legio 
mogelijkheden waarop deze achter elkaar te plaatsen zijn. Dit geeft de 
mogelijkheid om gigantisch veel verschillende eiwitten te coderen. De functie van 
zo’n eiwit binnen de cel wordt bepaald door de volgorde waarop de aminozuren 
gerangschikt zijn. Elk aminozuur heeft namelijk zijn eigen karakteristieke 
“trekjes”, die ervoor kunnen zorgen dat een eiwit op de goede plaats van 
bestemming komt binnen een cel, of dat een eiwit met de juiste andere eiwitten 
een ‘relatie’ aangaat. Alle informatie om een goed functionerende cel te krijgen 
ligt dus opgeslagen in het DNA,
In het eerste deel van dit proefschrift is gekeken naar foutjes die optreden bij het 
aflezen van DNA naar mRNA (transcriptie) tijdens het verouderen van neuronen 
en het verband van dit proces met AD. In hoofdstuk 1 wordt een literatuur 
overzicht gegeven van de achtergronden van AD en de eiwitten die bij het 
ontstaan er van een rol spelen. Een van de voornaamste eiwitten betrokken bij het 
ontstaan van AD is het reeds genoemde APP. Bij de familiaire vorm van AD zijn 
foutjes (mutaties) in het DNA gevonden in het gedeelte dat codeert voor het APP 
eiwit. Dit resulteert in een gemuteerd eiwit, dat niet meer normaal kan 
functioneren en er voor zorgt dat de mensen die een dergelijke mutatie in hun 
DNA bij zich dragen, op jonge leeftijd reeds verschijnselen van AD vertonen. In 
hoofdstuk 2 laten we echter zien dat er niet alleen op het niveau van DNA 
mutaties op kunnen treden. We hebben aangetoond dat ook op mRNA niveau (dus 
tijdens het proces van transcriptie) foutjes kunnen optreden, waarbij het genetisch 
materiaal intact is. Deze mutaties kenmerken zich doordat ze vaak voorkomen in 
de buurt van zogenaamde ‘simpele herhalingen’ van nucleotiden. Het kan 
namelijk gebeuren dat een bepaalde volgorde van nucleotiden herhaaldelijk achter 
elkaar voorkomt in het DNA, bijvoorbeeld GAGAGA; dit wordt een ‘simpele 
herhaling’ genoemd. Er is gebleken dat er tijdens het verouderen van cellen 
gedurende het aflezen van DNA regelmatig iets mis gaat en wel dat er één 
herhaling ontbreekt. In het hiervoor genoemde voorbeeld heeft het DNA de keten 
GAGAGA en een fout bij het aflezen leidt tot een mRNA met GAGA. Doordat 
het mRNA als een leesraam van drie nucleotiden wordt omgezet in een eiwit, 
wordt het leesraam (het “frame”) nu verstoord, doordat er twee bouwstenen zijn 
weggevallen (een zogenaamde deletie). Men spreekt in dit geval van een “frame”- 
verschuiving. Dit zal er toe leiden dat er bij het aflezen vanaf deze plaats in het 
mRNA een andere keten van aminozuren ontstaat en dus ook een ander eiwit met 
zeer waarschijnlijk een veranderde functie gemaakt wordt. De mutaties in het
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mRNA hebben we niet alleen aangetoond in het eerder genoemde APP, maar ook 
in een mRNA dat codeert voor het eiwit ubiquitine. Ubiquitine zorgt ervoor dat 
alle overbodige, fout of niet goed gevouwen eiwitten worden afgebroken in de 
cel. In mRNA van APP zowel als ubiquitine hebben we een deletie van twee 
nucleotiden gevonden in de ‘simpele herhalingen’ van GAGAGA. Omdat het 
ubiquitine een soort van prullenbak-functie vervuld binnen de cel en de genoemde 
deletie leidt tot een “frame”-verschuiving, is het zeer interessant om te zien of het 
gemuteerde ubiquitine zijn functie nog kan vervullen. In hoofdstuk 3 hebben we 
daarom dit gemuteerde mRNA gebracht in humane cellen in kweek om het te 
laten vertalen in eiwit. Zo kunnen we bestuderen wat het effect van het 
gemuteerde eiwit op het functioneren van de cel is. Allereerst hebben we laten 
zien dat het gemuteerde eiwit in een reageerbuis-experiment niet meer in staat is 
om overbodige eiwitten af te laten breken. Ook de cellen die het gemuteerde eiwit 
vormen, vertonen een enigszins verminderde capaciteit in het afvoeren van 
eiwitten.
In hoofdstuk 4 hebben we aangetoond dat de ‘GA’-herhaling niet de enige 
‘simpele herhaling’ is waar mutaties op kunnen treden. Ook bij herhalingen zoals 
UCAUCA, CACACA, GAAGAA, CAAACAAA en GGUGGU komen deleties 
voor. Deze deleties leiden eveneens tot een verschuiving van het “frame” en dus 
tot een veranderd eiwit.
In hoofdstuk 5 is gekeken of in het mRNA van APP altijd het juiste startcodon 
wordt gebruikt als startplaats (initiatie) voor de synthese van het eiwit. In het APP 
mRNA zit namelijk nog een codon met de eigenschappen van een startcodon (op 
positie 596 van het mRNA) waar de translatie zou kunnen beginnen. Initiatie 
vanaf dit alternatieve startcodon bleek inderdaad te kunnen optreden. Tevens 
hebben we aangetoond dat aflezen vanaf positie 596 een eiwit oplevert, waaruit 
het Aß geknipt kan worden (Hoofdstuk 5).
De laatste drie hoofdstukken van het proefschrift gaan over een diermodel en wel 
de Zuid-Afrikaanse klauwkikker Xenopus laevis. Dit dier is in staat om de kleur 
van zijn huid aan te passen aan zijn omgeving. Zo zal zijn huid op een witte 
ondergrond licht van kleur en op een zwarte ondergrond donker van kleur zijn.
Deze kleurverandering komt tot stand doordat de informatie over de ondergrond 
via de ogen van de kikker doorgestuurd wordt naar de hersenen. Daar wordt de 
informatie verwerkt en doorgegeven aan het hormoonproducerende aanhangsel 
van de hersenen, hypofyse genaamd. Indien er een bericht komt dat de 
achtergrond donker is, worden de cellen in het middelste gedeelte van de 
hypofyse (de intermediaire lob) geactiveerd en worden er heel veel mRNAs en 
eiwitten geproduceerd. In deze zogenaamde melanotrope cellen wordt dan
• • • • M f ¡S
voornamelijk het voorloper-hormoon proopiomelanocortine (POMC) gemaakt.
Dit POMC wordt vervolgens door knipenzymen in kleinere eiwitjes geknipt. Deze 
kleinere eiwitjes zijn de bio-actieve producten, oftewel de hormonen van deze
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cellen. Eén van deze producten is het melanoforen-stimulerend hormoon (MSH). 
Dit hormoon wordt door de melanotrope cellen afgegeven aan het bloed en 
vervolgens getransporteerd naar de huid. Hier zorgt MSH ervoor dat de 
pigmentkorrels in de cellen, de melanoforen, van de huid zich gaan verspreiden, 
waardoor de huid een donkere kleur krijgt. Wanneer de kikker echter op een witte 
ondergrond wordt geplaatst, krijgen de hersenen andere informatie en wordt de 
synthese van mRNA en eiwitten geremd. De melanotrope cellen van een wit 
geadapteerd dier zijn dus inactief, terwijl dezelfde cellen gedurende adaptatie aan 
een zwarte achtergrond uitermate actief zijn. Dit maakt de intermediaire lob van 
de klauwkikker tot een mooi modelsysteem om allerlei eiwitten te bestuderen 
waarvan gedacht wordt dat ze een functie vervullen bij het activeren van cellen en 
alles wat daarbij komt kijken. Zo zullen er in actieve cellen de vele geproduceerde 
eiwitten getransporteerd moeten worden naar de goede plek van bestemming. 
Vaak zijn hier weer andere eiwitten voor verantwoordelijk.
Heel veel genen die in het DNA van mensen voorkomen, zijn ook terug te vinden 
in lagere organismen, zoals in gist, fruitvlieg en rondworm. Vooral genen die 
coderen voor eiwitten met een speciale en belangrijke functie zijn door de gehele 
evolutie aanwezig. Een eiwit waarvan gedacht wordt dat het zo’n belangrijke 
functie vervult, is het APP. Er is al heel veel onderzoek aan dit eiwit gedaan, maar 
zijn werkelijke fysiologische functie is nog steeds onduidelijk. Het bestuderen van 
APP in de klauwkikker was dus een voor de hand liggende stap. In hoofdstuk 6 
hebben we gekeken of APP al in de vroege ontwikkelingsstadia van de 
klauwkikker (van bevruchting tot kikkervis/dikkop) aanwezig is. Dit blijkt 
inderdaad het geval te zijn. Tevens hebben we vanaf een vroeg stadium van de 
kikkervis (stadium 38) een nieuw eiwit verwant aan APP gevonden, waarvan de 
precieze betekenis nog verder onderzoek vergt.
In hoofdstuk 7 hebben we de genetische informatie die codeert voor het APP 
eiwit in Xenopus laevis opgepikt en de nucleotiden-volgorde bepaald. Het bleek 
dat de volgorde en samenstelling van de aminozuren in het Xenopus APP eiwit 
heel veel overeenkomt met die van het menselijke APP eiwit. Dit behoud van 
aminozuur volgorde duidt op een belangrijke functie voor het eiwit. Verder 
hebben we gekeken in welke weefsels het APP mRNA aanwezig is. Het is 
gebleken dat in de klauwkikker, net als in zoogdieren, het APP eiwit in alle 
organen voorkomt.
In hoofdstuk 8 hebben we de aandacht gericht op de rol die het APP eiwit zou 
kunnen vervullen gedurende de achtergrond adaptatie van Xenopus. We hebben 
gevonden dat er in de actieve (‘zwarte’) cellen van de intermediaire lob van de 
hypofyse drie keer zoveel mRNA en eiwit van APP aanwezig is als in de 
inactieve (‘witte’) cellen. Verder hebben we onderzocht of het APP eiwit nog 
veranderingen ondergaat. Inderdaad blijkt het zo te zijn dat er aan het eiwit zowel
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fosfaatgroepen als suikergroepen kunnen worden toegevoegd. Opvallend is wel 
dat deze twee groepen niet op hetzelfde APP molecuul kunnen voorkomen. We 
hebben verder gezien dat de plaats binnen de cel waar het APP eiwit zich bevindt, 
verschilt tussen de actieve en de inactieve cel. In de actieve cel is het APP eiwit 
aanwezig in structuren die betrokken zijn bij het transporteren van eiwitten door 
de cel, terwijl het APP eiwit in de inactieve cel voornamelijk op de buitenzijde 
van de cel aanwezig is. Dit zou er op kunnen duiden dat APP in de ‘zwarte’ cel 
betrokken is bij het actief transporteren van eiwitten of eiwit bevattende blaasjes. 
Concluderend kan gezegd worden dat de resultaten van de in dit proefschrift 
beschreven experimenten nieuwe aangrijpingspunten geven voor verder 
onderzoek aan verouderingsziekten in het algemeen en dat de amfibie Xenopus 
laevis een goed diermodel is voor het bestuderen van het APP eiwit.
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Het laatste hoofdstuk van dit proefschrift is misschien nog wel het zwaarste om te 
schrijven, omdat het door de meeste mensen gelezen wordt en het zeer vervelend 
is als mensen naar hun naam gaan zoeken en deze dan niet terug kunnen vinden. 
Ik probeer niemand te vergeten, maar bij deze alvast iedereen bedankt die in 
meerdere of mindere mate heeft bijgedragen aan het totstandkomen van dit 
boekwerk, zowel op de werkvloer als daar buiten.
Natuurlijk zijn er heel veel mensen die ik met naam (en eventuele toenaam) zeker 
wil bedanken. In de eerste plaats wil ik mijn promotor bedanken. Gerard bedankt 
voor de vrijheid die jij me gaf om mijn experimenten op te zetten en uit te voeren. 
Ook bedankt voor het vertrouwen dat jij in mij stelde dat er uiteindelijk toch een 
boekje zou komen, hoewel ik het gevoel had dat ik regelmatig in heel diep water 
moest rond spartelen.
De “mensen uit Amsterdam” Fred, Dominique, Elly en Jacqueline wil ik 
bedanken voor de hulp en het meedenken tijdens de eerste jaren van mijn AIO- 
tijd.
Tijdens mijn AIO-jaren zijn er nog vele mensen geweest die een (groot of klein) 
steentje hebben bijgedragen aan het vaak zeer moeizaam lopende onderzoek. Mijn 
onderzoek heeft zijn naam eer aan gedaan. Het was echt een +1- ofwel een -2- 
project, waarbij elke stap vooruit resulteerde in twee stappen terug. Karel (is dat 
piekenpatroon nu wel anders of niet? Leg er nog maar een paar voorbeeldjes bij 
en staar er nog even een half uur naar), François, Louis en Frank v. K. bedankt 
voor het meedragen van de ‘last’. Franci, Rianka, Heidi, en ook de (toen nog) 
studenten Nikol en Lieke ontiegelijk veel dank voor jullie steun en gezelligheid 
tijdens het pipetteren, thee-leuten en de werkbesprekingen van ons +1-harem. Ik 
ben blij dat jullie niet allemaal afgeknapt zijn op het doen van wetenschappelijk 
onderzoek en wens jullie allemaal heel veel succes. Ook ‘mijn’ studenten Hicabi, 
Bas, Patrick en Heidi: bedankt voor jullie inzet! Helaas is mijn proefschrift geen 
weerspiegeling van het vele werk dat er door jullie is verzet en is het niet allemaal 
(bijna allemaal niet) terug te vinden in mijn boekje. Tja, soms zit het onderzoek 
mee, maar meestal zit het tegen!
Zonder de hulp van de zogenaamde mensen achter de schermen was er veel van 
mijn onderzoek niet mogelijk geweest. Ron E., Peter, Tony, Tom en de mensen 
van het gemeenschappelijk instrumentarium, met name Jelle en Liesbeth, bedankt 
voor jullie steun.
Mijn dank gaat ook uit naar de mensen van de tweede en de vierde verdieping en 
naar de vrijdag-tussen-de-middag-voetballers voor alle afleiding van het serieuze 
gepipetteer.
In ons eigen lab hebben de laatste jaren een groot aantal mensen vertoefd. 
Anneke, Cees, Diet, Joost, Martin, Frank C., Jörg, Louis, Hans, Franklin, Doug, 
Franci, Rianka, Frank K, Heidi, Ingrid, Quinten, Tjadine, Eric, Marjon, Susan, 
Gerrit, Karel, Marcel, Vincent, Roland, Jutta, Ron D., François en Bart bedankt 
voor jullie gezellige aanwezigheid gedurende kortere of langere tijd op het lab. 
Gerrit, Marcel, Heidi, Wouter en Marjon wil ik speciaal bedanken voor de (soms
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turbulente) stap/stad-avonturen. Hopelijk blijven de gezellige café-, film- en 
swingavondjes gewoon doorgaan!
Een speciaal woordje van dank wil ik geven aan een paar mensen die niet alleen 
op de werkvloer, maar zeker ook daarbuiten hebben bijgedragen aan mijn 
proefschrift. In de eerste plaats Annemarie die als een studentje bij ons het lab 
binnen kwam. Sindsdien hebben we heel wat afgekeuveld over goede en slechte 
tijden en ik ben je zeer dankbaar voor het goede contact dat we nog steeds 
hebben. Ook Marjon wil ik bedanken voor haar bijdrage aan het laatste deel van 
mijn AIO-tijd (en het eerste deel van mijn postdoc-periode), voor de gezellige 
samenwerking en voor de goede gesprekken die we hebben gevoerd (en gelukkig 
nog steeds regelmatig voeren). Ik hoop dat het lopen van de vierdaagse minder 
inspanning vereist dan het tot stand brengen van dit proefschrift. Ik ben er heel 
blij mee dat jij mijn paranimf wilt zijn. Verder wil ik Eric bedanken. Zonder hem 
zou het vervoer van en naar het UL een stuk minder soepel en gezellig zijn 
verlopen en zou het thuisfront het een heel stuk zwaarder hebben gehad. Bedankt 
voor de gezellige carpool ritjes waarbij we beiden ons ei kwijt konden (ondanks 
dat er wel eens iets mis was met de kwaliteit van die eitjes!). Hopelijk blijft ons 
carpoolteam nog lang in stand! Ook op de werkplek ben jij een geweldige collega 
op wie je altijd terug kunt vallen als je iets materieels of gewoon een luisterend 
oor nodig hebt. Je bent echt een super-collega!
Natuurlijk wil ik ook het thuisfront bedanken. Uitdrukkingen zoals: is het boekje 
nou nog niet af? Ligt het al bij de drukker? Staat de promotie al gepland? geven 
een beetje aan hoe er over een promotie wordt gedacht. Pap, mam, Ton, Masja, 
Maud, Mees, Melle, Marc, Petra (en Mark), Henk en schoonfamilie, bedankt voor 
jullie steun, geduld, interesse en vertrouwen!!
Buiten werktijd kon ik ook altijd terugvallen op Hanneke (en daarmee ook 
Roderik, Jesper en Niels). Han, bedankt voor je eeuwige enthousiasme en 
interesse en voor alle gezellige thee-uurtjes.
Op de laatste, maar zeker niet de minst belangrijke plek, wil ik mijn wederhelft 
Bart bedanken voor zijn steun en het aanhoren van al mijn gezeur (vooral mijn 
geklaag over computers). We hebben het saampjes toch maar mooi goed voor 
elkaar!!
Bedankt!!!!
Helma
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De assistent in opleiding
Assistent in opleiding, zo word je  getooid 
Nadat je  een academische opleiding hebt voltooid 
Veel werken en lange dagen 
Overal hoor je  ze klagen 
De eisen te hoog, het loon te laag 
Projectomschrijvingen vaak te vaag 
Frustraties kunnen de pan uit rijzen  
Toch probeert de A IO  zich te bewijzen 
En hoewel ze hevig worden gevreesd 
Leer je  van de tegenslagen het meest 
Maar als troost voor de moeilijke tijden 
Kun je  terecht bij je  collega's die evenzeer lijden 
Met als motto: eigenwijs aan de slag gaan 
maar vooral volhouden en stug doorgaan 
leer je  je  door tegenslagen heen te slaan 
en kom je  als A IO  stevig in de schoenen te staan 
Ik  ben nu bij de eindstreep van mijn beproeving gearriveerd 
Dank aan allen die mij de laatste jaren hebben gemotiveerd!
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Stellingen
Hoewel in vroegere tijden vaak werd gezegd dat je niet de 
boodschapper de schuld moet geven (don’t blame the messenger), 
kan op celniveau de messenger wel degelijk een schuldige zijn (dit 
proefschrift).
Het feit dat de activiteit van de melanotrope cellen van Xenopus 
laevis regelbaar is, maakt dit systeem tot een mooi modelsysteem 
voor het bestuderen van het APP eiwit (dit proefschrift).
Hoewel cellijnen vaak gebruikt worden voor expressie -en 
localisatie-studies, komt het ingebrachte construct vaak niet op 
fysiologische wijze tot expressie.
Al is Xenopus laevis niet het meest ontwikkelde dier op de evolutie- 
ladder, toch is zijn ontwikkeling wetenschappelijk van groot belang.
Vermindering van geheugen mag een kenmerk van de ziekte van 
Alzheimer zijn, maar onderzoekers op dit vakgebied zullen hun 
onderzoeksperiode niet snel vergeten.
Hoewel wiskundig niet juist, geldt bij leesramen van eiwitten dat +1 
gelijk is aan -2.
De termen promoter en promotor worden regelmatig met elkaar 
verward, maar er bestaan dan ook duidelijke overeenkomsten tussen. 
Zo zal een AIO onder controle van een promotor met weinig 
silencer- en veel enhancer-activiteit beter tot expressie komen.
Een ontwikkelingsbioloog is niet per definitie een bioloog met een 
betere algemene ontwikkeling.
Niet elke gang vooruit is een vooruitgang.
Het schrijven van een proefschrift is bezig zijn met het uitwerken 
van leuke experimenten en creatieve ideeën, maar door de enorme 
omvang en tijdsdruk kun je er niet echt van genieten.
Roken is en blijft een teer onderwerp
Het zou mooi zijn als mensen net als Xenopus-eitjes ‘ge-dejellied’ 
konden worden om ze dichter bij elkaar te brengen.
Ouderdom komt met de jaren
Het openbaar vervoer is te vergelijken met veel top(b)sporten: er 
wordt met een schema vertrokken, maar het lukt maar zelden om 
zich hieraan te houden.
Een schilder heeft een kleurrijke baan
De kwantiteit van de plaques in de hersenen is omgekeerd evenredig 
met de kwaliteit van het leven
If the world wouldn’ t suck, we would all fall off.
Een UFO is geen UFO meer, nadat hij als UFO geïdentificeerd is.
